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Abstract
This dissertation describes accomplishments in three areas of cancer research: the
development of a new method to detect carcinogen DNA adducts, the synthesis of modified
oligonucleotides for structural and biological studies, and the development of candidate
cancer chemotherapeutic agents designed to damage DNA and to inhibit their own DNA
repair selectively in tumor cells.
In an effort to facilitate progress in the evaluation of DNA adduct measurements as
biomarkers of genotoxic exposure, a new method was developed to detect and to quantify
DNA adducts. The method, which we have termed Adduct Detection by Acylation with
Methionine (ADAM), involves the acylation of DNA adducts with a protected methionine
derivative, t-butoxycarbonyl-L-methionine N-hydroxysuccinimidyl ester (TBM-NHS). This
dissertation describes the optimization and the structure determination of the acylation
products of 2'-deoxyguanosine (dGuo), used as a prototypical deoxynucleoside, and N-
(deoxyguanosin-8-yl)-4-aminobiphenyl (dGuo-8-ABP), the major DNA adduct formed after
exposure of cells to 4-aminobiphenyl, a known bladder carcinogen. Under optimized
reaction conditions, a major product (greater than 88% isolated yield after chromatography)
resulted from the TBM acylation of either dGuo or dGuo-8-ABP.
In an attempt to define the relationship between the structures and the biological
consequences of chemical carcinogens and ionizing radiation, a series of site-specifically
modified oligonucleotides was synthesized. My efforts have led to the synthesis of four site-
specifically modified oligonucleotides that have undergone, or currently undergoing,
biological experiments to determine the mutagenicity of the different DNA lesions. Two
methods of synthesis were utilized to create the modified oligonucleotides: chemical
modification of a preformed oligonucleotide or solid phase DNA synthesis utilizing a
modified phosphoramidite. The site-specifically modified oligonucleotides that were
synthesized contained the following lesions: dGuo-8-ABP, 7,8-dihydroguanin-8-one (G8 -°x),
3
7,8-dihydroadenin-8-one (A8-°x°), and 5-hydroxy-deoxyuridine (oh5dU). Preliminary studies
are also described on the synthesis of a fifth modified oligonucleotide containing 5-hydroxy-
deoxycytidine (oh5dC).
As part of ongoing studies to improve the selectivity of anticancer drugs that mediate
their genotoxicity as a consequence of reacting with DNA, novel chemotherapeutic
compounds were designed, synthesized and tested for biological activity. The designed
chemotherapeutic agents consist of a chemically reactive DNA damaging domain linked to a
second domain that attracts a tumor specific protein. The initial step in the functioning of
these chemotherapeutic agents is the covalent modification of DNA by the warhead domain.
Although damage occurs in both cancer and noncancerous cells, we propose that the
selective binding of a tumor specific protein in cancerous cells can prevent the repair of the
DNA lesion. The end result would be the higher relative toxicity of the drug in a cancer
cell than in a noncancerous cell. Initial studies involved the synthesis and testing of a
modified ss DNA capable of binding with high affinity to a targeted protein and capable of
covalently modifying a ds DNA target. Although a designed compound could be
synthesized, covalent modification of a ds DNA probe did not occur. Ensuing studies with
a psoralen-linked biotin molecule did result in a DNA lesion that demonstrated in vitro that
the binding of a targeted protein in the vicinity of a DNA lesion can inhibit the repair of
DNA damage. Recent studies have involved the synthesis of a series of genotoxic
compounds utilizing an estradiol recognition domain. These genotoxic compounds were
designed to cause enhanced toxicity solely in tumor cells by exploiting the property of breast
tumor cells to overexpress the estrogen receptor (ER) which can bind to and protect the
designed DNA lesions.
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Thesis supervisor: Gerald N. Wogan
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INTRODUCTION
Ionizing and UV radiation, chemotherapeutic drugs and environmental chemicals can
damage various cellular constituents including proteins, lipids, RNA and DNA (Miller and
Miller, 1981; Singer and Grunberger, 1983; Skipper and Tannenbaum, 1990; Perera, 1988).
The resulting cellular damage can affect the growth, survival and proliferation of a cell
(Hutchinson, 1989). DNA damage that eludes cellular repair mechanisms in particular has
special significance because these lesions can destroy or heritably alter essential genetic
information. The resulting genetic changes can convert a cell irreversibly to an altered
neoplastic phenotype (Wogan, 1989). In an attempt to understand and to treat cancer, this
thesis describes studies undertaken 1) to develop a new method to detect carcinogen-DNA
damage, 2) to synthesize substrates with which to understand the biological consequence of
particular DNA lesions, and 2) to develop a novel cancer treatment based on the inhibition
of DNA damage selectively in tumor cells.
In an attempt to provide qualitative and quantitative information on human exposure to
carcinogens, several DNA adduct detection methods have been developed (Beach and Gupta,
1992; Kaderlik et al., 1992). Results of a number of studies involving cells in culture and
pilot trials involving animals and humans suggests that if the biologically critical DNA
adduct can be determined and measured, there is a good correlation between the level of that
DNA adduct and the frequency of induced mutations (Perera, 1988). As part of an ongoing
effort in the Wogan laboratory to determine which chemical lesions form within DNA and to
ascertain how prevalent the resulting lesions are, I report in the first chapter of this
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dissertation the development and validation of a new method to detect DNA adducts. Our
objective was to develop a method for detecting carcinogen-DNA adducts that could be
broadly applicable to carcinogens from diverse chemical classes, have sensitivity adequate to
detect adduct levels resulting from ambient human exposures, be capable of identifying
individual adducts as well as mixtures resulting from complex exposures, have potential for
quantifying adduct recovery, and utilize readily available reagents and equipment. The
developed method, which we have termed Adduct Detection by Acylation with Methionine
(ADAM), involves the acylation of DNA adducts with a protected methionine derivative, t-
butoxycarbonyl-L-methionine N-hydroxysuccinimidyl ester (TBM-NHS). The first section
of this dissertation describes the optimization and the structural determination of the
acylation products of 2'-deoxyguanosine (dGuo), used as a prototypical deoxynucleoside,
and N-(deoxyguanosin-8-yl)-4-aminobiphenyl (dGuo-8-ABP), the major DNA adduct formed
after exposure of cells to 4-aminobiphenyl, a known bladder carcinogen.
A second aspect of my research has involved the preparation of biological substrates
with which to investigate the mutagenic potential of oxidative and aromatic amine DNA
damage. While DNA adduct measurements can provide evidence that a particular chemical
has reacted with DNA, the biological importance of the lesion is, however, usually
unknown. A crucial obstacle hindering an understanding of the importance of some DNA
damaging agents arises from the general property of carcinogenic agents to form a variety of
DNA adducts (Wood and Essigmann, 1991). By using viral or plasmid DNA singly
modified with a specific adduct, the in vivo mutagenic potential for a particular DNA lesion
can be determined. As part of ongoing efforts in the Essigmann laboratory to define the
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relationship between DNA adducts and the biological consequences of chemical carcinogens
and ionizing radiation, I report in the second chapter of this dissertation the synthesis of four
site-specifically modified oligonucleotides for use in in vivo mutagenesis experiments and in
vitro repair studies. My efforts have led to the synthesis of site-specifically modified
oligonucleotides containing dGuo-8-ABP, 7,8-dihydroguanin-8-one (G8-°x), 7,8-
dihydroadenin-8-one (A&°x), and 5-hydroxy-deoxyuridine (oh5dU). Preliminary studies are
also described on the synthesis of a fifth modified oligonucleotide containing 5-hydroxy-
deoxycytidine (oh5dC).
A third aspect of my research has involved the development of a novel cancer
treatment strategy. A crucial aspect of the proposed strategy is the specific binding of a
protein to a DNA lesion. A number of studies have reported the existence of proteins in
eucaryotic cells that bind to DNA damaged by chemical or physical agents, including
platinum crosslinks (Donahue et al., 1990; Pil and Lippard, 1992; Brown et al., 1993;
Treiber et al., 1994), ultraviolet light induced photoproducts (Feldberg and Grossman, 1976;
Chu and Chang, 1988; Hirschfeld et al., 1990) and 1,N6-ethanoadenine (Rydberg et al.,
1991). Additional studies suggest that protein binding to a DNA lesion can shield the lesion
from repair, thereby increasing the biological efficacy of a genotoxic compound (Donahue et
al., 1990; Brown et al., 1993; Treiber et al., 1994). Presumably, a therapeutic compound
designed to react with DNA and concurrently be tightly bound by a tumor specific protein
would provide a means of achieving a favorable therapeutic index. In principle, if the
binding took place only in a tumor cell, the complex formed between the designed
compound and a tumor specific protein would selectively slow the rate of repair of the
16
lesion in the tumor cell. The end result would be a higher relative toxicity of the drug in
cancer cells compared to normal cells. I report in the third chapter of this dissertation the
design and synthesis of model compounds to test our hypothesis. A key feature of our
strategy, which we have termed Fatal Engineering, is the ability to control the specificity
and affinity of the protein recognition domain in these candidate drugs. This ability should
allow us to exploit the different molecular changes that are characteristic of various
malignancies, including the expression or overexpression of oncogene-encoded or suppressor
gene-encoded proteins.
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I. DEVELOPMENT OF ADDUCT DETECTION BY
ACYLATION WITH METHIONINE (ADAM) 1
A. Introduction
Electrophilic genotoxic carcinogens and ionizing radiation can form a variety of
covalent adducts with cellular macromolecules (Singer and Grunberger, 1983).
Measurement of the levels of such adducts in DNA and proteins can provide important
qualitative and quantitative information about biologically effective doses of genotoxic agents
to which individuals have been exposed (Perera, 1988; Wogan, 1989; Wogan, 1992).
Information acquired through such investigations would be useful in identifying individuals
within populations at high risk for cancer by virtue of exposure. In addition, the
measurement of molecular biomarkers provides a means to assess the efficacy of molecular
interventions such as chemoprotective agents (Lippman et al., 1990).
In an effort to facilitate progress in utilizing DNA adduct measurements as biomarkers
of genotoxic exposure, Dr. Gerald Wogan, Dr. Fayad Sheabar, and I sought to develop a
new analytical procedure to detect carcinogen-DNA adducts. The methodology we
developed is based on chemical derivatization of mononucleoside adducts by acylation with
I. Portions of this section have been taken verbatim from Sheabar et al., 1994 and Sheabar, F.Z.,
Morningstar, M.L., and Wogan, G.N. (1994) Chemical derivatization of nucleosides by acylation with
methionine: An experimental strategy for analysis of carcinogen-DNA adducts. Chem. Res. Tox. (accepted for
publication).
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an activated methionine reagent. The following sections describe my efforts as a member of
the Wogan laboratory to develop and validate this new method for the measurement of
carcinogen-DNA adducts. The two main objectives of my research were: 1) to synthesize
standards of carcinogen-DNA adducts, including tritium-labeled, and 2) to synthesize and to
elucidate the structure and regiochemical assignment of the acylation reaction products.
B. Background and Basis of Biomonitoring
a. Human Biomonitoring
Human exposure to xenobiotics occurs as a result of chemicals present in the
environment (Perera et al., 1992), occupational settings (Melick et al., 1971), and food
(Ames et al., 1990; Gold et al., 1992). One approach to estimate an individual's exposure
to toxicants is accomplished by questionnaires, personal external monitors, and measurement
of chemicals in the ambient environment. Unfortunately, extrapolating this information to
calculate the chemical fraction each individual encounters has been difficult. The
complexity arises from the heterogeneous nature of most environment exposures and because
many chemicals require subsequent metabolic activation in order to cause molecular damage
(Miller and Miller, 1981). In particular, the capability for metabolic activation varies
between individuals (Harris et al., 1982; Harris et al., 1984), in different organs (Autrup et
al., 1982; Selkirk et al., 1983), and probably in the same organ of one person over time.
Consequently, assessing individual chemical exposures and risks by these methods has been
very imprecise predicting only the approximate dose received by an individual.
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A second approach for assessing the exposure of people to chemicals involves the
measurement of biomarkers, internal markers of chemical exposure (Groopman and Kensler,
1993; reviewed in Biomarkers in Human Cancer-Part I (1992) and Part II (1993)).
Biomarkers provide unequivocal identification of chemical exposure and offer a means to
measure the amount of activated chemical directly interacting with critical cellular targets.
Three strategies have been employed to assess this internal dose of chemical agents. One
method involves indirect measurement of biological responses such as mutations, sister
chromatid exchange, chromosome aberrations, and abnormalities in cells and tissues of
exposed individuals. The other two methods involve the direct measurement chemical
exposure. One method involves the detection of carcinogens, their metabolites, and/or
derivatives in body fluids or excreta (Wogan and Gorelick, 1985; Shuker and Farmer, 1992;
Simic, 1992). The other method involves the detection of the products of a chemical's
reaction with cellular macromolecules such as DNA, RNA, or protein (Tannenbaum, 1990;
Perera et al., 1992; Kaderlik et al., 1992). Although all damaged macromolecules can
potentially compromise cellular integrity, adducts within DNA have special significance
because of their potential to initiate events leading to mutation and/or malignant
transformation (Ozturk et al., 1991; Bressac et al., 1991). Consequently, efforts in this
laboratory have focused on the measurement of carcinogen-DNA adducts in target tissues or
accessible surrogate cells.
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b. DNA Adducts
Carcinogen-DNA addition products (DNA adducts) are formed from the covalent
binding of reactive mutagens and carcinogens to sites on all four DNA bases as well as the
phosphate and sugar backbone of DNA. The products of reaction can involve exocyclic
amino and oxygen groups, purine or pyrimidine ring nitrogens, ribose carbons, or phosphate
oxygens. The factors that influence the relative reactivity of an electrophilic compound
toward specific sites in DNA are the electrophilicity of the chemical mutagen (O'Connor et
al., 1975), the nucleophilicity of the DNA sites (Lawley et al., 1975), the steric accessibility
of a reagent to a nucleophilic DNA site (Lawley et al., 1975), electrostatic interactions
(Abnnon and Verly, 1972), and van der Waals interactions between the electrophile and the
DNA (Swenson and Kadlubar, 1980). The relative contribution of these factors varies with
different compounds. Consequently, a variety of DNA lesions can result from a single
carcinogen or mutagen. However, the stability of the resulting DNA lesions varies as a
consequence of the type of adduct or as a consequence of enzymatic repair (Singer and
Grunberger, 1983; Swenson and Kadlubar, 1980). Some adducts involving covalent
modification of the purine N7 and N9 positions and pyrimidine N1 position decompose
spontaneously through chemical depurination or depyrimidination. Some adducts such as
phosphotriesters and glycosidic adducts are transiently stable and ultimately decompose
slowly. Other adducts are stably attached to DNA but are removed enzymatically by DNA
repair. However, a proportion of chemically stable DNA adducts is not repaired (or not
rapidly repaired) and, as such, remains fixed to DNA over long periods of time. In these
cases, the modified nucleotides can cause mutations.
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c. Methods for Detecting Carcinogen-DNA Adducts
A variety of analytical techniques have been devised to measure DNA adducts (Wogan,
1989; Kaderlik et al., 1992). These methods include immunoassays (Poirier, 1993), 32p_
postlabeling (Beach et al., 1992), and physiochemical methods (Weston, 1993). While each
of the analytical methods has some specific advantages for detecting particular DNA
adducts, none of the currently available techniques is capable of accurately detecting every
class of DNA adducts. Some of the advantages and limitations for each method are briefly
described below.
i. Radiolabeled Carcinogens
One widely used method to study the interaction of chemical carcinogens with DNA
uses radiolabeled carcinogens (Baird, 1979). By treating animals with radiolabeled
carcinogens or reacting DNA in vitro with the reactive form of a carcinogen, DNA modified
at 1 adduct/108 nucleotides can be detected when a carcinogen of high specific activity (>
25 Ci/mmol) is used. Accordingly, this method depends on the availability of highly
radioactive carcinogens. Since human exposure rarely if ever involves radiolabeled
carcinogens, this method is not applicable to the detection of ambient chemical adducts in
humans.
ii. Ultraviolet absorbance and Fluorescence Spectroscopy
Detection of DNA adducts by ultraviolet and fluorescence spectroscopy depend on the
absorption and, in the case of fluorescence, reemission of light. Because of the strong
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absorbance of most DNA bases at 254 and 280 nm, ultraviolet absorbance is useful for the
detection of a large number of carcinogen-DNA adducts. Unfortunately, this method, when
compared with other available methods, is relatively insensitive (1 adduct/104 nucleotides
using 2600 tg of DNA). In contrast, fluorescence spectroscopy can be very sensitive
depending on the adduct under study and the instrumentation used (Weston and Bowman,
1991). The use of low temperature techniques and synchronous scanning, for instance, can
detect 1 adduct/107 nucleotides using 100 tg of DNA and allow unambiguous adduct
identification. However, this improvement depends on adduct fluorescence and the use of
expensive instrumentation. One drawback for both ultraviolet absorbance and fluorescence
spectroscopy is the limitation for providing structural information concerning unknown DNA
adducts. Other disadvantages include the lack of quantitation due to broad peaks in many
samples studied and cross-detection of other unrelated chromophores.
iii. Immunoassays
Immunoassays take advantage of the specificity of antibody-antigen reactions to detect
DNA adducts. Consequently, immunoassays are limited to the detection of DNA adducts
for which antibodies are available (Phillips, 1990; Santella, 1988). Two commonly used
techniques for DNA adduct detection are the radioimmunoassay (RIA) or the enzyme-linked
immunosorbent assay (ELISA). Both assays depended the detection of an antigen-antibody
complex. In order to detect the antigen-antibody complex by RIA, a radiolabeled tracer
with specific activity of > 10 Ci/mmol is required (Muller and Rajewsky, 1981).
Consequently, RIA is limited to carcinogen-DNA adducts where a radioactive tracer is
available. Although ELISA can be done when a radiolabeled tracer is not available, greater
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intra- and inter-assay variability occurs because of the multiple steps involved in assaying for
binding (Poirier, 1993). Some of the factors affecting the sensitivity of ELISA or RIA
detection of carcinogen-DNA adducts include: 1) the antibody affinity; 2) the physical state
of the biological sample (native, denatured, or digested DNA); 3) the amount of the sample
that can be assayed without altering the standard curve; and 4) in the case of RIA, the
specific activity of a radiolabeled tracer (Poirier, 1993). Sufficient sensitivity to assay
human DNA adducts for both methods generally requires antisera with affinity constants in
the range of 108 to 109 liters/mole. Before a particular antibody can be used in either
immunoassay, however, extensive characterization is required to insure that unknown cross-
reactivity with other chemicals does not occur. Unfortunately, the very high antibody
specificity to a particular antigen can be a disadvantage. When studying a spectrum of
related adducts, a battery of antibodies is needed.
iv. Gas Chromatography / Mass spectrometry
Gas chromatography / mass spectrometry (GC-MS) involves the separation of volatile
compounds by gas chromatography and subsequent detection by mass spectrometry.
Because nucleosides are not suitable for gas chromatography, a carcinogen-DNA adduct
must be derivatized prior to analysis. One method commonly used involves the release of
the adduct from DNA by acid treatment and chemical derivatization of the adduct with
trimethylsilyl groups (Dizdaroglu, 1986). To increase the sensitivity of detection, selected-
ion mode of data collection is often employed. This method offers high selectivity and
sensitivity (1 adduct/108 nucleotides) (Kaderlik et al., 1992). Unfortunately, the selected-ion
mode limits the structural data obtained for a peak and consequently cannot be used for the
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detection of unknown DNA adducts. Other drawbacks of this method include: 1) large
amounts of DNA are required for analysis; 2) that the DNA adduct under study must be
stable to enzymatic digestion or, commonly, acid treatment; 3) that the DNA be stable to
chemical derivatization; 4) that the derivatized DNA adduct be sufficiently volatile for gas
chromatography; and 5) the relatively high equipment cost.
v. Electrochemical Conductivity
Electrochemical conductivity involves the detection of voltage passed through a solution
(Dahmen, 1986). Therefore, electrical conductance is limited to determining the
concentration of chemicals capable of accepting an electrical charge. Since most carcinogen-
DNA adducts can not accept an electrical charge, the types of DNA adducts that can be
detected by this method are limited. In addition, one class of DNA adducts that can be
detected by this method, oxidized DNA bases, is commonly generated during DNA
extraction (Kasai et al., 1986). Therefore, the accurate quantitation of this adduct is
problematic.
vi. Atomic Absorbance Spectroscopy
Atomic absorbance spectroscopy is based on the absorbance of radiation by free atoms
released by high temperature combustion. The high temperatures of combustion limits this
technique to the detection of metal ions. While this assay is very sensitive for detecting
certain metals (1 adduct/107 nucleotides for 200tg of DNA) (Weston, 1993), the
determination of different metals requires different preparations and cannot be done
simultaneously. In addition, since the adduct is destroyed prior to detection by the high
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temperature of combustion, it is not possible with this method to determine the specific
adduct that was present. Consequently, this method is limited to detecting the total amount
of metal bound to a sample.
vii. 32P-postlabeling
32P-postlabeling involves enzymatic derivatization of nucleic acid monomer or
dinucleotide with a radioactive reagent, chromatographic separation of the derivatized
products, and then measurement of the radioactivity of the separated products. The protocol
originally developed for 32P-postlabeling involved 1) enzymatic digestion of DNA to
deoxynucleoside 3'-monophosphates; 2) enzymatic phosphorylation of the 5'-hydroxyl
group with [y- 32P]ATP; 3) chromatographic separation of the labeled products; and 4)
quantitation of adducts by measurement of radioactivity (Randerath et al., 1981; Gupta et
al., 1982). In order to increase the sensitivity of adduct measurement, the following
changes to the original 32 P-postlabeling protocol were made: 1) the use of high specific
activity [,y- 32P]ATP, ['y- 35S]ATP, or different ATP concentrations; 2) improved separation
of labeled unmodified nucleotides (the original separation technique used thin layer
chromatography, TLC); and 3) purification of adducts from hydrolyzed DNA before
postlabeling (Gorelick, 1993; Beach and Gupta, 1992; Randerath et al., 1985). With these
improvements, the sensitivity of the 32P-postlabeling method is between 1 adduct per 107 to
101° adducts/nucleotide using 1 to 10 /zg of DNA.
Although 32 P-postlabeling is widely used (Reddy et al., 1981; Reddy et al., 1984;
Randerath et al., 1981; Randerath et al., 1989; Lo et al., 1982; Haseltine et al., 1983), a
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variety of inherent methodological problems limits the usefulness of this technique. An
important limitation of the postlabeling method is that accurate quantitative and qualitative
measurements are achievable only if appropriate authentic adducts are available for use in
recovery determinations and as chromatographic standards. Results for a number of
different DNA adducts indicate that recoveries are variable and generally not quantitative.
For example, the overall adduct recovery, reported as the percentage of a known amount of
the adduct standard recovered as the 32P-labeled derivative, can vary from as high as 89-
92% for 06-methylguanine-DNA (Wilson et al., 1988) to as low as 10-15% for
fluoranthene-DNA (Gorelick and Wogan, 1989). An additional limitation to accurate
quantitation arises due to poor chromatography resulting in incomplete separation of
adducts. Even when adducts are separable, analysis of different chemically modified DNA
often shows one or more radiolabeled compound after chromatography, originally seen as
"spots" on TLC. Detected radioactivity does not always correspond to adducts; rather,
radioactivity may be associated with metabolites (Masento et al., 1989), naturally occurring
ribonucleotides (Beach and Gupta, 1992), and components extracted from polypropylene test
tubes (Beach and Gupta, 1992). Only by applying "correction" factors has this method
been useful for determining DNA adduct levels.
d. Summary
Analytical methods have been developed that are capable of detecting and quantifying
levels of covalent adducts of DNA. Unfortunately, the different methods have specific
advantages for the detection of only certain classes of DNA adducts. Human biomonitoring,
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however, requires a method that is sensitive enough to detect the effects of subtle, low-level
exposures to complex chemical mixtures of unknown composition. The following sections
discuss the validation of a new method of sufficient sensitivity and specificity to detect
ambient levels of DNA adducts.
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C. Design of Adduct Detection by Acylation with Methionine (ADAM)
a. Introduction
The features that we sought to incorporate into a new analytical procedure for detecting
carcinogen-DNA adducts included the following: 1) broad applicability to detect
carcinogens from diverse chemical classes; 2) sensitivity adequate to detect adduct levels
resulting from ambient exposures; 3) the ability to identify individual adducts as well as
mixtures resulting from complex exposures; 4) the potential for quantifying adduct recovery;
5) the ability to allow structural identification of specific carcinogen adducts; and 6) the
utilization of readily available reagents and equipment. A strategy under development in the
Wogan laboratory to fulfill these requirements involves the chemical acylation of
carcinogen-modified deoxynucleosides (Figure 1).
The following sections in this chapter examine the chemical basis for the peracylation
of nucleosides with BOC-methionine as a means to label carcinogen-DNA adducts. The first
section begins by examining the crucial labeling reagent, [35S]t-butoxycarbonyl-L-
methionine, N-hydroxysuccinimidyl ester ([35S]TBM-NHS). The second section examines
the advantages and possible disadvantages of methionine acylation of nucleosides as the
method of attaching a radioactive label. The particular points examined include: i) the
peracylation of nucleosides; ii) the synthesis of amino acid esters of ribonucleosides; iii) the
synthesis of amino acid esters of deoxynucleoside; and iv) the extent of methionine
racemization upon activation. The third section discusses carbodiimide activation. We have
experimentally established that the addition of diisopropylcarbodiimide to the acylation
procedure for pmol or less of nucleoside is necessary for good yields.
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Figure 1. Adduct Detection by Acylation with Methionine (ADAM). (1) R=H: dGuo,
R=ABP: dGuo-8-ABP, (2) TBM-NHS, (3) O-acyl-isourea-BOC-methionine, (4) BOC-
methionine, (5) mono-TBM acylation products, (6) bis-TBM acylation products, (7) tris-
TBM acylation products.
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i. Applications of [35S]TBM-NHS
[35S]TBM-NHS (also known as [35S]Sulphur labeling reagent, 35SLR) is sold by
Amersham as a general purpose 35S-labelling reagent. Amersham reports that the [35S]TBM-
NHS will react rapidly with E amino group of lysine and the x amino group of the N-
terminal amino acid of a polypeptide. Slower reaction is supposed to take place with the
thiol groups of cysteine, the indole groups of tryptophan, and the guanidyl group of
arginine, although no data are available from Amersham to support these product claims.
Because the [35S]TBM-NHS reagent has been commercially available for only a few
years, the number of literature examples where this reagent is used is limited (Boxberg,
1988; Stockes, 1986; Rabilloud and Therre, 1986). The first reported use of [35S]TBM-
NHS was as a protein labeling reagent (Rabilloud and Therre, 1986). The authors found
that labeling proteins with [35S]TBM-NHS was more sensitive than silver staining, a
common method for detecting proteins. The authors determined that as much as 106 cpm
could be incorporated into as little as 5 g of protein. Two years later, Boxberg confirmed
that [35 S]TBM-NHS was a sensitive means to detect proteins. Boxberg determined that the
[35S]TBM-NHS reagent increased the sensitivity of detection compared with silver staining
by 100-fold, allowing detection as little as 6 pg of protein.
In contrast to the random modification of proteins with [35S]TBM-NHS, Knaus et al.
(1992) showed that [35S]TBM-NHS can be used to synthesize a small [35S] radiolabeled
molecule. Knaus et al. reacted [35S]TBM-NHS with the alkyl amine, 1,4-dihydro-2,6-
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dimethyl-4-(2-trifluoromethylphenyl)-3,5-pyridine carboxylic acid 2-aminoethyl)ethyl ester in
ethyl acetate. The [35S] radiolabeled molecule, [35S]sadopine, was obtained in > 85 %
yield. Based on this result, we predicted that the reaction of [35S]TBM-NHS with amino
(and possibly hydroxyl groups) in a DNA adduct would be an effective method to radiolabel
a carcinogen-deoxynucleoside.
ii. Reagent choice
The [35S]t-butoxycarbonyl-L-methionine, N-hydroxysuccinimidyl ester ([35S]TBM-NHS)
(2) was postulated to be a useful labeling reagent for the detection of modified nucleosides
for six reasons. First, the acylation of nucleosides is a high yielding reaction (Schaller et
al., 1963). High yields are required in order to insure that the method being developed can
detect low levels of DNA modification. Second, a chemical acylation procedure would be
applicable for all chemical classes of adducts (both bulky and non-bulky) since it depends
only on the availability of free hydroxyl and/or amine groups on the nucleoside and/or
carcinogen moiety. Third, the 35S TBM-NHS reagent is commercially available at high
specific activity (> 1,000 Ci/mmol). For comparison, the highest commercial specific
activity for [32P]-ATP is 6,000 Ci/ mmol. Fourth, the long half-life of 35S (87.1 days) and
relatively low energy of radiation makes the 35S reagent easier to handle than a 32p
compound. In contrast to 32 p compounds that require shielding to prevent radiation
exposure to laboratory personnel, 35S compounds required no shielding for safe handling.
In addition, the low-energy emissions of 35S result in sharper autoradiographic bands
compared to those generated by 32p, allowing more resolution for the analysis of a two-
dimensional TLC, for instance. Fifth, the lower-energy emissions of 35S cause less
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radiolysis to occur. In practice, this means that 35S -reaction products can be stored at -20
'C for several weeks without significant degradation (Current Protocols in Molecular
Biology). Sixth, the 35S TBM-NHS reagent is not prone to racemization and is stable to a
variety of reaction conditions. The following section examines this last point in detail.
iii. Reagent Stability
A basic criterion for the ADAM procedure is that the acylation reaction should lead to
a single product. The fulfillment of this intention is endangered by the racemization of the
labeling reagent. The reversible loss and gain of the oe proton of an amino acid results in
the loss of chiral purity. Coupling of racemized amino acid with a chiral nucleoside results
in the formation of two diastereoisomers. Because the resulting diasteroisomers may result
in two chromatographically separable products, the quantitation and identification of the
acylation products would become more problematic. Fortunately, the alkoxycarbonyl
protected amino acids (eg. BOC-amino acids), except under very harsh conditions (Bailey
1990), do not racemize.
The BOC protecting group is stable to mild acid and base, oxidizing and reducing
reagents, and a variety of nucleophiles (Greene and Wuts, 1991). If the protecting group
employed to block the ao amino group were not stable to the acylation conditions, then the
activated methionine labeling reagent could react with itself forming polymethionine
polymers. Since the ADAM procedure does not need to manipulate the methionine labeling
reagent subsequent to acylation, the only requirement of a nitrogen protecting group is that
it be stable over time and to a variety of reaction conditions involving bases and
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temperature. Only under strongly acidic conditions (eg. treatment with trifluoroacetic acid)
is the BOC group removed (Bodanszky, 1993).
iv. Summary
[35S]TBM-NHS has been useful for the labeling of proteins and small molecules.
Although all of the literature examples of using [35S]TBM-NHS involve the labeling of an
amine, we postulated that this reagent could be used to acylate carcinogen-DNA adducts.
The chemical and physical properties that appear to be ideal for a labeling reagent for
carcinogen-DNA adducts include the easy of handling, the high specific activity, and the
chemical stability of the reagent. The following section discusses the rationale for expecting
the acylation of nucleosides with [35S]TBM-NHS to be a high yielding reaction.
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c. Acylation of Nucleosides
i. Peracylation of Nucleosides
Since the pioneering studies of Todd and coworkers (Hayes et al., 1954; Anderson et
al., 1954) on the acylation of deoxynucleosides, over thirty acyl groups have been shown to
react with the exocyclic amino groups of cytosine, adenine, and guanine (Beaucage and Iyer,
1992). In most cases, the acyl blocking groups were introduced by the peracylation of the
parent nucleoside. The yields for these procedures is generally good (> 70%) (Jones et al.,
1984). Therefore, the (per)acylation of deoxynucleosides would be an effective means of
attaching a radioactive or fluorescent probe suitable for subsequent detection and
quantitation.
ii. Acylamino esters of ribonucleosides
Particularly relevant to the development of a methionine acylation procedure involving
modified nucleosides are studies on the synthesis of acylamino acid esters of
ribonucleosides. Synthetic acylamino acid esters of ribonucleosides have been synthesized
and tested as substrates in order to understand the biochemistry of peptidyltransfer (Harris
and Symons, 1973; Krayevsky et al., 1975). The first synthetic method for the preparation
of 2'(3')-O-aminoacyl ribonucleoside 5'-phosphates was by Wieland and coworkers
(Wieland et al., 1958) (Figure 2A). Treatment of a ribonucleoside 5'-phosphate (pA, pG,
pC, and pU) with amino phenyl thioester hydrochlorides (or hydrobromides) afforded the
2'(3')-O-amino derivatives of the four common ribonucleoside 5'-phosphates. The
disadvantages of this method include the high temperatures <100 C required for reaction,
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Figure 2. Literature methods for the synthesis of O-acylamino acid esters of
ribonucleotides. A) acylation of pA with methionine phenyl thioester (Wieland et al.,
1958).
B) acylation of pA with N-benzyloxycarbonylglycine (CBZ-NH2C(OC2Hs)3 via a two step
acid catalyzed procedure (Zemlicka and Chladek, 1966)
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small yield of aminoacyl-nucleotides (2-17%), and the contamination of the aminoacyl-
nucleotides with a number of by-products.
One technique that is suitable only for glycine involves the trifluoroacetic acid
catalyzed coupling of N-benzyloxycarbonylglycine ethyl ortho ester with a variety of
ribonucleosides and ribonucleotides (Zemlicka and Chladek, 1966; Zemlicka and Chladek,
1968; Chladek and Zemlicka, 1968; Chladek and Zemlicka, 1967) (Figure 2B). The
product from acid catalyzed coupling was a cyclic 2',3' orthoester acylamino-nucleoside.
A second step was then required to hydrolyze the cyclic 2',3' orthoester acylamino-
nucleotide to the 2'(3') acylamino-nucleoside. The rather drastic conditions of condensation
(DMF with CF3COOH) and hydrolysis (80% acetic acid, 20 'C, 24 h) would racemize any
amino acid other than glycine.
An alternative method for the synthesis of 2'(3')-O-aminoacyl derivatives involves the
reaction of N-benyloxycarbonylamino anhydrides with 5' protected ribonucleotides
(Rammler and Khorana, 1963) (Figure 3A). The symmetrical N-benyloxycarbonyl-DL-
phenylalanine anhydride used in their study was prepared by carbodiimide activation.
Reaction of N-benyloxycarbonyl-DL-phenylalanine anhydride with 5'-O-trityl (or 5'-O-di-p-
methoxytrityl) ribonucleosides resulted in greater than 60% conversion to 2'(3')-O-
aminoacyl derivatives. However, because the anhydride used in the acylation procedure was
a racemate, it is uncertain whether any racemization occurred during the coupling step.
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One method that is useful for all amino acids and does not lead to racemization
involves the formation of BOC amino imidazole esters (Gottikh et al., 1970). Gottikh and
coworkers determined that BOC-amino imidazole ester can be synthesized from BOC amino
acids without racemization. Subsequent reaction of the BOC-amino imidazole esters with all
four ribonucleoside 5'-phosphates occurs in modest yields without racemization (Figure 3B).
The solvent medium providing the highest yield of BOC-amino acyl ribonucleoside esters
was determined by Gottikh et al., as a 5:1 mixture of water:DMF. Because the BOC-amino
acid imidazole ester was hydrolyzed to some extent by the water present, a ten-fold excess
of BOC-amino acid-imidazole to nucleotide was required for optimal yields (as high as 88%
for pU). For nucleotides soluble under completely anhydrous conditions, only a two-fold
excess of BOC-amino acid imidazole esters was required for the same yield.
Gottikh and coworkers additionally showed that the acylation products and yield
changed with the choice of solvent system (Gottikh et al., 1970). With pC, it was
demonstrated that if the content of strongly solvating aprotic solvents (Me2SO, DMF,
formamide, or pyridine) was increased to more than 30%, the reaction with BOC-amino
imidazole esters resulted mainly in acylation of the amino group of the cytidine residue. On
the other hand, if the content of weakly-solvating aprotic solvents (acetonitrile, THF,
acetone) was increased above 50%, the reaction of BOC-amino imidazole esters took place
only at the ribose hydroxyls. This result illustrates the importance of solvent choice when
attempting to per-acylate a deoxynucleoside.
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Seven years later, Azhayev et al. (1977) reported the same procedure but in larger
quantities than the small scale preparations of Gottikh et al. (1970) (Figure 3C). Azhayev et
al. additionally reported the acylation of ribonucleotides with BOC-methionine imidazole
ester and N-formyl-methionine imidazole ester. The extent of acylation with BOC-
methionine imidazole ester varied from as low as 22% yield for pC to 50 % yield with pU.
While Azhayev et al. found that no racemization occurred when preparing BOC-methionine
imidazole ester, differing degrees of racemization occurred with N-formyl-L-methionine with
three in situ carboxyl activating reagents. In the case of p-toluenesulfonyltriazole, no
racemization was observed. Partial racemization was encountered with
mesitylenesulfonyltriazole. In the case of dicyclohexylcarbodiimide (DCC), complete
racemization occurred. These results illustrate the importance of the ao amino protecting
group for preventing racemization of amino acids. In the procedure under development in
small yield of aminoacyl-nucleotides (2-17%), and the contamination of the aminoacyl-
nucleotides with a number of by-products.
iii. Acylamino esters of deoxynucleosides
In direct support of our postulation that amino acid acylation would be an effective
method to label modified deoxynucleosides, Sanda et al. (1987) and Hirohashi et al. (1987)
showed that a modified deoxynucleoside, 2'-deoxy-5-fluorouridine, could react with in situ
activated BOC-gly. Using DCC activation, 5' protected derivatives of 2'-deoxy-5-
fluorouridine were acylated with BOC-gly.
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Figure 3. Literature methods for the synthesis of O-acylamino acid esters of
ribonucleotides. A) acylation of 5'-O-di-p-methoxytrityl adenosine with N-
benyloxycarbonyl-DL-phenylalanine anhydride (Rammler and Khorana, 1963).
B) acylation of pA with BOC-alanine imidazole ester (Gottikh et al., 1970).
C) acylation of pA with BOC-methionine imidazole ester (Azhayev et al., 1977).
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iv. Summary
The acylation with an activated BOC-methionine derivative appears to be a facile
method of attaching a radiolabel to modified nucleosides based on three lines of research.
First, the work of Sanda et al. (1987) and Hirohashi et al. (1987) indicates that modified
deoxynucleosides can be acylated with a BOC protected amino acid. Second, the work by
Azahayev et al. (1977) indicates that imidazole activated BOC-methionine, in particular, can
serve as the acylating reagent. Third, Gottikh et al. (1970) found no racemization occurring
during activation or subsequent acylation of ribonucleosides with a BOC protected
methionine derivative. Based on these findings, we have proposed that the acylation of
modified deoxynucleosides with an appropriately activated BOC-methionine reagent,
[35S]TBM-NHS, will result in facile labeling.
In terms of developing a general method to label a wide variety of modified
deoxynucleosides, the study of Gottikh et al. indicates that solvent choice will be a crucial
factor to optimize. In particular, Gottikh et al. found that the site of reaction with
ribonucleosides changes with solvent conditions. Since we are attempting to peracylate
modified deoxynucleosides, a solvent that is ideal for acylation of exocyclic amino groups
and sugar hydroxyls simultaneously needs to be chosen.
d. Carbodiimide Activation
As was seen in the previous section, carbodiimide activation is a useful method to
activate amino acids for coupling to ribo- and deoxyribonucleosides. Carbodiimide
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activation can be used to prepare amino acid anhydrides (Rammler and Khorana, 1963) for
subsequent acylation of ribonucleotides or to activate amino acids in situ for reaction with
deoxynucleosides (Sanda et al., 1987; Hirohashi et al. 1987). The following section
examines the advantages and limitations of carbodiimide activation.
i. Formation of activated carbonyl
The introduction of carbodiimides (Sheehan and Hess, 1955; Khorana, 1953), DCC
and diisopropylcarbodiimide (DIC) as reagents for the formation of the peptide bond, was a
major improvement in the synthesis of peptides. The novel feature of these coupling
reagents was that they could be added to the mixture of the carboxyl and amine components.
With these reagents, carboxyl activation and coupling with the amine of another amino acid
proceed concurrently. The process of activation involves reaction of a carboxylic acid with
a carbodiimide to form an O-acylisourea. This product results from the attack of one of the
oxygens of the carboxylic acid onto the central carbon of the carbodiimide. This initial
attack is enhanced by protonation of one of the nitrogens of the carbodiimide N = C = N
bond. The carbonyl of the resulting O-acylisourea is then activated towards displacement by
hydroxyls and amines (Bodanszky, 1993). The O-acyl-isourea intermediate, in addition, is
somewhat basic thus increasing the reactivity of coupling via general base catalysis.
Subsequent to displacement by a nucleophile, the isourea rearranges to a urea
(dicyclohexylurea and diisopropylurea) which is a particularly stable molecule whose
formation is also a driving force for the reaction. In the case of carboxyl activation by
carbodiimides in the absence of a nucleophile, a second bond forming reaction occurs which
leads to the formation of symmetrical anhydrides (Schlusser and Zahn, 1962). As shown by
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the work of Rammler and Khorana (1963), symmetrical anhydrides are useful for acylation
of ribonucleotides.
ii. Drawbacks of carbodiimide activation
Carbodiimide couplings have four drawbacks. One drawback is that in certain
solvents, such as methylene chloride or acetonitrile, the acylurea formation is suppressed
(Sheehan et al., 1956). A second drawback of overactivation in the reactive intermediate is
the loss of chirality in the case of amino acid activation (Konig and Geiger, 1970;
Bodanszky, 1993). The extent of racemization increases with temperature and is more
pronounced in polar solvents such as DMF than in methylene chloride (Weyland et al.,
1963). A third drawback is that the nitrogen center of the N=C bond on the O-acylisoureas
competes with other nucleophiles for the acyl residue (Figure 4A). The rearrangement of
the intermediate O-acylisourea to produce N-acylureas, results in the loss of acylating amino
acid. A fourth drawback is that amines can react with carbodiimides to yield stable
guanidine derivatives under certain conditions (Figure 4B).
iii. Addition of auxiliary nucleophiles
Racemization, N-acylureas and guanidine formation can be suppressed by the addition
of auxiliary nucleophiles such as 1-hydroxybenzotriazole (HOBt) (Konig and Geiger, 1970)
or N-hydroxysuccinimide (NHS) (Wunsch and Dress, 1966; Zimmerman and Anderson,
1967). The HOBt or NHS can react with the carbodiimide or anhydride intermediates to
yield semi-stable HOBt or NHS esters. The presence of these nucleophiles in the reaction
mixture reduces the concentration of the O-acylisourea and thereby the extent of
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racemization. The resulting NHS ester are less reactive to nucleophilic displacement and, as
such, can be isolated and stored (Anderson et al., 1963). In the case of some NHS esters,
the material can be recrystallized from alcohol (Bodanszky and Ondetti, 1966). The slightly
acid nature of HOBt and NHS also prevent proton abstraction from the a carbon atom. In
the case of a chiral acid, such as an amino acid, these additives can thus contribute to the
conservation of chiral purity. Finally, the inclusion of HOBt or NHS in a DIC coupling
reaction efficiently shortens the lifetime of the overactivated O-acyl-isourea intermediate and
thus diminishes the extent of O-> N acyl migration leading to N-acylureas.
iv. Summary
Although carbodiimide activation has some drawbacks such as the potential to racemize
an amino acid substrate or to react unproductively, under optimal conditions carbodiimide
activation is an effective method of ester/amide bond formation.
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Figure 4. Side reactions involving DIC.
A. rearrangement of O-acylisourea to N-acylurea.
B. reaction of amine with carbodiimide
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D. Results and Discussion
a. Introduction
While a number of analytical methods can detect certain classes of DNA adducts, a
general, inexpensive method capable of detecting all classes of DNA adducts is not
available. Consequently, work was begun in the Wogan laboratory to develop a new
method for detecting DNA adducts. The approach taken was to develop optimal conditions
to peracylate nucleosides with [35S]TBM-NHS, an 35S labeling reagent previously used in the
detection of proteins. In support of our approach, a number of researchers have established
that ribonucleotides can be acylated in good yields with protected amino acids. A study by
Azhayev et al. (1977), in particular, showed that all four ribonucleotide 5'-phosphates can
be acylated with BOC-methionine imidazole ester in fair to good yields. Consequently, the
reaction of TBM-NHS with deoxynucleosides was envisioned be an effective method to label
carcinogen-DNA adducts.
As depicted in Figure 1, a mixture of products can result from the acylation of
deoxynucleosides. In order to simplify detection and quantitation, ideally only one product
should result from the acylation procedure. Therefore, efforts in the Wogan laboratory have
focused on developing conditions whereby all reactive sites on a carcinogen-DNA adduct are
acylated. In addition to simplifying detection and quantitation, peracylation would allow the
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attachment of more than one radiolabel to a target molecule. Consequently, the radioactive
signal for a peracylated molecule would be greater.
The following sections examine the development of optimal conditions to peracylate
dGuo and dGuo-8-ABP, a carcinogen-DNA adduct. Our studies began by examining the
peracylation of dGuo. It was postulated that the optimal reaction conditions developed for
the acylation of dGuo could then be applied to modified deoxynucleosides. In addition, the
physical characterization of dGuo would later help in understanding the NMR and other
physical characteristics of acylmethionyl-carcinogen-deoxynucleosides.
b. Deoxyguanosine Acylation
The following sections discuss the development of the optimal conditions for acylation
of dGuo with TBM. The first section compares the peracylation of mmol quantities of dGuo
with TBM by two methods: 1) reaction with TBM activated in situ with DIC; and 2)
reaction with activated TBM-NHS. The second section compares the conditions for the
peracylation of mmol quantities of dGuo with the conditions needed for the peracylation of
pmol (or less) quantities of dGuo. Finally, the third section discusses the characterization of
the acylation products.
i. Acylation dGuo with BOC-methionine and DIC
The first conditions chosen to peracylate dGuo involved in situ activation of TBM with
DIC using the conditions of Sanda et al. (1987) and Hirohashi et al. (1987). Under these
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conditions a mixture of products, as detected by TLC or HPLC, were obtained (Figure 5).
Conditions examined to force the reaction to a single product included time of reaction (4 to
14 hr), temperature (room to 70 C), ratio of reagents (5 to 10 fold excess BOC-Met and
DIC/dGuo), solvent (Me2SO, pyridine, THF), and addition of base (triethylamine) or
catalyst (DMAP). Optimal reaction conditions involved the reaction of dGuo (0.40 g, 1.40
mmol), BOC-Met (1.76 g, 7.07 mmol, 500 M%), DIC (1.00 ml, 6.43 mmol, 460 M%) and
DMAP (0.354 g, 2.90 mmol, 207 M%) in THF (20 ml) and Me2SO (2 ml) at 70 °C. The
reaction, as monitored by HPLC or TLC, showed only one product, peak 4, after 4 hr.
Peak 4 could be purified by normal phase silica chromatography in 97 % yield.
Crucial to forcing the reaction to one product was the choice of solvent and
temperature. When conducted at low temperature (room temperature to 50 C), the
acylation reaction yielded a mixture of peaks (starting material, peakl, peak 3 and peak 4).
By increasing the reaction temperature, a single product (peak 4) resulted within 4 hr.
However, unless a polar solvent such as Me2SO was added, the dGuo failed to dissolve and,
consequently, no reaction occurred. Unfortunately, the reaction in Me2SO was not effective
because of byproducts arising from the reaction of the DCC with the Me 2SO solvent
(March, 1985). A mixed solvent of pyridine and Me2SO was somewhat effective, but
consistently higher yields of recovered product occurred with THF and Me2SO as the
solvent.
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ii. Acylation of dGuo with TBM-NHS
Having developed optimal conditions for the acylation of dGuo with TBM activated in
situ, the same reaction conditions of solvent, time, and temperature were repeated with
TBM-NHS as the acylating species. As seen with in situ activated TBM, one major product
as detected by TLC or HPLC resulted after 4 hr. The same major product, peak 4, was
isolated in 94 % yield after chromatography. However, in addition to this major peak, a
minor less polar product, peak 5, was isolated in 2 % yield.
Based on the retention time peak 5 was proposed to result from additional acylation over
that found with peak 4. In an attempt to synthesize larger quantities of the material eluting
under peak 5, peak 4 was resubjected to acylation with TBM-NHS. Because of the
increased solubility of peak 4 in THF as compared to dGuo, Me2SO was not added as a
cosolvent. Peak 4 (1.35 g) was treated with TBM-NHS (0.95 g, 2.74 mmol) and DMAP
(0.21 g) in 15 ml THF and heated at 70 °C. No reaction occurred even after 24 hr at 70
°C as monitored by HPLC. Although conversion of peak 4 to peak 5 did not occur, peak 4
proved to be completely stable at 70 °C for prolonged time (24 hr).
iii. Acylation of [3H]dGuo with TBM-NHS
Under similar conditions of solvent, time, and temperature as developed for mmol scale
acylation of dGuo, experiments conducted by F. Sheabar with pmol or less of dGuo or
[3H]dGuo established that a similar elution profile resulted (Figure 5). Unfortunately, the
extent of conversion of dGuo to acylated products was not identical. In order to achieve the
same extent of conversion of dGuo to acylated dGuo products when conducted on pmol
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Figure 5. HPLC profile of TBM acylated products of A) dGuo and B) [3H]dGuo.
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scale conditions, three modifications of the reaction conditions were required which
included: 1) the amount of acylating reagent; 2) the requirement for DIC; and 3) the choice
of solvent.
A major difference between the acylation of pmol and mmol quantities of dGuo was the
amount of acylating reagent used. While only a 5 fold excess of acylating reagent was used
with mmol quantities of dGuo, over 104 molar equivalents were necessary to achieve the
same extent of acylation in the case of pmol quantities of [3H]dGuo. Complete acylation of
the [3H]dGuo did not occur with less than 5 x 104 molar equivalents.
A second difference between mmol and pmol acylation reactions was the requirement
for DIC, in the case of pmol reactions. In the case of mmol acylation of dGuo, DIC was
required only for the activation of unactivated TBM. In contrast, the extent of conversion
of pmol quantities of dGuo using TBM-NHS without DIC was only 19%. By including DIC
when TBM-NHS was used as the acylating reagent in pmol scale reactions, the extent of
acylation increased to 88 %.
The third difference between acylation of mmol and pmol quantities of dGuo was the
choice of solvent. In the case of mmol reactions, Me2SO was required to insure that the
dGuo dissolved. Because a 50 fold or greater dilution was used with pmol reactions, the
poor solubility of dGuo in THF was not a problem. Consequently, Me 2SO was not required
as a cosolvent for pmol reactions. However, the addition of a basic cosolvent did increase
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the extent of conversion for pmol reactions. Two solvents that have proved to be very
effective in increasing the yield are triethylamine and pyridine.
With these changes in the acylating conditions [TBM-NHS (2 x 104 molar equivalents),
DIC (1 pzl), THF (50 Al), and triethylamine (1 l) at 75 C for 2 hr], the acylation
efficiency for dGuo exceeded 90% as detected by radioactivity measurement. As was
determined for mmol scale acylation of dGuo, peak 4 was the major acylation product
accounting for 88% of the total radioactivity eluting under the peaks derived from acylation.
Subsequent experiments have demonstrated that the temperature used can be decreased to 37
°C by increasing the molar excess of TBM-NHS slightly and using pyridine instead of
triethylamine as a solvent. When acylation of pmol or smaller quantities of dGuo were
incubated for 2 hr at 37 C with TBM-NHS (5 x 104 molar equivalents), DIC (1 tl),
pyridine (50 l), and THF (50 Al), the conversion of starting nucleoside to acylated products
exceeded 95%. Similar to the mmol scale acylation of dGuo with TBM-NHS, the major
product was peak 4 in greater than 82% yield.
iv. Structure Determination of Acylation Products of dGuo
The structural identity of the acylation products (Figure 5, peaks 1 to 6) was
determined by UV, 3H radioactivity, liquid SIMS, FAB-MS, H NMR, and 13C NMR. The
first information used to assign to the structure of the TBM acylation products was UV
spectra. The UV spectrum of the acylation products (peaks 1-6), irrespective whether
conducted on mmol or pmol scale, revealed that the products all had UV absorption spectra
characteristic of guanine. In fact, the UV absorbance spectrum of peaks 1, 3, and 4 were
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almost identical (Figure 5, inset). The Xmax determined for all three products was 255 nm.
In contrast, a shift to 260 nm in the UV Xmax was observed for peaks 2, 5, and 6. In
addition, the shoulder seen at 270 nm for peaks 1, 3, and 4 became a distinctly separate
peak with X = 280 nm. This bathochromic shift, a shift to longer wavelengths, was
attributed to a change in electronic character of the purine ring. Since attachment of TBM
to the 5' or 3' hydroxyls would not be expected to change the UV absorbance spectra,
peaks 2, 5 and 6 were proposed to be substituted at the N2 position of the purine ring.
HPLC experiments conducted by F. Sheabar involving acylation of [3H]dGuo help to
establish that the products of acylation contained the deoxyribose portion of dGuo. As seen
in Figure 5, the products of acylation coeluted irrespective of the detection method (3H or
UV absorbance). This coelution meant that the products of acylation must have a purine
chromophore (for UV detection), a sugar (since the tritium in H]dGuo was in the 1' and
2' positions in the deoxyribose group of dGuo), and the methionine labeling reagent.
Assuming that no rearrangements took place, seven products would possible: three mono-
TBM-dGuo products (5'-; 3'- ; and N2-), three bis-TBM-dGuo products (5',3'-; 3',N2 -;
and 5',N2-), and one tris-TBM-dGuo product (5',3',N2-) (Figure 1).
Definitive proof for the extent of acylation for peaks 1 to 5 was obtained by mass
spectroscopy. In order to insure that the reaction products detected when conducted in pmol
and mmol scale were the same, peaks from both methods were collected and submitted for
mass spectroscopy using different instruments. Peaks 1 to 4 from a nmol scale reaction
were submitted for liquid SIMS using a two sector MAT 731 secondary ion mass
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spectrometer while peaks 1, 3, 4, and 5 from a mmol scale reaction were submitted for
FAB-MS using a Finnigan mass spectrometer. Mass spectra of the acylation products from
both methods and samples agreed with respect to the molecular weight of the parent ion. To
insure the identity of the products of acylation, the exact molecular weights were determined
for the parent ions of peaks 1, 3, 4, and 5.
The mass spectra of the polar acylation products, peaks 1 to 3, all showed parent
proton and sodium molecular ions of 499 and 521 m/z, respectively. The parent proton
molecular weight of 499 m/z corresponds to that of a mono-TBM-dGuo product (Figure 1,
R=H: 5a,b,c). In the case of peaks 1 and 3, the exact high resolution result (499.1972
and 499.1977, respectively) agreed with the expected exact molecular weight for [M+H]+
of 499.1975 for a mono-TBM-dGuo product. The fragmentation pattern for peaks 1 to 3,
unfortunately, did not allow unambiguous assignment as to which peak corresponded to the
5', 3' or N2 product. However, based on the bathochromic shift seen for peak 2, this
product was tentatively assigned as the N2-mono-TBM-dGuo product (Figure 1, R=H: 5c).
The mass spectrum determined for peak 4 showed a parent proton and sodium
molecular ions of 730 and 752 m/z, respectively. This parent proton molecular weight
corresponds to that of a bis-TBM-dGuo product (Figure 1, R=H: 6a,b,c). The exact high
resolution result (730.2909) additionally agreed with the expected exact molecular weight of
[M+H] + = 730.2904 for a bis-TBM-dGuo product. Since no bathochromic shift was seen
in the UV spectra of this acylation product, peak 4 was tentatively assigned as the 5',3'-bis-
TBM-dGuo product (Figure 1, R=H: 6a).
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Finally, the mass spectrum for peak 5 showed a parent proton and sodium molecular
ions of 961 and 983, respectively. This molecular weight corresponds to that of a tris-
TBM-dGuo product (Figure 1, R=H: 7). The exact high resolution result (961.3841)
additionally agreed with the expected exact molecular weight of [M+H]+ = 961.3833 for a
tris-TBM-dGuo product. In the case of this product, the molecular weight allowed us to
unambiguously assign this product as the product of acylation at the N2, 5', 3' positions of
dGuo (Figure 1, R=H: 7).
Confirmation of the regiochemical assignments peaks 1, 2, 3 and 4 depended on NMR.
In assigning the regiochemistry of the mono-TBM-dG and bis-TBM-dGuo products, the
chemical shifts of the H3', H5' protons and C3' and C5' carbons were used. The H
NMR of peak 1 showed a 0.6 ppm down field shift of the H5' signal relative to
underivatized dGuo. In contrast, the H NMR of peak 3 showed a 1 ppm down field shift
of the H3' proton. This down field shift in the 'H NMR were postulated to reflect the
attachment of an electron withdrawing group on the different hydroxyl groups of dGuo.
Therefore, peak 1 was tentatively assigned as the 5'-mono-TBM-dGuo product and peak 3
was tentatively assigned as the 3'-mono-TBM-dGuo product. The unambiguous assignment
of peaks 1 and 3 was accomplished with 13C NMR. The '3C NMR of peak 1 showed a 3
ppm down field shift of C5' carbon relative to dGuo, confirming the regiochemical
assignment of this peak as 5-TBM-dGuo. With peak 3, the C3', in contrast, shifted 5 ppm
down field relative to dGuo, confirming the regiochemical assignment of this peak as 3'-
TBM-dGuo.
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Based on the FAB-MS and the absence of a UV bathochromic shift, peak 4 had been
tentatively assigned as the 5',3'-bis-TBM-dGuo product (Figure 1, R=H: 6a). The H
NMR confirmed this product as a bis-TBM-dGuo product. In addition, the distinct chemical
shifts seen for BOC and thio methyl groups for the 5'-mono-TBM-dGuo (1.40 and 2.01
ppm, respectively) and the 3 '-mono-TBM-dGuo (1.45 and 2.10 ppm, respectively) products
were both seen in this sample (1.39, 1.44, 2.00, and 2.09 ppm). In addition, the H3'
signal seen for this product was identical to the chemical shift for H3' seen in the 3'-mon-
TBM-dGuo product; whereas, the H5' signal was identical to the chemical shift for the H5'
proton in the 5'-mono-TBM-dGuo product. This result strongly indicated that acylation had
taken place at both hydroxyls. Finally, 13C NMR confirmed this product as the 5',3'-bis-
TBM-dGuo product. Except for the tertiary carbon of the BOC group and the a carbon of
methionine, which were not separable at 300 MHz, all the 3C resonances expected for
5',3'-bis-TBM-dGuo product were seen.
In the case of peak 5, the earlier FAB-MS result indicated that this peak was a tris-
TBM-dGuo product. The 3C and 'H NMR confirmed this assignment. In the 'H NMR of
peak 5, the chemical shifts determined for the thiomethyl and BOC methyls were identical
with the resonances seen with the 5',3'-bis-TBM-dG product. The 13C chemical shifts for
the ribose portion of this molecule were similar to those seen for the 5',3'-TBM-dGuo
product, indicating attachment of TBM groups to both the 5' and 3' hydroxyls. However,
both the 3C and 'H NMR showed changes in the purine resonances that were not seen for
the 5', 3' and 5',3'-TBM-dG products. Specifically, a downfield shift of the H8 proton of
0.3 ppm occurred. In addition, the C6, C2, C4, C8 and C5 purine resonances that were
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almost identical in 5'-TBM-dG, 3'-TBM-dG, and 5,3'-bis-TBM-dG products shifted both
upfield and down field with this product. Based on the bathochromic shift and the shift in
the purine resonances in the '3C and '11H NMR, peak 5 was unambiguously assigned as the
5',3',N2-tris-TBM-dGuo product (Figure 1, R=H: 7).
In the case of peak 6, insufficient material was formed for unambiguous structural
determination. Based on the UV, 3H radioactivity, and relative retention time, this peak
was tentatively assigned as a bis-TBM-dGuo product (Figure 1, R=H: 6b, c).
v. Summary
Whether done on a mmol or pmol scale, dGuo was acylated in greater than 94% yield
with BOC-Met activated as an activated NHS ester or as an activated O-acylurea formed by
in situ with DIC. The optimal reaction conditions for mmol acylation involved using greater
than 500 M% of acylating reagent (TBM-NHS or BOC-Met + DIC), THF and Me2SO as a
solvents and heating at 70 C for 4 hr. The optimal conditions for pmol acylation involved
using TBM-NHS (5 x 104 molar equivalents), DIC (1 l), THF (50 Al), and pyridine (50 l)
at 37 C for 2 hr. Under nonoptimal conditions, a mixture of products, peaks 1-6, resulted.
Under optimized conditions, one major product, peak 4, resulted in both cases.
Structures of acylation products, peaks 1-5, were unambiguously assigned by UV,
FAB-MS, 1H and 13C NMR. Peaks 1-3 were determined to be mono-TBM-dGuo products:
5', N2, and 3', respectively. Peak 4, the major product of acylation under optimized
conditions, was determined to be the 5',3'-bis-TBM-dGuo product. Peak 5, a minor
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product formed under optimized conditions, was determined to be the N2,5',3'-tris-TBM-
dGuo product. The only peak not assigned was peak 6. Based on the retention time, this
peak probably corresponded to one of the two bis-TBM-dGuo products not assigned.
c. Acylation of a DNA Adduct
Using the optimal reaction conditions developed for dGuo, acylation was next tested
with a prototypical carcinogen-DNA adduct. In order to insure that the newly developed
method could peracylate all the reactive sites normally present on a deoxynucleoside, we
choose to study a DNA adduct that did not involve covalent attachment to exocyclic groups.
Having optimized acylation reaction conditions for dGuo, we chose to study a C8 guanine
adduct, N-(deoxyguanosin-8-yl)-4-aminobiphenyl (dGuo-8-ABP). The dGuo-8-ABP adduct
accounts for 80 % of the total ABP-DNA adducts resulting from exposure to 4-
aminobiphenyl, a known bladder carcinogen (Melick et al., 1955; Melick et al., 1971). The
biological importance of this DNA lesion is discussed in more detail in Chapter II of this
dissertation.
i. Synthesis of dGuo-8-ABP and [3H]dGuo-8-ABP
The carcinogen-DNA adduct, dGuo-8-ABP, was synthesized according to the procedure
of Famulok et al. (1989). In addition, in order to detect the dGuo-8-ABP and the TBM
acylation products when optimizing the acylation reaction in amounts insufficient to be
observed by UV absorption, the synthesis of a radiolabeled dGuo-8-ABP was required.
Three methods were examined to synthesize a tritium labeled carcinogen-nucleoside: 1) in
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vitro reaction of N-acetoxy-[ 3H]aminobiphenyl with dGuo; 2) in vitro reaction of N-acetoxy-
aminobiphenyl with [3H]dGuo; and 3) in vivo adduct formation with 4-[3H]aminobiphenyl.
The first method used to synthesize tritium labeled dGuo-8-ABP involved reaction of
N-acetoxy-[ 3H]aminobiphenyl with dGuo. The first step involved tritium labeling of 4-
nitrobiphenyl (8) according to Breeman et al. (1978) and Thissen et al. (1980). The 4-
[3 H]nitrobiphenyl (9) was then reduced with an ammonium sulfide solution to N-hydroxy-
[3 H]aminobiphenyl (10) according to the procedure by Lee and King (1981). Activated N-
acetoxy-[3H]aminobiphenyl (11) was prepared by reaction of the N-hydroxy-
[3H]aminobiphenyl (10) with acetylcyanide at -45 C. Unfortunately, as detected by HPLC,
subsequent reaction of the N-acetoxy-[ 3H]aminobiphenyl (11) with dGuo failed to yield dG-
8-[ 3H]ABP (12), reflecting the small extent of reaction (4 % yield) when only one equivalent
of N-acetoxy-aminobiphenyl is added to dGuo (Famulk et al., 1989).
Failure to synthesize dGuo-8-[ 3H]ABP through the above route led us to synthesize
[3H]dG-8-ABP (Figure 6b). The rationale for this approach was that synthesis of N-acetoxy-
aminobiphenyl could be done on a large scale as compared to limited quantities of N-
acetoxy-[ 3H]aminobiphenyl (11) that could be prepared. Consequently, the formation of
[3H]dGuo-8-ABP could be forced, in theory, to 100 % conversion by the addition of a very
large excess of N-acetoxy-aminobiphenyl to [3H]dGuo. The [3H]dGuo was prepared by F.
Sheabar by dephosphorylation of [3H]dGTP (0.323 nmol, 31 Ci/mmol) using calf intestinal
and bacterial alkaline phosphatases. The [3H]dGuo was then reacted with a large excess of
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N-acetoxy-4-aminobiphenyl (1 mmol). After 3.5 hr, additional N-acetoxy-aminobiphenyl (1
mmol) was added. The [3H]dGuo-8-ABP was isolated in 29% yield after chromatography.
In vivo adduct formation involved treating nine month old female Fischer rats with 4-
[3H]aminobiphenyl (5 mg, 200 mCi/mmol). 4-[3H]aminobiphenyl prepared by reduction of
commercially available 4-[3H]nitrobiphenyl with hydrazine and Pd/C. Treatment of animals
and isolation of carcinogen labeled DNA was done by F. Sheabar.
ii. Acylation of dGuo-8-ABP with TBM-NHS
Using the optimal ratio of reactants, solvent, time, and temperature conditions
developed for TBM-NHS acylation of mmol quantities of dGuo, acylation of dGuo-8-ABP
yielded a mixture of products after 4 hr (Figure 7). After adding additional TBM-NHS (810
M%), a major peak, peak 3, resulted after 3 hr additional incubation. Peak 3 was isolated
in 88 % yield after silica gel chromatography. When monitored by normal phase-HPLC,
peak 2 was found to consist of two products. Synthetic standards of these two products of
peak 2 were synthesized by using less TBM-NHS (400 M%) and lowering the temperature
to 50 C. In order to synthesize a large quantity of peak 4 for structural characterization,
acylation of dGuo-8-ABP was done with a very large excess of TBM-NHS (730 M%) with
only a minimum of solvent [Me 2SO (100 /l) and triethylamine (100 1l)]. Triethylamine was
specifically included in this reaction in order to increase the nucleophilicity of the N2 amino
group by general base catalysis. Under these conditions, the reaction still produced a
mixture of peaks 3 and 4.
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Figure 6. Synthesis of tritium labeled dGuo-8-ABP.
A) Synthesis of dGuo-8-[3H]ABP.
B) Synthesis of [3H]dGuo-8-ABP.
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iii. Acylation of [3H]dGuo-8-ABP with TBM-NHS
As was the case with the acylation of pmol quantities of dGuo, optimal acylation
conditions developed for mmol quantities were not ideal for the acylation of pmol quantities
of dGuo-8-ABP. Under non-optimal conditions, a mixture of products resulted (Figure 7).
However, if the optimal conditions developed for the acylation of pmol quantities of
[3H]dGuo were used, the extent of acylation was greater than 95 % (F. Sheabar, personal
communication). The major acylation product was peak 4, representing greater than 80 %
of acylated products.
iv. Acylation of [3H]dGuo-8-ABP with [3SS]TBM-NHS
Having developed optimal conditions to acylate a DNA adduct in pmol scale, the
acylation procedure was repeated with the crucial 35S labeling reagent, [35 S]TBM-NHS. As
depicted in Figure 7, the acylation profile obtained with [35S]TBM-NHS is identical to the
acylation profile when conducted with TBM-NHS. It was necessary to demonstrate a linear
relationship between the amount of adduct subjected to the acylation reaction and the 35S
incorporated into the acylated products (Sheabar et al., 1994). In a series of experiments
conducted by F. Sheabar, [3H]dGuo-8-ABP (10 fmol to 30.6 pmol) was acylated with [35S]
TBM-NHS and the incorporation of 35S was determined. As required for our method, the
amount of 35S incorporated in the acylated products was linearly (r = 0.992) related to the
amount of adduct reacted. A linear relationship (r = 0.971) also existed between the
amount of dGuo-8-[ 3H]ABP isolated from rat liver DNA (formed as the result of treatment
of female Fischer rats with 4-[3H]aminobiphenyl) introduced into the acylation reaction and
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Figure 7. HPLC profile of TBM-acylated products of dGuo-8-ABP.
69
1- - i I I I I I
dGuo-8-[3H]ABP
[3H]dGuo-8-ABP
TrnA 1_,.- rulA rD
I DIVI-U UU-O-LnjDr-
1.5
06 4
x x
0.
0 50 90
TBM-[3H]dGuo-8-ABP
0 10 20 30 40 50 60
Time (min)
TBM-dGuo-8-ABP
1
3
4
It2 
-80 '"
) o
240 280 320 360
Wavelength (nm)
t 1)
(2)
(3)
(4)
70
A7.27
Co
.
7.80
6To X
0-
,C"
3.80
C\
I x0
Cr)
- E0-
,C
b
I x
C-oo.
100 - E
II ~ ~
50-
E
I I I I Il l I I I I
0 10 20 30 40 50 60
Time (min)
AMA -- - -
w--
-
B 1
O-A~ -A- --- .
I I I I I I
I
.
.
_- ~~ - --
I
I
I
,. Ibj
the amount of 35S in the acylated products over the range of 10 fmol to 7.8 pmol (Sheabar et
al., 1994).
v. Structure Determination of Acylation Products of dGuo-8-ABP
Structural information concerning the acylated products of dGuo-8-ABP was obtained
as described above for dGuo. Similar to the results obtained for the TBM-acylated products
of dGuo, the UV spectra of the TBM acylation products of dGuo-8-ABP were similar,
whether conducted on mmol or pmol scale. In the case of the underivatized dGuo-8-ABP,
peak 1, or TBM-acylated dGuo-8-ABP, peaks 2 and 3, the the UV absorbance spectra were
identical (Figure 7). However, in the case of peak 4, the X. shifted from 300 nm to 310
nm and the guanine absorbance at 254 nm shifted to 274 nm. Based on this bathochromic
shift, peak 4 was tentatively assigned as a product resulting from acylation of the N2 amino
group.
TBM acylation and chromatographic separation of different 3H labeled dGuo-8-
ABP adducts confirmed that the nucleoside remained intact to the acylation procedure. As
seen in Figure 7, dGuo-8-rH]ABP (containing 3H in the ABP moiety) and [3H]dGuo-8-ABP
(containing 3H in the deoxyribose), as detected by 3H radioactivity, coeluted with the
acylation products of dGuo-8-ABP, as detected by UV absorbance. Furthermore, when
[35S]TBM-NHS was used instead of TBM-NHS, the products of acylation again coeluted as
determined by 35S radioactivity. This data indicated that the products of acylation retained
all three structural components of the adduct: the sugar H in the 1'- and 2'- positions in
the sugar moiety of dGuo), the guanine base (UV spectrum), the carcinogen (UV spectrum
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and 3H in the 4-ABP) (Figure 7C, D and E), and the methionine labeling reagent (35S in the
methionine). Under normal phase chromatography, it was subsequently determined that
peak 2 was not homogeneous. The two fractions were attributed to regioisomers of the
TBM group.
Preliminary characterization of the acylation products of dGuo-8-ABP was obtained by
mass spectroscopy. Based on the FAB-MS and liquid SIMS data, peaks 2, 3 and 4 were
unambiguously assigned as mono-, bis- and tris-acylated dGuo-8-ABP products,
respectively. As was done with the dGuo acylation products, material made in mmol
quantities was examined by FAB-MS whereas material made in nmol quantities was
examined by liquid SIMS. The same [M+H]+ peak was obtained for coeluting material by
both methods. In the case of the two fractions of peak 2, the same parent molecular ion of
666 m/z was determined. This molecular weight corresponded to that of a mono-TBM-
dGuo-8-ABP products (Figure 1, R = 4-ABP: 5a,b,c). Determination of the high
resolution molecular weight of the proton molecular ion for the more polar and less polar
fractions of peak 2 (666.2714 and 666.2707, respectively) confirmed that the two fractions
were both mono-TBM-dGuo-8-ABP products (expected exact molecular weight 666.2710).
In contrast to peak 2, peaks 3 and 4 appear to be homogenous by normal and reversed
phased HPLC using different gradients. The proton molecular ion detected for peak 3 by
both means of mass spectroscopy was 897 m/z, corresponding to the m/z of bis-TBM-dGuo-
8-ABP product (Figure 1, R = 4-ABP: 6a,b,c). The exact high resolution result
determined for the proton molecular ion (897.3635) agreed with the expected exact
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molecular weight for [M+H] + = 897.3639. Finally, in the case of peak 4, the proton
molecular ion of 1128 m/z for a tris-TBM-dGuo-8-ABP product was detected (Figure 1,
R=ABP: 7). The exact high resolution result (1128.4577) agreed with the expected
molecular weight for [M+H] + = 1128.4568.
The regiochemical assignment for peaks 2, 3, and 4 was again based on H and 13C
NMR. As was done for the TBM-dGuo products, the H3' and H5' protons were used to
assign regiochemistry. In the case of the more polar fraction of peak 2, the H5' protons
shifted 0.5 ppm downfield without a corresponding change in the chemical shift for the H3'
ribose protons. In the case of the other fraction, the H3' proton shifted 0.9 ppm downfield
without a change in the chemical shift of the H5' protons. Consequently, the more polar
fraction was tentatively assigned as the 5'-TBM-dGuo-8-ABP product (Figure 1, R=ABP:
5a) and the less polar component of peak 2 as the 3'-TBM-dGuo-8-ABP product (Figure 1,
R=ABP: 5b). Comparison of the 13C NMR of these two compounds confirmed the
assignment made by H NMR. All the carbon resonances of these two acylation products
were identical except for changes in the C3' and C5' signals. In the case of the more polar
fraction of peak 2, a downfield chemical shift of 3 ppm for C5' occurred. In contrast, in
the case of the less polar fraction, a downfield chemical shift of 4.5 ppm for C3' occurred.
Based on the chemical shifts of the C5' and C3' resonances as compared to the
underivatized dGuo-8-ABP, the two components of peak 2 were definitely assigned as the
5'-TBM-dGuo-8-ABP product (most polar fraction) and 3'-TBM-dGuo-8-ABP product (the
next fraction).
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In the case of peak 3, liquid SIMS and FAB-MS indicated that this peak corresponded
to a bis-TBM-dGuo-8-ABP product. H and 13C NMR confirmed the mass spectrocopy
structural assignment and allowed the regiochemistry to be assigned. The '3C NMR of this
acylation product showed a 2 ppm downfield shift for both C5' and C3'. Similarly, the H
NMR showed downfield shift in both the H5' and H3' protons. Based on the absence of a
UV bathochromic shift and the downfield shifts seen in both the 'H and '3C NMR, peak 3
was determined to be the 5',3 '-bis-TBM-dGuo-8-ABP product (Figure 1, R=ABP: 6a).
In the case of peak 4, the liquid SIMS, FAB-MS, H and 13C NMR all indicated that
this peak was a tri-acylated product. As described earlier, the UV spectra of this material
also showed a bathochromic shift. Based on our study of N2,5',3'-TBM-dGuo, the
bathochromic shift reflected the attachment of a TBM group to the purine ring. As was the
case with N2,5',3'-TBM-dGuo, the 13C NMR showed upfield and downfield shifts for the
purine carbon resonances. However, peak 4 could not be unambiguously assigned as the
N2 ,5',3'-tris-TBM-dGuo-8-ABP product (Figure 1, R=ABP: 7) because an additional
reactive site is present in this molecule, i.e., a secondary amine between the ABP and
guanine moieties. Based on the steric size of TBM-NHS and the sterically crowded nature
of this site of reaction, we have tentatively assigned this product as the N2 ,5',3'-tris-TBM-
dGuo-8-ABP product (Figure 1, R=ABP: 7).
vi. Summary
Under nonoptimal conditions, the acylation of dGuo-8-ABP with TBM-NHS resulted in
a mixture of unacylated starting material (peak 1) and acylated products (peaks 2,3,and 4)
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(Figure 7). Under optimized mmol conditions, the peracylation of dGuo-8-ABP occurred in
greater than 88% yield. The major product was peak 3. In contrast, acylation of pmol
quantities using TBM-NHS (5 x 104 molar equivalents), DIC (1 Al), THF (50 Al) and
pyridine (50 Al) at 37 C for 2 hr, the acylation efficiency was greater than 95 % with the
major product, peak 4, accounting for greater than 80 % of the acylation products.
The acylation products, peaks 2, 3 and 4, were unambiguously assigned by UV, liquid
SIMS, FAB-MS, 3H, 35S, 'H, 13C NMR. Peak 2 was determined to consist of two products,
5'-mono-TBM-dGuo-8-ABP and 3'-mono-TBM-dGuo-8-ABP. Peak 3, the major peak
under mmol conditions, was determined to be 5',3'-bis-TBM-dGuo-8-ABP. Peak 4, the
major product under pmol conditions, was determined to be N2 ,5',3 '-tris-TBM-dGuo-8-
ABP.
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E. Conclusions
My efforts in the Wogan lab form the basis for a new method for the detection of
carcinogen-DNA adducts. The method we have termed adduct detection by acylation with
methionine, ADAM. The new method involves the chemical derivatization of
deoxynucleosides with [35S]TBM-NHS, subsequent separation of acylation products by
HPLC, and quantification of the products by radioactivity. The chemical acylation of dGuo
and dGuo-8-ABP was studied in detail in order to establish optimal reaction conditions;
conditions for chromatographic separation of the reaction products; and the structural and
regiochemical identity of all the reaction products formed during acylation. Under
optimized reaction conditions, a major product (greater than 88% isolated yield after
chromatography) resulted from the TBM acylation of dGuo and dGuo-8-ABP.
The chemical identities of products of TBM acylation were determined through the use
of liquid SIMS, FAB-MS, UV, 3H and 35S radioactivity, H and 3C NMR. The
regiochemical identities of peaks 1-5 (Figure 5) resulting from the TBM acylation of dGuo
were 5'-mono-TBM-dGuo; N2 -mono-TBM-dGuo; 3'-mono-TBM-dGuo; 5',3'-bis-TBM-
dGuo; and N2,5',3 '-tris-TBM-dGuo, respectively. The regiochemical identities of peaks 2-
4 (Figure 7) resulting from reaction of the TBM acylation of dGuo-8-ABP were 5'-mono-
TBM-dGuo-8-ABP; 3'-mono-TBM-dGuo-8-ABP; 5',3'-bis-TBM-dGuo-8-ABP; and
N2,5',3 '-tris-TBM-dGuo-8-ABP, respectively. It is interesting to note that the relative
elution order of the acylation products of dGuo and dGuo-8-ABP by RP-HPLC was the
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same. In addition, this relative order of elution did not change when the chromatography
was done under normal phase conditions.
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F. Future Work
One important advantage we foresee for the ADAM procedure over all the methods
currently available is the ability to compare total chemical exposure and specific chemical
exposure. As depicted in Figure 8, by changing the method for adducted nucleoside
purification, different acylated products can be analyzed. For example, in order to
determine total adduct levels, adducted nucleosides would be acylated as a mixture of
adducts. After HPLC separation of the acylation products, the total adduct level can be
determined. In parallel, specific carcinogen adducts could be purified by employing
immunoaffinity purification with monoclonal antibodies, when available, to separate a
particular adduct of interest.
Possible changes to improve the ability of the ADAM procedure to detect chemical
damage include the labeling of 5'-mononucleotides and/or the labeling of DNA base
fragments. One of the biggest problems for the accurate quantification of DNA adducts by
ADAM is the possibile occurrence of multiple products. As was seen with dGuo and dGuo-
8-ABP, the amount of reaction with exocyclic amino groups can vary dramatically
depending on the chemical modification. Khorana and coworkers, however, found that
acetylation of the N2 amino group with acetic anhydride occurred quantitatively in the case
of pyridinium deoxyguanosine-5 '-phosphate (Ralph et al., 1963). The authors proposed that
the acetylation of the exocyclic amino group in this nucleotide occurred faster than that in
deoxyguanosine due to the intramolecular transfer of the acetyl group from the acetyl
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phosphate mixed anhydride. Therefore, the acylation of 5'-monophosphates might be a way
to increase the extent of acylation of exocyclic amino groups and lead to the formation of
only one product from TBM acylation. An alternative change to improve the detection of
DNA adducts would involve the labeling of DNA base fragments instead of carcinogen-
deoxynucleosides adducts. This change might be necessitated due to the instability of some
DNA adducts to the acylation procedure or by the desire to examine excision repair products
from in urine, for example. In either case, as long as the carcinogen-base fragment has
hydroxyl or amine groups, reaction of [35S]TBM-NHS should be an effective means tof
detection.
As an appendum to this last point, the ADAM procedure should be useful for the
detection of carcinogen derivatives other than DNA adducts. Chemical acylation with
[35S]TBM-NHS of carcinogens, their metabolites, and/or derivatives in body fluids or
excreta would be possible as long as hydroxyl, amine, and possibly thiol groups are present
on the molecule of interest. One class of damage, in particular, that would be suitable for
detection would be protein-carcinogen adducts. Subsequent to enzymatic hydrolysis,
reaction with TBM-NHS with a carcinogen-amino acid adduct via the a amino group of the
amino acid or hydroxyl or amines present on either the amino acid or carcinogen moiety
should be an effective method to measure this type of chemical damage. By using a similar
procedure as depicted in Figure 8, the total protein adducts and specific adduct exposure
could be determined.
79
Figure 8. Flow diagram for carcinogen-nucleoside adduct detection by acylation with
methionine.
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G. Experimental
a. General Procedures and Materials
Unless otherwise indicated, all reagents and solvents were used as obtained without
further purification. The following solvents were purified as follows: THF and CH2C12
were distilled from CaH2 and pyridine and triethylamine was distilled from sodium.
Chemicals were purchased as follows: dGuo from Sigma Chemical Co.; 4-aminobiphenyl
and DIC from Aldrich Chemical Co.; 2'-deoxy-1',2 '-[3 H]guanosine 5'-triphosphate
([3H]dGTP) (31-37 Ci/mmol) from Amersham Co.; alkaline phosphatase from calf intestine
from Boehringer Manheim Co.; TBM-NHS from Accurate Chemicals and Scientific Corp.
and Fluka Chemical Corp.; triethylamine from Fluka Chemical Corp. Authentic standards
of N-(deoxyguanosin-8-yl)-4-aminobiphenyl (dGuo-8-ABP) and N-(deoxyguanosin-8-yl)-4-
[3H]aminobiphenyl (dGuo-8-[3H]ABP) were gifts from Dr. F. Kadlubar, National Center for
Toxicological Research, Jefferson, Arkansas. Silica gel TLC plates were visualized with
UV illumination followed by charring with 5 % anisaldehyde in (95:5:1) EtOH-AcOH-
H2 SO4. Silica gel (230-400 mesh) was used for normal phase chromatographic separations.
All reactions were performed under an argon atmosphere except when working in aqueous
media.
Liquid secondary ion mass spectroscopy was obtained with a two sector MAT 731
secondary ion mass spectrometer combined with a Teknivent Vector/One workstation. Fast
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atom bombardment (FAB-MS) was obtained with a Finnigan 8200 mass spectrometer. 2-
nitrobenzyl alcohol (NBA) was used as the matrix for both methods. High-resolution mass
spectral (HRMS) data are reported in units of m/z for M+ or the highest mass fragment
derived from M +. H and 13C NMR were recorded on Varian VXR-300, VXR-301, or
Bruker AC-250 MHz spectrometers. Chemical shifts for H and '3C are expressed in parts
per million downfield from CDC13 (7.24 ppm or 77.00 ppm) or CD3OD (3.30 and 35.00
ppm), respectively. Data are reported as follows: chemical shift, integration, multiplicity,
and assignment.
Reversed phase HPLC analyses were performed on a Hewlett Packard model 1090 M
liquid chromatograph equipped with a photodiode array detector, Radiomatic flow-through
radioactivity detector model A250 and Microsorb 5/z C18 column (Rainin Instruments Co.)
or with a Beckman 114M solvent delivery system with Beckman 421A controller with
Hewlett Packard model 1040A photodiode array detector and either a Beckman C 8
ultrasphere column or Si ultrasil column. Gradient I: a linear gradient of 30-70%
acetonitrile in 0.1 M ammonium acetate over 20 min, 70-100% acetonitrile over 2 min and
100% acetonitrile over 7 min; gradient II: a linear gradient of 0-10 % acetonitrile in 0.1 M
ammonium acetate over 30 min and 10-50 % over 30 min; gradient III: isocratic elution
with 40 % methanol/H 20 over 13 min, a linear gradient of 40-60 % over 10 min, isocratic
elution with 60 % over 12 min, a linear gradient of 60-100 % over 20 min and isocratic
elution with 100% methanol over 25 min; gradient IV: isocratic elution with 100 % CH 2C12
for 5 min and then linear gradient of 100 % to 75 % CH2CL2 /methanol over 30 min. Flow
rate was 1 mL per min for all gradients and the column temperature was 35 C.
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b. Methods
Synthesis of mono-TBM-dGuo with TBM-NHS
dGuo (1.74 g, 6.10 mmol), TBM-NHS (2.10 g 6.06 mmol, 100 M%), and DMAP (0.52 g)
were suspended in THF (20 ml) and Me2SO (2 ml) and heated (70 'C). After 20 min, the
reaction became clear. After 4 hr with heat, the reaction was concentrated to near dryness
and the residue redissolved in CH2C12 (100 ml) and washed with NaHCO3 (sat) (100 ml) and
NaCl(sat) (100 ml). The organic solution was dried with Na2SO4, filtered and concentrated.
The 5'-TBM-dGuo-8-ABP and 3'-TBM-dGuo-8-ABP were separated by silica gel
chromatography (100 g) sequentially eluting with CH 2C12/MeOH (96:4), CH2Cl2/MeOH
(92:8), and CH2C12/MeOH (88:12). The major product isolated was 5 '-TBM-dGuo, although
most or the starting material had not reacted. Small amounts of 3'-TBM-dGuo and 5',3'-
TBM-dGuo were isolated. The mono-TBM products were repurified with an isocratic
gradient of 50% MeOH/Water on a Vydac C18 preparative column using a Waters Model
590 pump at 16 ml/min with a Waters 484 Tunable Absorbance Detector set at 254 nm.
5'-t-BOC-methionine-2 '-deoxyguanosine ester (5'-TBM-dGuo) (rf 0.50 CH2C12/MeOH
85:15). 'H NMR (CD3OD): 7.87 (1H, s, H8), 6.26 (1H, t, Hi'), 4.1-4.5 (5H, m,
H3',H4',H5', Ha Met), 2.75 (1H, m, H2'), 2.39-2.53 (3H, m, H2', H3 Met), 2.01 (3H,
s, CH 3S), 1.8-2.0 (2H, m, HX Met), 1.40 (9H, s, BOC).13C NMR (CD 3OD): 174.32 (C1,
Met), 159.95 (C6), 159.88 (BOC), 155.42 (C2), 153.06 (C4), 138.05 (C8), 118.27 (C5),
86.13 (C1'), 85.80 (C4'), 81.06 (OC(CH3)3), 72.97 (C3'), 66.44 (C5'), 54.37 (Ca Met),
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40.74 (C2'), 32.33 (Cx Met), 31.31 (CO Met), 29.05 (C(CH3)3), 15.53 (CH3S). FAB-MS
expected exact molecular weight for [M+H] + 449.19750, high resolution result 499.1972.
Xmax =255 nm (methanol)
3'-t-BOC-methionine-2 '-deoxyguanosine ester (3'-TBM-dGuo) (rf 0.64 CH 2Cl2/MeOH
85:15) 'H NMR (CD 3OD): 7.95 (1H, s, H8), 6.26 (1H, dd, H1'), 5.47 (1H, d, H3'), 4.30
(1H, dd, Ha Met ), 4.15 (1H,d, H4'), 3.81 (2H, d, H5'), 2.91 (1H, m, H2'), 2.49-2.63
(3H, m, H2', HB Met), 2.10 (3H, s, CH3S), 1.97-2.08 (2H, m, HX Met), 1.45 (9H, s,
BOC).13 C NMR (CD 3OD): 173.45 (C1, Met), 159.95 (C6), 159.07 (BOC), 155.42 (C2),
152.15(C4), 138.09 (C8), 118.21 (C5), 87.03 (Cl'), 86.25 (C4'), 80.72 (OC(CH3)3), 77.62
(C3'), 66.44 (C5'), 54.10 (Ca Met), 38.57 (C2'), 31.82 (Cx Met), 31.25 (CO Met), 28.74
(C(CH3)3), 15.35 (CH3S). FAB-MS expected exact molecular weight for [M+H]+
449.19750, high resolution result 499.1977. Xmax =255 nm (methanol)
Synthesis of bis-TBM-dGuo and tris-TBM-dGuo with TBM-NHS
dGuo (0.40 g, 1.40 mmol), TBM-NHS (2.60 g 7.51 mmol, 540 M%), and DMAP (0.343 g,
2.81 mmol, 200 M%) were suspended in THF (20 ml) and Me2SO (2 ml) and heated (70
°C). After 4 hr, the reaction was concentrated to near dryness and the residue redissolved
in CH 2C12 (100 ml) and washed with NaHCO3 (sat) (100 ml) and NaCl(sat) (100 ml). The
organic solution was dried with Na2SO4, filtered and concentrated. The bis-TBM-dGuo-8-
ABP and tris-TBM-dGuo-8-ABP were separated by silica gel chromatography (100 g)
sequentially eluting with CH2Cl2/MeOH (96:4), CH2C12/MeOH (92:8), and CH2Cl2/MeOH
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(88:12). The major product isolated was 5',3'-bis-TBM-dG (0.96 g 1.32 mmol 94% yield)
with a negligible amount of the N2 ,5',3 '-tris-TBM-dG product (4 mg, 2% yield). The bis-
and tris-TBM products were repurified with an isocratic gradient of 75 % and 85 %
MeOH/Water, respectively, on a Vydac C 8,, preparative column using a Waters Model 590
pump at 16 ml/min with a Waters 484 Tunable Absorbance Detector set at 254 nm.
5', 3 '-t-BOC-methionine-2 '-deoxyguanosine diester (5' ,3 '-bis-TBM-dGuo) (rf 0.50
CH2Cl2/MeOH 90:10) 'H NMR (CD3OD): 7.87 (1H, s, H8), 6.27 (1H, t, Hi'), 5.46 (1H,
m, H3'), 4.25-4.49 (5H, m, Hac Met, H4', H5'), 3.29 (1H, m, H2'), 2.44-2.65 (5H, m,
H2', Ho Met), 2.09 (3H, s, CH 3S), 2.00 (3H, s, CH 3S), 1.87-2.08 (4H, m, Hx Met), 1.44
(9H, s, BOC), 1.39 (9H, s, BOC).' 3C NMR (CDCl3): 172.33 (C1, Met), 171.90 (C1,
Met), 159.00 (C6), 155.51 (BOC), 153.78 (C2), 151.26 (C4), 136.35 (C8), 117.65 (C5),
84.55 (C1'), 82.07 (C4'), 80.31 (OC(CH3)3), 80.18 (OC(CH 3)3), 75.86 (C3'), 64.64 (C5'),
52.83 (Ca Met), 36.62 (C2'), 31.70 (Cx Met), 31.56 (Cx Met), 30.12 (CB Met), 30.01
(Col Met), 28.63 (C(CH3)3), 28.34 (C(CH3)3), 15.59 (CH 3S), 15.40 (CH3S). FAB-MS
expected exact molecular weight for [M +H] + 730.29041, high resolution result 730.2909.
Xmx =255 nm (methanol)
N2, 5', 3 '-t-BOC-methionine-2 '-deoxyguanosine triester (N2, 5', 3 '-tris-TBM-dGuo) (rf
0.75 CH2Cl2/MeOH 90: 10) 'H NMR (CD3OD): 8.12 (1H, s, H8), 6.36 (1H, t, Hi'), 5.46
(1H, m, H3'), 4.23-4.39 (6H, m, Hao Met, H4', H5'), 3.30 (1H, m, H2'), 2.44-2.70 (7H,
m, H2', Ho Met), 2.11 (3H, s, CH 3S), 2.00 (3H, s, CH 3S), 1.87-2.15 (6H, m, Hx Met),
1.45 (9H, s, BOC), 1.39 (9H, s, BOC).' 3C NMR (CDCl3): 176.79 (C1, Met), 173.90 (C1,
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Met), 173.63 (C1, Met), 158.18 (C6), 158.11 (BOC) (2 signals), 157.98 (BOC), 157.40
(BOC), 150.02 (C2), 149.15 (C4), 140.10 (C8), 122.20 (C5), 86.44 (Cl'), 83.70 (C4'),
81.05 (OC(CH3)3), 80.82 (OC(CH3)3), 80.76 (OC(CH3)3), 76.79 (C3'), 65.66 (C5 ), 56.08
(Ca Met), 55.96 (Cca Met), 54.05 (Coa Met), 37.50 (C2'), 32.39 (Cx Met), 32.02 (Cx
Met), 31.78 (Cx Met), 31.23 (Co Met), 31.15 (Co3 Met), 31.02 (CO3 Met), 28.73
(C(CH3)3), 15.37 (CH3S), 15.20 (CH3S). FAB-MS expected exact molecular weight for
[M+H] + 961.38333, high resolution result 961.3841. Xmax =260 nm, X=280 nm
(methanol)
Synthesis of bis-TBM-dG with BOC-Met and DIC
dGuo (0.40 g, 1.40 mmol), BOC-Met (1.76 g, 7.07 mmol, 500 M%), DIC (1.00 ml, 6.43
mmol, 460 M%) and DMAP (0.354 g, 2.90 mmol, 207 M%) were suspended in THF (20
ml) and Me2SO (2 ml) and heated (70 C). After 4 hr, the reaction was concentrated to
near dryness and the residue redissolved in CH2C12 (100 ml) and washed with NaHCO3 (sat)
(100 ml) and NaCl(sat) (100 ml). The organic solution was dried with Na2SO 4, filtered and
concentrated. The bis-TBM-dGuo was purified by silica gel chromatography (100 g)
sequentially eluting with CH2C12/MeOH (96:4), CH2C12/MeOH (92:8), and CH2Cl2/MeOH
(88:12). The major product isolated was 5',3'-TBM-dG (0.96 g 1.36 mmol 97% yield).
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Synthesis of N-(deoxyguanosin-8-yl)aminobiphenyl (dGuo-8-ABP)
N-acetoxy-aminobiphenyl (19.27 mmol) dissolved in CH2C12 (approximately 20 ml) was
added dropwise to dGuo (0.60 g) dissolved in 1:1 EtOH:H 20 (10 ml) at 40 C. During the
addition the CH2C12 solution, the dGuo began to precipitate from solution and required
additional EtOH (20 ml) for solubility. As monitored RP-HPLC, no difference in the ratio
of dGuo to dGuo-8-ABP occurred from 20 min following addition of N-acetoxy-
aminobiphenyl to 1 hr. After 3 hr, the reaction was diluted with CH2C12 (100 ml) and H2 0
(50 ml). The aqueous solution was collected and the organic solution was washed with H20
(50 ml). The combined aqueous solution was washed with CH2C12 (2 x 20 ml) and
concentrated to dryness. The residue was redissolved in a minimum of MeOH and chilled
(4 'C) overnight to precipitate dGuo. The filtrate was collected and chilled again to
precipitate additional dGuo. The 8-ABP-dGuo was purified on a Vydac C18 prep column
using a Waters Model 590 pump at 16 ml/min with a Waters 484 Tunable Absorbance
Detector set at 254 nm. An isocratic gradient of 15% B was used. The solvents were A:
1:1 MeOH/H20 B: MeOH. (12.2 mg, 1.3% yield)
N-(deoxyguanosin-8-yl)aminobiphenyl 'H NMR (CD3OD): 7.70 (2H, d), 7.53 (4H, q),
7.37 (2H, t) 7.24 (t, 1H, H5"), 6.45 (dd, 1H, Hi'), 4.57 (d, 1H, H3'), 4.02 (d, 1H, H4'),
3.90 (ddd, 2H, H5'), 2.70 (m, 1H, H2'), 2.17 (dd, 1H, H2'). ' 3C NMR (CD30D):
158.223 (C6), 154.14 (C2), 151.87 (C4), 146.32 (C1"), 142.04 (C5"), 141.14 (C8),
135.42 (C8"), 129.60 (C7"), 128.00 (C6"), 127.47 (C4" ), 127.27 (C3"), 119.46 (C2"),
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113.62 (C5), 88.76 (C1'), 84.83 (C4'), 73.03 (C3'), 62.70 (C5), 39.87 (C2). )max =300
nm (methanol)
Synthesis of 4-[3H]aminobiphenyl
4-[3 H]nitrobiphenyl (1.449 Mtmol, 6.9 mCi/mmol) dissolved in 95:5 ethanol: isopropanol (1
ml) treated with hydrazine (100 M/l) and palladium on activated carbon (1 mg). After 18 hr,
additional hydrazine (40 l ) and Pd/C (1 mg) were added. After 20 min. the reaction was
filtered to remove the palladium, dried in vacuo, redissolved in methanol/water (40:60), and
chromatographed by RP-HPLC using gradient I.
Synthesis of dGuo-8-[3H]ABP
4-nitrobiphenyl (1.10 g, 5.81 mmol) was dissolved in 3H20 (1 ml, 5 Ci/mmol), trifluroacetic
acid (7.8 ml, 11.60 g, 55. 22 mmol), and trifluoromethanesulphonic acid (600 Ml). After 24
hr at reflux, the reaction was diluted with water (20 ml) and the solid filtered. The washed
[3H]4-nitrobiphenyl was dissolved in DMF (50 ml) and treated with ammonium sulfide (20
wt% in water) (50 ml). After 4 hr, the reaction was diluted with CH2C12 (100 ml) and
washed with H20 (50 ml). The aqueous solution was back extracted with CH2CI2 (25 ml)
and the combined organic solution dried with Na2SO 4, filtered and concentrated using a
stream of N2 gas. The activated [3H]N-hydroxy-aminobiphenyl was then suspended in Et2O
(5 ml) and treated with acetyl cyanide at -45 C. After 1 hr, the suspension was dissolved
with CH2C12 (25 ml) and washed with NaCl(sat) (50 ml). The organic solution was dried with
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Na 2SO4, and filtered. The [3H] N-acetoxy-aminobiphenyl dissolved in CH 2Cl2 was then
added to dGuo (1.0 g) dissolved in water: ethanol: TEA (4: 4: 1) (10 ml). Unfortunately,
as monitored by RP-HPLC, no dG-8-[3H]ABP was detected.
Synthesis of [3H]dGuo-8-ABP
[3H]dGuo was prepared by dephosphorylation of [3H]dGTP (0.323 nmol, 31 Ci/mmol) for 1
hr at 37 'C in TE buffer (50 mM Tris-HCl, 50 mM EDTA) (pH 8.5) using calf intestine
and bacterial alkaline phosphatase (1 and 1.12 unit, respectively). Dephosphorylation was
monitored by RP-HPLC using gradient II and compared to the retention time of authentic
standards of dGTP, dGMP, and dGuo. The enzymes were removed by filtration through a
Millipore ultrafree-MC low-binding cellulose filter (nominal molecular weight limit,
30,000). N-acetoxy-4-aminobiphenyl (1 mmol) was added to the [3H]dGuo dissolved in a
4:4:1:1 mixture of water/ethanol/triethylamine/ chloroform (5.0 ml). The formation of
[3H]dGuo-8-ABP was monitored by reverse phase HPLC using gradient II. After 3.5 hr,
additional N-acetoxy-aminobiphenyl (1 mmol) was added. After 4.5 hr, the aqueous phase
was separated and the organic phase washed with H20 (9 x 5 ml). The combined aqueous
fractions were concentrated in vacuo, redissolved in methanol and stored overnight at -20
°C to precipitate any organic impurities. The adduct was purified using gradient III and
rechromatographed to verify its purity. About chromatography, [3H]dGuo-8-ABP was
recovered in 29% yield.
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Synthesis of 5',3'-bis-TBM-dGuo-8-ABP with TBM-NHS
dGuo-8-ABP (0.069 g, 0.16 mmol), TBM-NHS (0.48 g 1.39 mmol, 870 M%), and DMAP
(0.045 g,0.36 mmol, 230 M%) were suspended in THF (5 ml) and Me2SO (0.5 ml) and
heated at 70 'C. After 4 hr, additional TBM-NHS (0.45 g, 1.30 mmol, 810 M%) was
added to the refluxing solution. After 7 hr, the solution was concentrated and the residue
redissolved in CH2CI2 (25 ml) and washed with NaHCO 3 (sat) (15 ml) and NaCl(sat) (15 ml).
The organic solution was dried with Na2SO4, filtered and concentrated. The reaction was
purified by silica gel chromatography (50 g) sequentially eluting with CH2CI2/MeOH (98:2)
and CH2CI2/MeOH (94:6) to yield 5',3'-bis-TBM-dGuo-8-ABP (0.13 g 0.14 mmol 88 %
yield)
5',3'-t-BOC-methionine-N-(deoxyguanosin-8-yl)aminobiphenyl ester (5',3'-bis-TBM-
dGuo-8-ABP) (rf 0.66 CH2C12/MeOH 90 :10) 'H NMR (CD3OD): 7.56-7.40 (6H, m, Ar),
7.32 (2H, t), 7.22 (t, 1H, H5"), 6.30 (t, 1H, Hi'), 5.50 (m, 1H, H3'), 4.70-4.20 (5H, m,
Ha Met, H4', H5'), 3.5 (1H, m, H2'), 2.60-2.36 (5H, m, H2', Hf Met), 2.07 (3H, s,
CH 3S), 1.95 (3H, s, CH3S), 2.10-1.81 (4H, m, Hx Met), 1.43 (9H, s, BOC), 1.41 (9H, s,
BOC). 13C NMR (CDC1 3 / CD3OD): 172.17 (C1, Met), 171.74 (C1, Met), 157.36 (C6),
155.62 (BOC), 155.40 (BOC), 152.08 (C2), 150.34 (C4), 144.90 (C1l"), 140.33 (C5"),
140.07 (C8), 134.36 (C8"), 128.39 (C7"), 127.35 (C6"), 126.40 (C4" ), 126.23 (C3"),
117.84 (C2"), 113.50 (C5), 83.95 (C1'), 81.62 (C4'), 80.15 (OC(CH 3)3), 80.00
(OC(CH3)3), 75.32 (C3'), 64.30 (C5'), 53.30 (Ca Met), 52.53 (Ca Met), 34.52 (C2'),
31.39 (Cx Met), 30.96 (Cx Met), 29.92 (Co3 Met), 29.81 (C3 Met), 28.07 (C(CH3)3) (same
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Hz) 15.24 (CH3S), 15.05 (CH3S). FAB-MS expected exact molecular weight for [M+H]+
897.36391, high resolution result 897.3635. Xmax =300 nm, X=254 nm (methanol)
Synthesis of mono-TBM-dGuo-8-ABP with TBM-NHS
dGuo-8-ABP (0.17 g, 0.39 mmol), TBM-NHS (0.54 g 1.56 mmol, 400 M%), and DMAP
(0.071 g, 0.58 mmol, 150 M% ) were suspended in THF (5 ml) and Me2SO (0.5 ml) and
heated at 50 C. After 1 1/2 hr, the reaction was concentrated to dryness. The mono-
TBM-dGuo-8-ABP products were separated by silica gel chromatography (50 g) sequentially
eluting with CH 2Cl 2/MeOH (96:4), CH 2C12/MeOH (92:8), and CH 2Cl2/MeOH (88:12).
5'-t-BOC-methionine-N-(deoxyguanosin-8-yl)aminobiphenyl ester (5'-TBM-dGuo-8-
ABP) (rf 0.56 CH2Cl2/MeOH 90:10) H NMR (CD 3OD/CDCl3): 7.52-7.40 (6H, m, Ar),
7.37 (2H, t), 7.27 (t, 1H, H5"), 6.15 (t, 1H, Hi'), 4.40-4.35 (3H, m, H4', H5'), 4.3-4.0
(2H, H3', Ha Met), 3.1 (1H, m, H2'), 2.50-2.10 (3H, m, H2', Ho Met), 2.10-1.70
(2H, m, HX Met), 1.92 (3H, s, CH3S), 1.35 (9H, s, BOC). '3C NMR (CDC13 / CD 30D):
173.93 (C1, Met), 158.35 (C6), 157.68 (BOC), 153.64 (C2), 152.14 (C4), 146.62 (C1"),
141.72 (C5"), 141.32 (C8), 135.67 (C8"), 129.57 (C7"), 128.36 (C6"), 127.52 (C4" ),
127.26 (C3"), 119.37 (C2"), 114.23 (C5), 85.48 (Cl'), 85.24 (C4'), 80.66 (OC(CH 3)3),
72.60 (C3'), 66.04 (C5'), 53.82 (Cca Met), 38.42 (C2'), 31.91 (Cx Met), 30.83 (CB Met),
28.66 (C(CH 3)3), 15.27 (CH3S), 15.05 (CH3S). FAB-MS expected exact molecular
weightfor [M+H]+ 666.27100, high resolution result 666.2714. Xmax =300 nm, =254
nm (methanol)
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3'-t-BOC-methionine-N-(deoxyguanosin-8-yl)aminobiphenyl ester (3'-TBM-dGuo-8-
ABP) (rf 0.43 CH2Cl 2/MeOH 90 :10) 11H NMR (CD 3OD /CDCl3): 7.56-7.40 (6H, m), 7.32
(2H, t), 7.22 (t, 1H, H5"), 6.30 (t, 1H, Hi'), 5.50 (m, 1H, H3'), 4.70-4.20 (4H, m, HCa
Met, H4', H5'), 3.5 (1H, m, H2'), 2.50-2.15 (3H, m, H2', Hf Met), 2.10-1.80 (2H, m,
HX Met), 2.07 (3H, s, CH3S), 1.95 (3H, s, CH3S), 1.43 (9H, s, BOC), 1.41 (9H, s, BOC).
4.02 (d, 1H, H4'), 3.90 (ddd, 2H, H5'), 2.70 (m, 1H, H2'), 2.17 (dd, 1H, H2'). 13C
NMR (CDCl 3 / CD 3OD): 173.58 (C1, Met), 158.41 (C6), 157.93 (BOC), 153.95 (C2),
151.77 (C4), 146.24 (Cl"), 142.37 (C5"), 141.89 (C8), 135.52 (C8"), 129.64 (C7"),
128.09 (C6"), 127.54 (C4" ), 127.35 (C3"), 119.70 (C2"), 113.86 (C5), 886.34 (C1'),
84.82 (C4'), 80.78 (OC(CH3)3), 77.63 (C3'), 62.69 (C5'), 53.84 (Ca Met), 36.56 (C2'),
31.72 (Cx Met), 31.12 (C3 Met), 26.18 (C(CH 3)3), 15.49 (CH 3S), 15.49 (CH3S). FAB-MS
expected exact molecular weight for [M+H] + 666.27100, high resolution result 666.2707.
Xmax =300 nm, X =254 nm (methanol)
Synthesis of tris-TBM-dGuo-8-ABP with TBM-NHS
dGuo-8-ABP (0.072 g, 0.166 mmol) and TBM-NHS (0.42 g, 1.21 mmol, 730 M%) were
dissolved in Me2SO (100 l) and triethylamine (100 l) and heated (80 'C). After 5 1/2 hr,
additional TBM-NHS (0.186 g, 0.537 mmol, 325 M%), Me2SO (100 ,ul) and triethylamine
(100 l) were added. After 10 hr at 80 C, the reaction was diluted with CH2C12 (30 ml)
and washed with NaHCO3(sat) (10 ml). The organic solution was dried with Na2SO4, filtered
and concentrated to dryness. The tris-TBM-dGuo-8-ABP was separated from bis-TBM-
dGuo-8-ABP by silica gel chromatography (40 g) eluting with CH2Cl2/MeOH (96:4).
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N2,5 ',3 '-tris-t-BOC-methionine-N-(deoxyguanosin-8-yl)aminobiphenyl ester (N2,5 ',3 '-
tris-TBM-dGuo-8-ABP) (rf 0.53 CH2Cl2/MeOH 95:5) H NMR (CD3OD /CDCl3): 7.60-
7.45 (6H, m, Ar), 7.39 (2H, t), 7.25 (t, 1H, H5"), 6.33 (br, 1H, Hi'), 5.39 (br, 1H,
H3'), 4.45-4.20 (6H, m, Ha Met, H4', H5'), 2.70-2.20 (8H, m, H2', H3 Met), 2.09
(3H, s, CH3S), 2.08 (3H, s, CH3S), 2.06 (3H, s, CH3S), 2.00-1.90 (6H, m, HX Met), 1.52
(9H, s, BOC), 1.41 (18H, s, BOC). 13C NMR (CDC1 3 / CD30D): 172.77(C1, Met),
172.30 (C1, Met), 171.93 (C1l, Met), 156.00 (C6), 154.66 (BOC), 152.78 (C2), 148.20
(C4), 140.27 (C1l"), 138.90 (C5"), 139.5 (C8), 134.68 (C8"), 128.24 (C7"), 127.10
(C6"), 126.61 (C4" ), 126.09 (C3"), 118.27 (C2"), 118.18(C5), 84.01 (C1'), 81.57 (C4'),
80.02 (OC(CH3)3), 79.85 (OC(CH3)3), 79.68 (OC(CH3)3), 75.07 (C3'), 62.0 (C5'), 52.32
(Ca Met), 51.30 (Ca Met), 51.05 (Ca Met), 34.37 (C2'), 31.0 (Cx Met), 30.8 (Cx Met),
29.7 (Cx Met), 29.6 (Co Met), 29.4 (CB Met), 28.6 (CB Met), 27.70 (C(CH3)3), 27.62
(C(CH3)3), 27.31 (C(CH3 )3), 14.63 (CH3S), 14.49 (CH3S), 14.41 (CH 3S). FAB-MS
expected exact molecular weight for [M+H]+ 1128.45683, high resolution result
1128.4577. Xmax =310 nm, X=274 nm (methanol).
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II. SYNTHESIS OF SITE-SPECIFICALLY MODIFIED OLIGONUCLEOTIDES
A. Introduction
Site-specifically modified oligonucleotides are important tools that allow precise
physical and biological evaluation of DNA lesions (Basu and Essigmann, 1988). NMR
spectroscopic and X-ray crystallographic studies of site-specifically modified
oligonucleotides, for instance, provide unambiguous structural data on the conformational
changes resulting from a chemical lesion. Moreover, site-specifically modified
oligonucleotides can be used to characterize the types, amounts, and genetic requirements
for mutations induced by chemical carcinogens and radiation (Fowler et al., 1982; Green et
al., 1984; Loechler et al., 1984; Singer and Essigmann, 1991). In addition, site-specifically
modified oligonucleotides can be used to rank the toxic potentials of DNA lesions formed by
antitumor compounds (Bradley et al., 1993). In an attempt to define the relationship
between the structures and the biological consequences of chemical carcinogens, antitumor
drugs and ionizing radiation, the Essigmann laboratory has examined the mutagenic activity
and repair of modified oligonucleotides. My efforts have focused on the synthesis of
modified oligonucleotides.
B. Synthesis of Modified Oligonucleotides
Three methods are commonly used to synthesize a site-specifically modified
oligonucleotide: i) enzymatic synthesis, ii) chemical or physical modification of a preformed
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oligonucleotide, and iii) total synthesis. The choice of method depends on the chemical
nature and stability of a particular adduct or lesion to be studied.
a. Enzymatic Synthesis of a Modified Oligonucleotide
One method useful for the synthesis of some modified oligonucleotides involves
enzymatic incorporation of a modified deoxynucleotide. The enzymes that have been
utilized for this approach include DNA polymerase (Walker and Uhlenbeck, 1975),
bacteriophage T4 RNA ligase (Brennan and Gumport, 1985; Wood et al., 1990) and
terminal deoxynucleotidyl transferase (Hatahet et al., 1993). Although the method of
incorporation involves an enzyme-catalyzed step, chemical synthesis may nevertheless be
required to prepare the necessary substrate for study. One disadvantage of utilizing enzymes
to synthesize modified oligonucleotides is that the substrate specificity of the various
enzymes employed may limit the compounds that can be incorporated. For instance, only a
limited number of chemically modified triphosphates are suitable substrates for DNA
polymerase (Hatahet et al., 1993). In the case of RNA ligase and terminal deoxynucleotidyl
transferase, the versatility of these methods has not been established. T4 RNA ligase and
terminal deoxynucleotidyl transferase additionally have the problem that the modified
nucleoside can only be added to the 3' end of an oligonucleotide. Having a modified
deoxynucleotide on the end of an oligonucleotide chain can interfere with subsequent
incorporation of the oligonucleotide into a viral genome for genetic studies.
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b. Modification of a Preformed Oligonucleotide
A second method for the synthesis of modified oligonucleotides involves the treatment
of an oligonucleotide with a reactive DNA damaging agent (Basu and Essigmann, 1988). In
most cases, this method involves treating an oligonucleotide with a chemical carcinogen or
its activated metabolite. This method is useful for readily synthesized electrophilic reagents,
such as epoxides, alkylators (alkyl halides, etc.), and oxidants (osmium tetroxide, peroxide,
etc.), or radiation-induced lesions such as DNA photoproducts induced by UV light.
One of the limitations of this method is the preparation of the reactive form of the
carcinogen. In many cases of DNA damage, the reactive form of a carcinogen is not
available. Even when the reactive carcinogen is available, if a desired DNA sequence has
more than one reactive site, multiple products can and do arise (Basu and Essigmann, 1988).
Purification of the desired product from other reaction products, consequently, is
problematic. To prevent the formation of multiple products, a DNA sequence with only one
reactive site is often chosen. Therefore, this method may not be able to generate the DNA
lesion in a preferred (i.e., biologically relevant) sequence.
c. Total Synthesis of Modified Oligonucleotides
The total synthetic approach is the preferred method to prepare modified
oligonucleotides because of the ease of automated DNA synthesis (Basu and Essigmann,
1988). This method enables the facile production of sufficient amounts (g to mg quantities)
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of modified oligonucleotide for full structural characterization (NMR or X-ray diffraction
studies) and in-depth biological experiments. An additional advantage of the total synthetic
approach is the ability to control adduct placement in an oligonucleotide. The ability to
place a DNA adduct systematically in different sequence contexts is useful for determining
the effect of the local chemical environment on the biological activity of a DNA lesion.
The major limitation of a total synthetic approach is the availability and stability of
carcinogen-modified nucleosides. As was the case with an enzymatic procedure for
synthesizing modified oligonucleotides, the nucleoside adduct of interest may not be
available or may require multiple steps to synthesize. Even after preparing the desired
carcinogen-nucleoside adduct, additional steps are required to prepare modified
phosphoramidites (Beaucage and Iyer, 1992) or phosphotriesters (Reese, 1978). The
preparation of a reactive monomer (or dimer) can involve multiple steps of protection
deprotection and activation. In addition, when synthesizing a modified deoxynucleoside
phosphoramidite or phosphotriester, reactive groups on the carcinogen moiety must be
blocked prior to oligonucleotide synthesis. An additional source of problems may arise as a
consequence of the conditions employed for DNA synthesis. Synthesis of a modified
oligonucleotide may involve repeated treatments of mild acid (trichloroacetic acid), strong
oxidants (iodine), and reactive electrophiles (phosphorylating reagent), depending on the
position of the modified nucleoside in the DNA chain. In addition, after the desired
modified oligonucleotide is obtained, deprotection of blocking groups and removal of the
oligonucleotide from a resin support in the case of solid phase DNA synthesis commonly
involves treatment of a modified oligonucleotide with concentrated ammonium hydroxide
98
and heat (60 C). Consequently, in order for a modified oligonucleotide to be synthesized
by a total synthetic approach, the adduct of interest must be stable to acidic, basic, oxidizing
and electrophilic reagents.
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C. 4-Aminobiphenyl
a. Biological relevance of 4-aminobiphenyl.
4-aminobiphenyl (4-ABP) has been shown to be a potent bladder carcinogen in humans
(Melick et al., 1955; Melick et al., 1971). In a study that examined chemical workers
industrially exposed to 4-ABP, a striking 19 of 171 (11 %) workers developed bladder
tumors within 17 years of industrial exposure (Melick et al., 1955). A follow-up study of
315 exposed workers revealed that approximately 17% of this larger group had developed
bladder cancers (Melick et al., 1971). Despite the cessation over 40 years ago of the
industrial use of 4-ABP as an antioxidant in rubber manufacturing, exposure of people to 4-
ABP continues today owing to cigarette smoking, coal-derived synthetic fuels, and to other
as yet unknown sources (Talaska et al., 1991; Byrant et al., 1987; Kadlubar et al., 1988;
Guerin and Buchanan, 1987).
Three major DNA adducts have been found subsequent to ABP exposure in vivo
(Kadlubar et al., 1982; Beland and Kadlubar, 1985). The primary adduct formed is N-
(deoxyguanosin-8-yl)-4-aminobiphenyl (dGuo-8-ABP) (Figure 9A). Less frequently
occurring adducts are the N-(deoxyguanosin-N 2-yl)4-aminobiphenyl and N-(deoxyadenosin-8-
yl)-4-aminobiphenyl (Figure 9A).
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Figure 9. 4-ABP DNA adducts.
A) Structures and relative proportion of 4-ABP DNA adducts.
B) Two methods for synthesizing dGuo-8-ABP, the major 4-ABP DNA adduct.
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A. 4-ABP in vivo DNA adducts
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An earlier study conducted in the Essigmann lab showed that a single ABP adduct,
dGuo-8-ABP, when present in only one strand of a ds M13 genome, is weakly mutagenic
(mutation frequency < 0.02 %) in E. coli (Lasko et al., 1988). The reasons postulated to
explain the low observed mutagenic frequency of the dGuo-8-ABP lesion included: 1) the
dGuo-8-ABP may not be mutagenic, 2) the dGuo-8-ABP lesion may not have been
mutagenic in the sequence context evaluated, 3) the dGuo-8-ABP may have been rapidly
repaired, and 4) the dGuo-8-ABP selectively inhibited replication of the adducted strand. In
order to determine which of these possibilities were most feasible, S. Verghis began studies
of the mutagenic effects of the dGuo-8-ABP lesion in ss DNA. A site-specifically modified
genome was constructed using a modified tetramer, 5'-d(TG8 -ABPCA), synthesized by F.
Kadulbar and coworkers at the National Center for Toxicological Research. The method
used to synthesize the modified tetramer was that of Lee and King (1981). Unfortunately,
before biological testing of the site-specifically modified genome was complete, it became
evident that the modified oligonucleotide had undergone some degradation since its
synthesis. Since degradation products would confuse the biological results, a new modified
tetramer was required for biological study. Since the modified oligonucleotide synthesized
according to the procedure of Lee and King (1981) had undergone degradation, possibly as a
consequence of unknown contamination, I undertook the synthesis of the same modified
oligonucleotide, 5'-d(TG8 -ABPCA), by the method of Famulok et al. (1989).
b. Synthetic routes to dGuo-8-ABP
Only two methods have been published on how to modify DNA with aminobiphenyl in
vitro. The first published method involved the reaction of N-acetoxy-N-trifluoroacetyl-4-
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aminobiphenyl with guanosine (Lee and King, 1981) (Figure 9B). Although the product of
this reaction was the modified ribonucleotide, N-(guanosin-8-yl)-4-aminobiphenyl, this
electrophilic reagent was subsequently shown to react with deoxynucleotides as part of a
plasmid or short strands of DNA (Lasko et al., 1988). The procedure by Famulok et al.
(1989), by constrast, involves the reaction of N-acetoxy-4-aminobiphenyl as the electrophilic
species (Figure 9B). The N-acetoxy-4-aminobiphenyl reagent has been implicated as one of
the reactive metabolites of 4-ABP in vivo leading to DNA modification (Flammang et al.,
1988).
c. Synthesis of an aminobiphenyl modified tetranucleotide
As outlined in Figure 10, the N-acetoxy-aminobiphenyl can be prepared from
commercially available 4-nitrobiphenyl in two steps. The first step involved reducing 4-
nitrobiphenyl to N-hydroxy-aminobiphenyl with (NH4)2S. The N-hydroxy-aminobiphenyl
can then be acylated with acetyl cyanide at low temperature (-40 'C) to yield N-acetoxy-
aminobiphenyl. Although the N-acetoxy-aminobiphenyl, upon standing at room temperature
as a solid rapidly degraded, the reactive electrophile can be stored temporarily as a
dichloromethane solution at room temperature for a few hours or at -80 C for a few days.
The modified oligonucleotide, 5'-d(TG8 -ABPCA) was synthesized in 30 to 40% yield by
adding a large excess of N-acetoxy-aminobiphenyl (3.8 mmol) to unmodified tetramer (10
Itmol). The ABP-modified oligonucleotide prepared by this method coeluted with the major
peak present in the ABP-modified oligonucleotide used previously in this laboratory.
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Subsequent to purification by reversed phase HPLC, the identity of the modified
oligonucleotide was confirmed by FAB-MS and nucleoside digestion analysis. In the case of
the negative ion mass spectrum of the modified oligonucleotide (calculated molecular weight
= 1340 m/z), the major ion detected was 1339 corresponding to the [M-H]- ion. The
nucleoside composition of the modified oligonucleotide was subsequently determined by
enzymatic hydrolysis, reversed phase HPLC, and UV detection. Peak area analysis of the
digestion products of the oligonucleotide, d[TG8-ABPCA], showed the proper ratio of dT, dC,
dA and dGuo-8-ABP (Verghis, 1992; Verghis, Morningstar, and Essigmann, manuscript in
preparation).
d. Summary of Biological Results2
The modified oligonucleotide was subsequently incorporated into an M13 bacteriophage
vector and the genetic effects of the dGuo-8-ABP lesion determined. The targeted mutation
frequency of a single dGuo-8-ABP adduct in an M13 ss genome was determined to be
approximately 0.01 % (Verghis, 1992). This value is similar to the low mutability
determined for the same ABP lesion in ds DNA (Lasko et al., 1988). As mentioned earlier,
the study of the 4-ABP lesion in ss DNA was undertaken to determine whether the low
mutagenic frequency seen in ds DNA was because the dGuo-8-ABP lesion was 1) not
mutagenic, 2) not mutagenic in the sequence context evaluated, 3) rapidly repaired, or 4)
inhibitory to replication of the adducted strand selectively. The results from the most recent
ss DNA experiment rule out the third and fourth possibilities as the reason for the low
2 The biological results were obtained by S. Verghis.
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mutagenic frequency detected. Specifically, DNA repair enzymes function preferentially, or
exclusively, on ds DNA. Facile repair of the adduct in ss DNA is therefore unlikely to
account for the low mutagenicity of the dGuo-8-ABP lesion. Similarly, since the adduct was
situated in ss DNA, no unmodified strand was available to undergo preferential replication
as compared to the adducted strand. The mutagenicity results, therefore, must reflect actual
replication past the dGuo-8-ABP lesion. It was concluded that the dGuo-8-ABP lesion was
only a weakly mutagenic DNA lesion, at least in the sequence context evaluated.
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Figure 10. Synthesis of a ABP-modified tetranucleotide.
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D. Purine oxidative lesions:
8-oxoguanine and 8-oxoadenine 3
a. Introduction to Oxidative Damage
A high rate of spontaneous oxidative DNA damage occurs as a consequence of aerobic
metabolism, lipid peroxidation and immune responses (Ames and Gold, 1991). Some of the
reactive oxidizing species produced include superoxide, nitric oxide, hydroxyl radicals, and
hydrogen peroxide (Ames 1983; Cross et al., 1987; Floyd, 1990; Halliwell et al., 1990;
Ames and Gold, 1991). In addition to the effects of endogenous reactive oxygen species,
oxidative DNA damage can also occur if cells are exposed to carcinogens that generate
oxygen radicals, including ionizing radiation and some chemical oxidants (von Sontag 1987;
Halliwell et al., 1990). It has been estimated that the genome of a human cell receives on
average about 104 oxidative hits/day (Ames and Gold, 1991). Some of the DNA lesions that
result from oxidative damage include strand breaks, base modifications, protein-DNA cross-
links, and AP sites (Hutchinson, 1985). As a protection against this oxidative damage, cells
possess many defenses, including chemical antioxidants, DNA repair enzymes, catalase, and
superoxide dismutase (Sies 1986; Frei et al., 1988; Breimer, 1990). Since some adducts
escape repair, oxidative DNA damage can accumulate with time. These persistent DNA
lesions are thought to contribute to mutations found in the DNA. In fact, oxidative DNA
damage is believed by some to be a major contributor to both the aging process and various
3 Portions of this section have been taken verbatim from Wood et al. (1992).
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age-related degenerative diseases, including cancer (Ames, 1983; Cross et al., 1987; Floyd,
1990; Halliwell et al., 1990; Ames and Gold, 1991).
b. Biological importance of 7,8-dihydro-8-oxoguanine (G 8 o° )
One of the predominate oxidative lesions detected in human tissues samples is 7,8-
dihydro-8-oxoguanine (G8-°x) (Figure 11). This lesion, originally detected in y and X-
irradiated DNA, has subsequently been shown to be mutagenic in vitro (Kuchino et al.,
1987; Shibutani et al., 1991) and in vivo (Wood et al. 1990; Moriya et al., 1991; Cheng et
al., 1992). A possible association between G8-°O ° and neoplastic transformation has been
suggested (Floyd, 1990). The predominant mutation induced by G8-°x, a G to T
transversion, was determined in this laboratory (Wood et al., 1990) and subsequently
confirmed in others (Moriya et al., 1991; Cheng et al., 1992; Shibutani et al., 1991).
Although it has been the subject of less study, 7,8-dihyrdo-8-oxoadenine (A8-° °)
(Figure 11) has also been detected in DNA irradiated in vitro (Fuciarelli et al., 1989;
Gajewski et al., 1990) as well as in urine and liver samples from in vivo sources (Stillwell et
al., 1989; Malins and Haimanot, 1990). In irradiated DNA, this adduct is present at
approximately one-third to one-half of the level of G8-°xo (Fuciarelli et al., 1989; Stillwell et
al., 1989). Structural studies performed on A8-°x° (Cho and Evans 1991) have shown that
this lesion, like G8-°xo, exists predominantly as the 6,8-diketo tautomer at physiological pH.
In addition, both modified bases are in the syn glycosidic conformation as contrast to the
normal anti conformation in B DNA. Since these two structural features appear central to
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Figure 11. Oxidized purines: G8-°X° and A8- x°
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the known miscoding properties of G8-°x (Culp et al., 1989; Cho et al., 1990; Kouchakdjian
et al., 1991; Oda et al., 1991), it was speculated that the A8-°x ° might also be a
premutageneic lesion. We speculated that the presence of A8-°"" in DNA may explain the
appearance of mutations at AT base pairs in the genomes of cells or viruses that have been
exposed to ionizing radiation or chemical oxidation (Glickman et al., 1980; Grosovsky et
al., 1988; Miles and Meuth 1989; McBride et al., 1991). In order to study the mutagenic
potential of the A8-°xo lesion, an oligonucleotide containing the A8-°x° was required.
c. Synthesis of AX ° Phosphoramidite
Although the structurally similar G8-°x° lesion was incorporated into a modified
oligonucleotide by an enzymatic method (Wood et al., 1990), the sequence context chosen to
study A8-°x, 5 '-d(GCTA 8-°X°G), was not amenable to the same enzymatic procedure.
Additionally, treatment of unmodified GCTAG with oxidizing conditions that would produce
the A8-oxo lesion would additionally result in a mixture of oxidized purine and pyrimidine
residues. Consequently, a total synthetic approach was taken to synthesize GCTA8 -°X°G.
The 5'-d(GCTA8 -°ox G) oligonucleotide was synthesized by the method of Guy et al.
(1988) with a few modifications (Figure 12). The first step of the procedure involved
oxidation of the C8 position of dA by bromination (Guy al., 1988; Long et al., 1967;
Ikehara and Uesugi, 1969). The next step of the procedure involved simultaneous
displacement of the bromide with NaOAc and protection of the 5' and 3' hydroxyls of the
nucleoside. Unfortunately, the method by Guy et al. (1988) involving phenoxyacetyl
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anhydride protection was not high yielding when preformed in the Essigmann lab. The
method was more reproducible when acetic anhydride was used instead of the phenoxyacetyl
anhydride (Ikehara and Maruyama, 1975). After 2.5 hr at reflux, the reaction yielded a
mixture of tetra- and penta-acetylated dA8 -°ox. By varying the amount and molarity of
sodium hydroxide added, the tetra- and penta-acetylated dA8-°x could be converted
quantitatively to either dA8 -°x or N2 -acetyl-dA 8ox °. The following steps (protection of the
5' hydroxyl with dimethoxytrityl and formation of the 3' phosphoramidite) were done
according to standard literature procedures (for a review on phosphoramidite synthesis, see
Beaucage et al., 1992; Gait 1984).
Purification of the fully protected dA8-°ox phosphoramidite proved to be problematic.
Chromatographic conditions whereby decomposition of the activated phosphoramidite did
not occur could not be developed. Bodepudi et al. (1991) similarly found that partial
hydrolysis (5 to 20 %) during aqueous work-up and substantial decomposition occurred with
dG8-oxo phosphoramidite. Consequently, the crude reaction dA8-°xo phosphoramidite product
was used for solid phase DNA synthesis. This procedure was inefficient and resulted in
poor coupling between the modified phosphoramidite and the 5' hydroxyl group of the
oligonucleotide undergoing elongation. This process, however, did permit the synthesis of
enough of the site-specifically modified oligomer for characterization and genetic evaluation.
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Figure 12. Preparation of A8-°x phosphoramidite.
115
i.
0o
\/-t,, O z0 z
0
tz ; zI,
:L
0
x
CD
(D0
CD
I-I
I"
0
z
2· .
m tr
z
CD.
wu h- 
- toUn =
CD -
= E.
X ,
to
0
o0
zo cz
©01
Ii
-
0
zz
' I to
sA 0
CD RO0 
O
z
tQj
to
10CD O CDr
5
C 
o
I I
116
I I
0
I'4
4p
II
II
1
I
d. Characterization of d(GCTAX°G)
The identity of the modified oligonucleotide was confirmed by mass spectrometry and
nucleoside digestion analysis. The observed values (M-H)- = 1518.5 and (M-H+ Na)- =
1541.2, as determined by matrix-assisted laser desorption and time of flight mass
spectrometry, agreed with the calculated m/z= 1518.1 for d(GCTA-°X°G). The
oligonucleotide composition was subsequently determined by enzymatically hydrolyzing the
oligomer and examing the digestion products by RP-HPLC. Peak area analysis of the UV
chromatogram indicated that the modified oligonucleotide, d(GCTA-°xG), contained the
proper ratio of dT, dC, dG, and dA8 °x (Wood et al., 1992).
e. Discussion of the mutagenicity of AX °
Biological evaluation of d(GCTA-°X°G) was performed simultaneously with d(GCTAG 8-
o), previously synthesized in this laboratory, to determine the relative mutagenicities of A8-
oxo and G8-°x°. To determine the relative genetic effects of A8-°x° and G8- °x° in vivo,
bacteriophage genomes containing either of the two lesions were constructed and used to
transform a DNA repair proficient strain of E.coli. Mutant progeny were scored and the
nature of the mutations determined by DNA sequencing. Analysis of phage DNA from
mutant plaques obtained by plating immediately after transformation (infective centers assay)
revealed that G8-°x° induced G to T transversions at an apparent frequency of 0.3 %; this
finding agreed with previous work of this lab (Wood et al., 1990). The frequency and
spectrum of mutations derived from the A8-°ox modified DNA were almost indistinguishable
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from those generated from an adenine-containing control genome. No evidence was
obtained to indicate that the A8-°x° adduct induced any targeted base substitution mutations.
It was estimated that A8-°x° was at least an order of magnitude less mutagenic than G8-°x° in
E. coli cells with normal DNA repair capabilities.
A possible conclusion from this study was that A8-°x° does not contribute significantly
to the spectrum of mutations that occur at AT base pairs in oxidatively-damaged DNA. A
possible reason for the lack of mutagenicity of A8-°x° was that these studies were performed
in repair proficient E. coli cells. It is conceivable that the A8-°x adduct was removed from
the M13 genome by an E. coli repair enzyme(s) prior to DNA replication, preventing the
fixation of mutations. Another possibility is that A8-°x° may be one of many lesions that is
mutagenic only in bacterial cells that are expressing the SOS response.
f. Introduction to GX ° oligonucleotides
In order to understand whether the low mutagenic potential of A8-°x° in the previous
mutagenicity experiment was due to facile DNA repair, work was started in the Essigmann
lab by L. Miller to compare A8-°ox and G8-°x in a repair deficient cell line. In order to
compare the results obtained in the previous study with any new mutagenic results in a
repair-deficient cell strain, the same M13 genomes would be required. This requirement
meant that the desired G8-°x containing oligonucleotide would again require the sequence
d(GCTAG8-°x). Since a large amount of oligonucleotide was need for these new studies, it
was determined that the relatively inefficient enzymatic method previously used to generate a
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G8-oxo containing oligonucleotide would not allow the production of a sufficient amount of
oligonucleotide. Since the G8-°x° is the 3' terminal nucleotide of the desired oligonucleotide,
a modified resin containing G8-°x° would be required if solid phase DNA synthesis was
employed.
g. Background on the synthesis of GX' ° resin
At the time this work was begun, three groups had reported the synthesis of dG8-°ox
phosphoramidites. We postulated that the derivatives used to prepare the modified
phosphoramidite would also be suitable for the preparation of a G8-°x° resin. Kuchino et al.,
(1987) had developed a method to prepare N2-acetyl-8-methoxy-5-O-monomethoxytrityl-2 -
deoxyguanosine 3'-(2-chlorophenyl)phosphate. This phosphoramidite results in the synthesis
of 8-methoxy modified oligonucleotides. The methyl group on the C8 hydroxyl can
subsequently be removed in the last stage of the oligonucleotide synthesis by treatment with
triethylamine in aqueous DMF. A second method involved the preparation of 3'-0-
(diisopropylamino-2-cyanoethoxyphosphinyl)-5 '-O-dimethoxytrityl-N 2-isobutyryl-8-oxo-2 ' -
deoxy-7H-guanosine (Bodepudi et al., 1991; Bodepudi et al., 1992). This method does not
require a deprotection step to yield an G8-°x° oligonucleotide. A third method by Roelen et
al. (1991) reported a similar procedure to Bodepudi et al. However, Roelen et al. found
that the final step used by Bodepudi et al., the phosphitylation, did not occur without
protection of the N7 position with a diphenylcarbamoyl protecting group. Nevertheless,
both Bodepudi et al. and Roelen et al. found that the 4,4'-dimethoxytrityl-N 2-protected-8-
oxo-deoxynucleoside could be prepared in good yields. This protected G8-° ° molecule
appeared to be ideal for the preparation of a G8"-°x resin.
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Figure 13. Synthesis of G8-°ox resin and G8-°ox phosphoramidite.
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h. Synthesis of G8X° oligonucleotides
The protected 4,4'-dimethoxytrityl-N 2-acetyl-8-oxo-deoxynucleoside monomer was
prepared by adapting the procedures of Bodepudi et al. (1991) and Roelen et al. (1991)
(Figure 13). The method involved oxidation of the C8 position with bromine (Lin et al.,
1985), displacement of the C8 bromide with sodium benzylate (Bodepudi et al., 1991), and
subsequent protection of the N2 amino and 5' hydroxyl groups with acetic anhydride
(Roelen et al., 1991). In contrast to the earlier dA8 -°x synthesis in this laboratory, the
bromination of dGuo occurred very rapidly (Long et al., 1967). Also in contrast to the
dA8 -° x° synthesis, the displacement of the C8 bromine from 8-Br-dGuo involved reaction
with sodium benzylate (Lin et al., 1985) whereas the displacement of the C8 bromide of 8-
Br-dA occurred with sodium acetate, a poorer nucleophile. In my hands, the procedure of
Lin et al. led to a mixture of 8-benzyloxy-deoxyguanosine and 8-oxo-deoxyguanosine. The
ratio of the products varied depending on the aqueous content of the DMSO used in the
reaction. Procedurally, I found that separation of the two nucleosides difficult as
unprotected monomers and routinely separated the two compounds after peracylation with
acetic anhydride. The purified tetra-acetyl dG8-°X was subsequently deprotected with NaOH
(5M) in methanol to yield the N2 protected nucleoside monomer, N2-acetyl-dG8- °x °.
Subsequent protection of the 5' hydroxyl was done selectively with dimethoxytritylchloride
in pyridine to yield the 5 '-dimethoxytrityl-N2-acetyl-dG8 °x ° (Roelen et al., 1991). A
succinate linker arm for attaching the G8-°x to a resin was appended to the 5'-
dimethoxytrityl-N 2 -acetyl-dG8°x ° with succinic anhydride and dimethylaminopyridine in
pyridine (Chow et al., 1981). The crude 3'-succinate-5 '-dimethoxytrityl-N2 -acetyl-dG 8 -x °
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was subsequently treated with DIC and p-nitrophenol to form the 3 '-succinate-p-nitrophenyl
ester 5'-dimethoxytrityl-N2-acetyl-dG8 x° . Modified G8-°x resin was prepared by mixing the
3'-succinate-p-nitrophenyl ester 5'-dimethoxytrityl-N2-acetyl-dG 8 -° x° with long chain amine
control pore glass resin. The extent of loading of the nucleoside onto the solid support was
established according to a described procedure (Gait et al., 1982). The determined loading
was approximately 4 to 5 zmol of G8-°x/g resin. Modified G8-°x resin columns were
subsequently prepared and used for solid phase DNA synthesis. The desired d(GCTAG ° xo°)
was prepared by normal solid phase DNA synthesis.
Preliminary characterization of the d(GCTAG 8 '°x °) oligonucleotide was preformed by
enzymatic digestion and HPLC analysis of the digestion products, as described previously
for the d(GCTA8-O ° G) oligonucleotide. Peak area analysis of the UV chromatogram
obtained from digested d(GCTAG8 -°X °) indicated that the oligonucleotide compound contained
dC, dG, dT, dA and dG8-°Ox. Unfortunately, the amount of dG relative to dG8-°X° was
slightly off. The reason for this discrepancy was not determined. Because of the unexpected
departure of the postdoctoral fellow responsible for the biological studies, research on this
project stopped before mutagenicity data were obtained in repair deficient cell lines.
i. Synthesis of dG ' °x phosphoramidite
Although further study of the G8-°x° lesion has not been done in this laboratory, as part
of a collaborative effort with L. Williams at Emory University, a dodecamer, d(CCA G8-
O°°CGC TGG), was synthesized for X-ray analysis. In order to synthesize the necessary
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phosphoramidite, the 5 '-dimethoxytrityl-N2-acetyl-dG 8 ° x° used in the synthesis of a G8- xo
resin was phosphitylated with 2-cyano N,N diisopropyl chlorophosphoramidite (Figure 13).
Unfortunately, the prepared phosphoramidite did not couple well, in agreement with Roelen
et al. (1991). However, suitable amounts of the dodecamer, 5 '-d(CCA G-°XOCGC TGG),
was synthesized and purified for X-ray analysis. No structural data from this
oligonucleotide are available at this time.
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E. Pyrimidine oxidative lesions:
5-hydroxyuridine and 5-hydroxycytidine
a. Importance of oxidized cytidines
Although our previous study (Wood et al., 1992) confirmed that dG8-°o causes G to T
transversions, the lesion responsible for the major oxidative mutation at GC bases (GC-
> AT transitions) has not been established. Since it appears that oxidative damage of dG
does not explain the predominance of GC to AT transitions, we began the study of dC
oxidative lesions. Recent work by Wagner et al. (1992) established the steady state levels of
three oxidative damage products of dC (Figure 14). Wagner et al. determined that 5-
hydroxy-deoxycytidine (ohsdC) and deoxyuracil glycol (dUg) occurred at similar levels to
those of dG8 -°Ox in rat liver kidney and brain DNA. A third oxidative lesion, 5-hydroxy-
deoxyuracil (ohsdU) which is formed to an equal extent by various oxidative processes (e.g.,
y-radiation, UV, H20 2 with Fe or Cu), however, occurred less often. The abundant
existence of ohSdC, ohsdU and dUg in the genome implies that these lesions are not
completely or rapidly repaired by the organism, and thus they may contribute to
mutagenesis.
As a means to understand the potential mutagenic effects of oxidative cytosine lesions,
work was begun in the Essigmann laboratory to develop site-specifically modified
oligonucleotides containing ohsdU, ohSdC and dUg. The synthesis of a dUg containing
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oligonucleotide was undertaken by D. Mathur. The approach used involved preferential
oxidation of the uracil in the mono-uracilated oligonucleotide 5'-d(GUAGC) with osmium
tetroxide. This method was used previously in this laboratory for the oxidation of a thymine
to thymine glycol (Basu et al., 1989). In contrast, treatment of an oligonucleotide with
oxidizing reagents capable of forming ohsdU and oh5dC would lead to the production of
multiple products. Based on the stability of oh5dU and oh5dC to oxidizing, acidic and basic
conditions (Beltz et al., 1955; Shen et al., 1966; Zorbach et al., 1968; Udea, 1960), a total
synthetic approach appeared more suitable for the preparation modified oligonucleotides
containing these lesions.
b. Synthesis of a ohsdU containing oligonucleotide
The synthesis of a modified oligonucleotide containing ohsdU began with the
preparation of the oxidized nucleoside. Three literature methods have been published for
the preparation of oh5dU. The first method developed to prepare oh5dU involved the
addition of aqueous bromine to dU, followed by treatment of the resulting dihydro
intermediate with lead oxide (Beltz et al., 1955). A second method to synthesize oh5dU
involves formation of 5-bromo-dU and subsequent base catalyzed displacement of the
bromide (Shen et al., 1966). A third method of synthesis involves the addition of aqueous
bromine to dU resulting in formation of dUg and subsequent elimination with pyridine to
form ohsdU (Zorbach et al., 1968; Udea, 1960). This last method is the highest yielding
(47 %) method for synthesizing oh5dU and was the method used in this laboratory to
prepare ohsdU.
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Figure 14. Oxidized cytosine products.
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Figure 15. Synthesis of oh5dU phosphoramidite.
129
HN
0 N
HO
HO
Br 2 / H2 0
pyridine
2'-deoxyuridine
0 O
HN
0 N
HO
13
0 O
HN
DMTrCI ON
pyridine DMTrO
HO
14
Ac20 / pyridine
O
OAc
HN BSTFA
O'N pyridine 100 °C
TMSO I
TMSO
I I
GC-MS
0
OHN
HO
16
I I
1 D-NOE
TCA
CH2CI 2
0
ON
DMTrO
HO
15
NC(CH 2) 20PCI[N(iPr) 2]
CH 2C12
O
HN OAc
DMTrO O
NCo N(iPr)2
17
solid phase
DNA synthesis
FAB-MS
nucleotide digestion " d(Goh5UAGC)
130
The key problem in synthesizing a ohsdU phosphoramidite was the problem of
selectively blocking and activating the various hydroxyl groups. Based on the general
reactivity of deoxynucleosides, the 5' hydroxyl was expected to be more reactive than the
3' hydroxyl (Gait, 1984). However, the reactivity of the 5-hydroxyl as compared to the 5'
or 3' hydroxyl was not known. The reactivity of the three hydroxyl groups was determined
by sequential treatment of the oh5dU (13) with different protecting groups (Figure 15).
Treatment of the ohsdU (13) with DMTCl yielded a mono-DMT product. Based on the
reactivity of DMTrCl with nucleosides, this product was proposed to be the 5'-DMT-ohdU
product (14). Treatment of 5'-DMT-oh5dU with one equivalent of acetic anhydride resulted
in a mono acetylation product, either 5'-DMT-5-acetoxy-dU or 5'-DMT-3'-acetoxy-oh 5dU.
The regiochemistry of this product was subsequently determined by gas chromatography-
mass spectroscopy (GC-MS) (Figure 16) and NMR spectroscopy (Figure 17).
The initial evidence for the regiochemical assignment of the mono-acetylated 5-DMT-
ohsdU product came from GC-MS. If the acetate were on the riboside portion, the uracil
base fragment determined by GC-MS would not contain an acetoxy group; however, if the
acetate were on the uracil portion, the uracil base fragment would contain an acetoxy group.
Because the 5'-DMT group would not be stable for gas chromatography, the DMT group
was deprotected with trichloracetic acid. The deprotected nucleoside was the treated with
N,O-bis(trimethylsily)-trifluoroacetamide (BSTFA) to persilylate the molecule for GC-MS
analysis. GC-MS of bis-TMS-acetoxy-oh 5dU showed the presence of m/z= 314 and 299 (M-
CH3)+ (Figure 16). The 314 molecular ion corresponds to a bis-TMS-acetoxy-uridine base
131
fragment; therefore, the product from mono-acetylation must have been 5'-DMT-5-acetoxy-
dU. This result was then confirmed by a one dimensional Nuclear Overhauser Effect (1D-
NOE) (Figure 17). If the product were 5'-DMT-3 '-acetoxy-ohsdU, no NOE would be
expected between a 3'-acetoxy group and the H6 proton. As seen in Figure 17, a positive
NOE was found with H6. Unfortunately, because one of the H2' protons was also excited a
positive NOE was additionally seen with H3'. This NOE result, consequently, can not
prove that the product of acylation occurred only at the 5-OH, nevertheless, the 5'-DMT-
3'-acetoxy-ohSdU product would not be consistent with the NOE data. Therefore, based on
the GC-MS and this NOE result, the product from the mono-acetylation of 5'-DMT-ohSdU
(14) must have been 5'-DMT-5-acetoxy-dU (15).
Since the 5'-DMT-5-acetoxy-dU product (15) was properly protected for solid phase
DNA synthesis, subsequent formation of the 3'-phosphoramidite did not require additional
manipulation of the protecting groups. Treatment of the 5'-DMT-5-acetoxy-dU product
(15) with 2-cyano-N,N-diisopropylaminechlorophosphoramidite resulted in the necessary 3'-
phosphoramidite (17). The desired oligonucleotide GOhUAGC was prepared by solid phase
DNA synthesis. The coupling efficiency of of 5'-DMT-5-acetoxy-dU 3'-[(2-cyanoethyl)
N,N-diisopropylphosphoramidite] was determined by dimethoxytrityl cation quantification to
be greater than 65 % (not optimized).
The identity of the purified oligonucleotide containing °hsdU was established by a
combination of enzymatic DNA digestion followed by HPLC analysis and laser assisted
matrix desorption mass spectrometry. Laser assisted matrix desorption of the modified
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Figure 16. GC-MS of mono-acetylated 5-DMT-ohSdU.
133
H
) TCA
TMSO
N 4, O Ac
ON
TMSO
TMSO
257
TMSO
TMSO<N
CloH2oN204 Si 2
272
241
158
101 117 131 14 , 174185 211 225 .j
1 j. I, .. I .. , ;. i.. I .,.. I . . I ..' 'i-
100 120 140 160 180 200 220 240
M/Z
ElMS
TMSO
N O Ac
TMSO N
272
C1 2H 22N 20 4 Si 2
314
299
II 314
260 280 300 320
134
) BSTFA
_ _? ..
DMTr
I UUUU
600000
500000
o 400000
O
300000
200000
100000
0
Minutes
1200000ooo A
1000000-
800000
600000-
400000-
C)
U
.0<~
200000
0
.
-
- -
- - ·r· __· r __I
." ,.._ 
------
__r 4nA
_ _ _ _
_
Figure 17. 1D-NOE of 5-acetoxy-dU.
135
-I
C,
i
I
I~
0
=> CO0
i 0
m
C_
i _I
m,,-
-;l 
T-
C)
CD
CD
CD
0
D
0
m A
136
-j
1
0-
0' -
4h; 
0-
3 -
w
0.
m.
(0
0.
r -01
3
0
0
CD
0
o
:= 
.
I
---
0o
Figure 18. Enzymatic digestion of GOhSUAGC.
137
GCAGC BAP"- nucleosides
or SVPDE
G 50HU A GC SVPDE
HPLC
A
160
E
C
v 120
80
D 80
C
50HU A
I 
I
138
60
40
20
0
0 2 4 6 8 10 12 14 16 18
MINUTES
oligonucleotide showed a parent molecular ion of m/z= 1504, in agreement with the
calculated molecular weight for the modified oligonucleotide (m/z= 1504.1). Subsequent
enzymatic digestion of the modified oligonucleotide and HPLC analysis confirmed the
presence of the modified base, °hdU (Figure 18). At this time, no biological results are
available for this modified oligonucleotide.
c. Preliminary studies to synthesize ohSdC containing oligonucleotides.
Synthesis of oh5dC containing oligonucleotide is more difficult than sythesizing a
ohsdU oligonucleotide for two reasons: 1) oh5dC has one additional reactive site, the N4
amino group, that must be blocked prior to oligonucleotide synthesis; and 2) it is unknown
under what conditions oh5dC would deaminate to oh5dU. Three approaches have been
utilized to synthesize oh5dC containing oligonucleotides. The first approach involved the
oxidation of a protected cytosine. If the N4 amino group was protected prior to formation of
the 5-hydroxy, the resulting functional groups in an N4-protected-oh5dC would be the same
as the oh5dU nucleoside, the 5',3' and 5-hydroxy groups. Subsequent protection and
activation steps developed for oh5dU could, in theory, be used to synthesize a N4 protected
ohsdC phosphoramidite. Unfortunately, of the two methods examined to oxidize N6-
benzoyl-dA: bromine/water and pyridinium bromide perbromide, the oxidation products did
not appear to have yielded a 5-hydroxy product. Based on this inability to oxidize N6-
benzoyl-dA, studies were undertaken to examine the potential of differentially protecting
ohsdC.
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A procedure involving differential protection of ohSdC began with the synthesis of
oh5dC. A similar oxidation procedure as with ohsdU was used (Eaton and Hutchinson,
1973). Unfortunately, preliminary studies involving peracylation of ohSdC with acetic
anhydride or benzoyl chloride commonly led to multiple products. The production of
multiple products seemed to indicate that some deamination was taking place while the N6
amino group was being protected. These studies seemed to indicate that even if a protected
N4 -ohSdC could be synthesized, the ohsdC nucleotide might not be stable to oligonucleotide
synthesis. Consequently a new approach was needed that would avoid the potential problem
of deamination of the ohSdC nucleoside.
Only preliminary studies have been done on a third approach to synthesize a ohsdC
modified oligonucleotide. As depicted in Figure 19, this approach involved the in situ
generation of oh5dC from ohSdU. In 1986, Zhou and Chattopadhyaya reported the in situ
site-specific modification of uracil to cytosine. The method involved displacement of 2,4,6-
trimethylphenyl (TMP) or 2-nitrophenyl from the 04 position of uridine with ammonia.
Sproat et al. (1989) and MacMillan and Verdine (1990) subsequently reported the
displacement of these 04 activated uridines with a variety of alkylamines. We reasoned that
synthesis of a TMP-oh5dU phosphoramidite would allow us to synthesize oh5dC containing
oligonucleotides. Initial studies indicate that a TMP-5-hydroxy-dU derivative can be made
in five steps. The current method begins by protection of ohSdU with acetic anhydride. The
04 position of ohSdU can subsequently be activated with triisopropylbenzensulfonyl chloride
and blocked with TMP. Using a methanolic ammonia solution, the acetate protecting groups
can be removed without displacing the 04-TMP group. Work is continuing to validate this
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approach. It is proposed that a reactive phosphoramidite could be synthesized in three more
steps: 1) protection of the 5' hydroxyl with a dimethoxytrityl group, 2) protection of the 5
hydroxyl with an acetate protecting group, as done in the ohSdU synthesis, and 3) formation
of the 3' phosphoramidite.
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Figure 19. Proposed synthetic pathway for O°hdC.
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F. Conclusions
The previous sections have described the synthesis of four modified oligonucleotides
and an approach to synthesize a fifth modified oligonucleotide. The oligonucleotides were
made in order to determine the mutagenic and structural consequences of an aromatic amine
carcinogen and three different oxidative DNA lesions. The methods utilized to synthesize
the modified oligonucleotide involved either the modification of a preformed
oligonucleotide, in the case of 4-ABP, or solid phase DNA synthesis utilizing a modified
phosphoramidite. In the case of the ABP oligonucleotide, reaction of N-acetoxy-
aminobiphenyl with an oligonucleotide containing only one guanine residue was a facile
method for the preparation of the modified oligonucleotide containing the major
aminobiphenyl adduct. Subsequent biological study of the modified oligonucleotide by S.
Verghis showed that the major ABP adduct was not mutagenic in ss DNA in the sequence
context studied. Synthesis of two purine oxidation products, G8-°x and A8-° °, were made by
total synthetic procedures. Subsequent biological studies conducted by M. Wood and A.
Esteve established that the A8-°X° lesion was weakly mutagenic. Ongoing studies by L.
Williams are attempting to establish the structural consequences of G8-°x by X-ray
crystallography. In contrast to the problems synthesizing oxidized purine lesions, a oh5dU
phosphoramidite was readily synthesized and utilized in solid phase DNA synthesis.
Ongoing studies are attempting to determine the mutagenic potential of this lesion. Further
studies are required before a ohSdC oligonucleotide can be synthesized. One strategy that
appears hopeful involves the in situ generation of ohSdC via a 04 modified ohSdU
oligonucleotide.
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G. Experimental
a. General Procedures and Materials
Unless otherwise specified, all chemicals were bought from Aldrich or Sigma chemical
companies. Long chain amine (LCA) control pore glass was bought from CPG, inc.
(Fairfield, NJ). THF and CH2Cl2 were distilled from CaH2 and pyridine and triethylamine
were distilled from sodium. Silica gel TLC plates were visualized with UV illumination
followed by charring with 5 % anisaldehyde in ethanol-acetic acid-sulfuric acid (95:5:1).
Silica gel (230-400 mesh) was used for normal phase chromatographic separations. All
reactions were performed under an argon atmosphere except when working in aqueous
media.
Mass spectrometry data were obtained by matrix-assisted laser desorption and time of
flight mass spectroscopy with 2-nitrobenyzl alcohol as the matrix. GC-MS was performed
on a Model 5971A mass selective detector interfaced to a Model 5890 Serives II gas
chomatograph (both from Hewlett Packard). The injection port, ion source and interface
were maintained at 240 C. Separations were carried out on fused silica column (12.5 M x
0.20 mm) coated with cross-linked methyl silicone gum phase (film thickness 0.33 m)
(Hewlett Packard). Helium was the carrier gas at an inlet pressure of 37.5 psi. Scan mode
of monitoring was performed at 70 eV using the electron-impact mode of ionization. The
A8-°X°nucleoside base fragment was obtained by hydrolyzing the dA8 -°x nucleoside with 0.5
ml of formic acid (98%) in an evacuated and sealed tube at 150 'C for 30 min follow by
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lyophilization and subsequent conversion to the trimethylsily (TMS) derivative in a Teflon-
capped vial with 40 Al of N,O-bis(trimethylsily)-trifluoroacetamide (BSTFA)
acetonitrile/pyridine (2:1 v/v) at 85 C for 30 min. After cooling the derivatized products
were injected directly onto the GC without further treatment.
'H and '3C NMR spectra were recorded on Varian VXR-300, VXR-301, or Bruker
AC-250 MHz spectrometers. Chemical shifts are expressed in parts per million downfield
from CDC13 (7.24 ppm or 77.00 ppm), CD 3OD (3.30 ppm and 35.00 ppm), and Me2SO
(2.49 ppm and 39.5) for 'H and 13C, respectively. Data are reported as follows: chemical
shift, integration, multiplicity, and regiochemical assignments.
Reversed phase HPLC analyses were performed with a Beckman C,8 ultrasphere or
Phenomenex Ultramex 5-pzm C18 columns. Chromatography was done with either a
Beckman 114M solvent delivery system, Beckman 421A controller, and Hewlett Packard
model 1040A photodiode array detector or with a Beckman Ultrasphere C, 8 column using a
Nec PC-8300 controller, Beckman Analog Interface Module 406, Beckman 110B solvent
Delivery Module, Nelson Analytical 760 series Interface, and Gateway 2000 computer. The
compounds were monitored at 280 and 254 nm. The follow rate was 1 ml/min. Gradient I:
a linear gradient from 0-50% acetonitrile in 0.1 M ammonium acetate pH 5.8.
Oligodeoxynucleotides were synthesized by solid phase DNA synthesis on an Applied
Biosystems DNA synthesizer using phosphoramidite chemistry. The modified
phosphoramidite could be added either manually (for less than 10 mol synthesizes) or
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automatically for large scale preparation. Manual coupling of a modified phosphoramidite
involved: 1) halting the oligonucleotide synthesis before the modified phosphoramidte was
to be added; 2) adding the phosphoramidite dissolved in CH 3CN (100 l) and ABI
tetrazole/CH 3CN solution (100 lI) via two disposable 1 ml syringes; and 3) resuming
automated DNA synthesis after the phosphoramidite coupling steps. Automatic coupling
involved dissolving the phosphoramidite with CH 3CN and attaching the solution to the X
port on the DNA synthesizer. Subsequent to oligonucleotide synthesis in either case, the
oligonucleotide was cleaved from the resin with NH4OH(cOn) (3 x 5 ml). The ammonium
hydroxide solution containing the oligonucleotide was heated overnight at 60 C. The
deprotected oligonucleotide was purified by gel electrophoresis or RP-HPLC. The base
composition of the modified oligonucleotide was determined by RP-HPLC after digestion
with bacterial alkaline phosphatase and snake venome phosphodiesterase.
Coupling yields were determined by dimethoxytrityl cation quantification. The
procedure involved 1) mixing the oligonucleotide dimethoxytrityl eluent (0.5 ml) with 0. 1M
toluene sulfonic acid dissolved in acetonitrile (4.5 ml); 2) diluting the dimethoxytrityl
solution/acetonitrile solution (0.1 ml) with 0. 1M toluene sulfonic acid dissolved in
acetonitrile (0.9 ml); and 3) measuring the UV absorbance at X=298 nm .
b. Methods
5'-d(TGABPCA) (1)
The tetranucleotide, TGCA (10 Armol, - 0.18mg), prepared by solid phase DNA syntheis on
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an Applied BioSystems DNA Synthesizer, was dissolved in 30 ml of CHC13 / EtOH / H20
(7:4:4) and triethylamine (1.0 ml). After warming to 40 C, N-acetoxy-aminobiphenyl
(0.86 g, 3.79 mmol) was added in 5 portions at approximately 15 min invervals. After 2.75
hr, the dark red solution was diluted with CH2C12 (20 ml) and H20 (5 ml). The aqueous
layer was collected and washed CH2C12 (2 x 25 ml). The combined aqueous solution was
concentrated in vacuo. HPLC analysis using gradient I indicated that 30-40% of the
d(TGCA) had reacted. The d(TG8-ABPCA) was purified by reversed phase HPLC using
gradient I. After HPLC purification the d(TG8-ABPCA) was desalted using the same HPLC
column and a linear H20, CH 3CN gradient. Laser assisted matrix desorption mass
spectrometry was used to analyze the d(TGSABPCA). The tetranucleotide was calculated to
have a molecular weight of 1340. The negative ion spectrum showed the major [M-H]- ion
to be m/z= 1339.
8-Bromo-2'-deoxyadenosine (2).
Deoxyadenosine (2.03 g 8.08 mmol) suspended in 20 ml of 1 M NaOAc buffer (pH 5.4)
was treated with aqueous bromine Br2/sodium acetate buffer (37 ml) prepared by dissolving
Br2 (2 ml) in sodium acetate buffer (40 ml). After 2 hr, solid NaHSO3 was added until the
intense brown color of the reaction solution faded. The pH of the solution was adjusted to
pH 7.0. The solution was left to chill at -20 C for 20 min. The brown solid was collected
by filtration, washed with water, and dried on kugelrohr (60 'C, 0.3 mm Hg) overnight to
yield 1.72 g, 5.21 mmol (65%) of 8-Bromo-2'-deoxyadenosine (2). (TLC rf 0.42 MeOH/
CH2C12 9:1) mp > 250 C; H NMR ((CD3 )2SO): 2.19 ( 1H, m, H2"), 3.24 (1H, m,
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H2'), 3.47 (1H, m, H5"), 4.62 (1H, m, H5'), 3.87 (1H, d, H4'), 4.47 (1H, d, H3'), 5.28
(1H, dd, 5'-OH), 5.33 (1H, d, 3'-OH), 6.28 (1H, t, H'), 7.50 (2H, br, 6NH2), 8.10 (1H,
s, H2). 13C NMR ((CD3 )2 SO): 36.96 (C2'), 62.04 (C5'), 71.08 (C3'), 86.28 (C4'), 88.25
(C1'), 119.0 (C5), 127.0 (C4), 149.5(C6), 152.2 (C2), 154.9 (C8). UV (CH3OH) Lx =
265 nm ( = 15,500) [no apparent shift in Xmax with pH].
2'-Deoxy-7,8-dihydro-N 6 -acetyl adenosin-8-one (3).
The 8-bromo-2'-deoxyadenosine (2) (0.80 g, 2.42 mmol), dimethylaminopyridine (0.08 g,
0.655 mmol), and sodium acetate (1.63 g, 19.87 mmol), pre-dried under high vacuum on a
kugelrohr at 0.5 mm Hg and 100 C, were suspended in acetic anhydride (23 ml). After
refluxing for 2 hr, the reaction was cooled to room temperature and quenched with
Na2CO3(con) (50 ml). The aqueous solution was extracted with EtOAc (2 x 50 ml) and the
combined organic solution was washed with Na2CO3(con) (2 x 75 ml), dried with Na2SO4,
filtered, concentrated, and evaporated twice from toluene. The residue was suspended in
CH2C12 and filtered.
The crude mix acetylated material was dissolved in 100 ml of pyridine/ MeOH/ water
(35/10/5) and treated with 2 N NaOH (5 ml). After 15 min, the reaction (pH = 11.5) was
quenched by the addition of AcOH(con) until pH 7.0. The solution was concentrated to
dryness and evaporated twice from toluene. The solid was suspended in CH2C12 and
filtered. The collected solid was suspended in water, chilled to -20 'C for 15 min, and
filtered again. The white solid was dried on a kugelrohr (60 C and 0.5 mm Hg) to yield
1.01 g, 3.27 mmol (63 %) of 2'-deoxy-7,8-dihydro-N 6
-acetyl adenosin-8-one (3). (TLC rf
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0.46 MeOH/ CH2Cl 2 95:5); mp 247-250; 'H NMR ((CD3 )2SO): 2.06 (1H, m, H2'), 2.12
(2H, s, N6Ac), 3.05 (1H, qt, H2'), 3.43 (1H, dd, H5"), 3.59 (1H, dd, H5'), 3.78 (1H, m,
H4'), 4.41 (1H, br, H3'), 4.80 (1H, br, OH), 5.22 (1H, br, OH), 6.20 (1H, t, Hi'), 8.39
(1H, s, H2), 10.27 (1H, br, NH), 10.83 (1H, br, NH). ' 3C NMR ((CD3)2SO) 23.11 (Ac),
35.58 (C2'), 62.20 (C5'), 71.10 (C3'), 81.25 (C4'), 87.47 (C5'), 110. 98 (C5), 138.03
(C4), 149.61 (C2), 150.16 (C8), 150.96 (C6), 169.4 (Ac). UV (CH 3OH) X,m290 nm (E
=11,000) (pH 7.2); 290 nm ( = 11,000) (pH 1.0); 307 nm ( = 13,000), 271 nm (E
=6,400) (pH 12).
2'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-7,8-dihydro-N 6 -acetyl adenosin-8-one (4).
2'-Deoxy-7,8-dihydro-N 6 -acetyl adenosin-8-one (3) (0.30 g, 0.970 mmol), 4,4'-
dimethoxytrityl chloride (0.68 g, 2.01 mmol, 200M%), and dimethylaminopyridine (0.002
g) were suspended in pyridine (10 ml). Upon addition of triethylamine (0.400 ml, 2.87
mmol, 300 M%), the brown solution turns a red color and within 30 min, the solution
became a clear light brown. After 4.5 hr, additional dimethoxytritylchloride (0.35 g, 1.03
mmol, 100 M%) and Et3N (0.150 ml, 1.08 mmol, 110 M%) were added. After 7 hr, the
reaction mixture was diluted with CH2C12 (30 ml) and quenched with NaHCO3(,,) (40 ml).
The organic layer was collected and the aqueous layer back extracted with CH2C12 (30 ml).
The combined organic solution was washed with 40 ml NaCl(sat) (40 ml), dried with Na 2SO4,
filtered and concentrated to dryness. 2'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-7,8-dihydro-N 6 -
acetyl adenosin-8-one (4) was purified by silica gel chromatography (35 g) by eluting with
MeOH/CH 2Cl 2 (5:95) and > 1 % Et3N to yield 0.484 g (0.790 mmol, 81 %). (TLC Rf 0.27
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MeOH/ CH2Cl2 97:3); mp 133-136; H NMR (CD 3OD): 2.11 (1H, m, H2"), 2.12 (3H, s,
Ac), 3.04 (1H, m, H2'), 3.14 (2H, m, 2 x H5'), 3.70 (6H, d, 6H, 2 x CH30), 3.92 (1H, q,
H4'), 4.48 (1H, q, H3'), 6.20 (1H, t, H1'), 6.78 (4H, m, DMT), 7.18 (7H, m, DMT),
7.34 (2H, d, DMT), 8.20 (1H, s, H2), 10.20 (1H, br, NH), 10.82 (1H, br, NH). 13C
NMR (CD3OD): 23.81 (Ac), 37.48 (C2'), 56.16 (DMT-OMe), 66.22 (C5'), 73.80 (C3'),
83.618 (C4'), 87.76 (DMT), 88.02 (C1'), 111.55 (C5'), 114.36 (Ph-OMe C3"), 128.11 (Ph
C4"), 129.02 (Ph C2"), 129.84 (Ph C3"), 131.78 (Ph-OMe C2"), 137.93 (Ph-OMe C1"),
140.05 (C4), 147.10 (Ph C1"), 151.82 (C2) 152.58 (C8), 153.589 (C6), 160.45 (Ph-OMe
C4"), 172.68 (Ac); UV (CH 3OH) Xmax 285 nm (E =12,600) (pH 8.25); 284 nm (e
= 13,000) (pH 1.0); 305 nm (e = 12,600), 270 nm (e =900) (pH 12).
2'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-7,8-dihydro-N 6 -acetyl adenosin-8-one 3'[(2-
cyanoethyl) N,N-diisopropylphosphoramidite] (5).
2-Cyanoethyl N,N-diisopropylchlorophosphoramidite (50 /l) was added to 2'-deoxy-5'-O-
(4,4'-dimethoxytrityl)-7,8-dihydro-N 6 -acetyl adenosin-8-one (4) (73.5 mg, 120 /mol)
dissolved in CH3CN (500 zl) with tetrazole (50 ,l of a 3 M soln in CH3CN). After 2 hr,
additional 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (50 /l) was added. The
crude reaction mixture was used for DNA synthesis. (TLC rf =0.42 MeOH/ CH2C12 97:3)
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2'-Deoxy-7,8-dihydroadenosin-8-one (6).
8-Bromo-deoxyadenosine (2) (0.87 g, 2.64 mmol), dimethylaminopyridine, and sodium
acetate (2.11 g, 25.72 mmol), pre-dried on high vacuum on kugelrohr at 0.5 mm Hg and
100 C, were suspended in Ac20 (40 ml). After 2 1/2 hr at reflux, the solution was cooled
to room temperature and quenched with Na2CO3 (sat) (100 ml) and extracted EtOAc (2 x 50
ml). The organic solution was washed Na2CO3 (sat) (2 x 50 ml), dried with Na2SO 4, filtered,
concentrated, and evaporated twice from toluene.
Sodium hydroxide (10 M, 5 ml) was added to the crude mix acetylated material dissolved in
50 ml of pyridine/ MeOH/ water (35/10/5). After 19 hr at room temperature, the reaction
(pH 11.5) was quenched with AcOH(cfnc.) until pH 7.0. The solution was concentrated to
dryness and evaporated twice from toluene. The 2'-deoxy-7,8-dihydroadenosin-8-one (6)
was purified by silica chromatography (20 g) by eluting with 20% MeOH/CH 2Cl 2. (TLC rf
0.26 MeOH/ CH2C12 90:10); mp > 235 'C; H NMR (CD 3OD): 2.12 (1H, dd, H2"), 2.92
(1H, m, H2'), 3.68 (1H, dd, H5"), 3.83 (1H, dd, H5'), 4.02 (1H, s, H4'), 4.55 (1H, d,
H3'), 6.37 (1H, dd, H1'), 7.94 (1H, s, H2). 13C NMR (CD 30D): 39.14 (C2'), 64.54
(C5'), 74.04 (C3'), 84.72 (C4'), 89.49 (Cl'), 111.61 (C5), 148.55 (C4), 149.63 (C2),
150.00 (C6), 157.78 (C8); UV (0.1 M NH 4OAc) Xmax260 nm ( =11,000) (pH 6.85); UV
(CH3OH) Xmax 270 nm ( = 10,000) (pH 8.6); 283 nm (e = 14,000) (pH 1.0); 269 nm (=
8,500), 289 nm (= 9,400) (pH 12).
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2'-Deoxy-7,8-dihydro-N 2,3 ',5'-triacetylguanosin-8-one (7).
Sodium benzylate was prepared by chilling benzyl alcohol (10 ml, 96.6 mmol) with an ice
bath and then adding NaH (0.080 g, 3.33 mmol). After gas evolution ceased, DMSO (10
ml) and 8-bromo-deoxyguanosine (3.00 g, 8.67 mmol) were added. After 24 hr at 110 C,
the mixture was diluted with acetone whereby a brown solid precipitated from solution. The
crude 2'-deoxy-7,8-dihydro-guanosin-8-one was washed with CH2C12 and acetone and dried
under a high vaccum.
The crude 2'-deoxy-7,8-dihydro-guanosin-8-one was dissolved in pyridine (50 ml) and
treated with acetic anhydride (20 ml). After 2.5 hr at 80 C, the reaction was concentrated
to dryness, diluted with CH2C12 (100 ml) and washed with Na2CO3(st) (40 ml) and NaCl(sat
(40 ml). The organic solution was dried with Na2SO4, filtered and concentrated. The 2'-
deoxy-7,8-dihydro-N 2,3',5'-triacetylguanosin-8-one (7) was purified by silica gel
chromatography (50 g) by eulting with CH2Cl2/MeOH (96:4) (0.87 g, 2.12 mmol, 25 %
yield) (TLC rf 0.29 CH2Cl2/MeOH 95/5) H NMR (CDC13): 9.51 (1H, s, NH), 6.38 (1H,
dd, Hi'), 5.42 (1H, m, H3'), 4.83 (1H, m, H5'), 4.44-4.36 (2H, m, H4', H5"), 2.97 (1H,
m, H2"), 2.38 (1H, m, H2'), 2.32 (2H, s, NHAc), 2.13 (3H, s, OAc), 2.12 (3H, s, OAc).
2 '-Deoxy-7,8-dihydro-N 2-acetylguanosin-8-one (8).
Sodium hydroxide (5 M, 0.50 ml) was added to 2'-deoxy-7,8-dihydro-N 2,3 ',5'-
triacetylguanosin-8-one (7) (0.70 g, 1.71 mmol) dissolved in MeOH (10 ml). After 20 min
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at room temperature, the reaction was quenched by adding acetic acid(cOl) (0.50 ml) and the
solution was concentrated to dryness. The 2'-deoxy-7,8-dihydro-N 2-acetylguanosin-8-one
(8) was purified by silica gel chromatography (10 g) by eluting with CH2Cl 2/MeOH (90: 10).
(0.33 g, 1.01 mmol, 60 % yield). (TLC rf 0.27 CH2Cl2/MeOH 90/10). H NMR
(CDC13): 9.51 (1H, s, NH), 6.38 (1H, dd, Hi'), 5.42 (1H, m, H3'), 4.83 (1H, m, H5'),
4.44-4.36 (2H, m, H4', H5"), 2.97 (1H, m, H2"), 2.38 (1H, m, H2'), 2.32 (2H, s,
NHAc).
2'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-7,8-dihydro-N 2 -acetylguanosin-8-one (9).
2'-Deoxy-7,8-dihydro-N 2-acetylguanosin-8-one (8) (0.33 g, 1.01 mmol),
dimethoxytritylchloride (0.704 g, 2.1 mmol), and DMAP (0.08 g, 0.65 mmol) were
dissolved in pyridine (5 ml) and triethylamine (0.50 ml). After 12 hr at room temperature,
the reaction mixture was concentrated to dryness. The residue was dissolved in CH2C12 (50
ml) and washed with NaHCO3 (sa) (20 ml) and NaCl(sat) (20 ml). The organic solution was
dried with NaSO 4, filtered and concentrated. The 2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-7,8-
dihydro-N 2-acetylguanosin-8-one (9) was purified by silica gel chromatography by eluting
with CH2CI2/MeOH (92:8) (0.70 mmol, 69 % yield) (TLC rf 0.52 CH2Cl2/MeOH 90:10)
1H NMR (CDC13/CD 3OD): 7.45-7.14 (9H, m, Ar), 6.80-6.74 (4H, m, Ar), 6.64 (1H, dd,
Hi'), 4.65 (1H, m, H3'), 3.99 (1H, m, H4'), 3.85 (6H, s, DMTOCH3), 3.38-3.30 (2H, m,
H5' and H5"), 3.14 (1H, m, H2"), 2.19 (1H, m, H2'), 2.03 (3H, s, NHAc). 13C (CDC13):
173.4, 158.1, 144.9, 135.9, 151,6, 146.9, 145.1, 129.9, 129.8, 127.9, 126.6, 113.0,
103.7, 85.8, 85.4, 81.1, 71.2, 65.0, 55.1, 36.2, 23.8.
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2'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-7,8-dihydro-N 2 -acetylguanosin-8-one 3'-succinate p-
nitrophenyl ester (10).
2'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-7,8-dihydro-N 2-acetylguanosin-8-one (9) (0.45 g,
0.719 mmol), succinic anhydride (0.386g, 3.86 mmol, 540 M%), and
dimethylaminopyridine (0.136 g, 1.11 mmol, 155 M%) were dissolved in pyridine (5 ml)
and triethylamine (1.0 ml). After 13 hrs at room temperature, p-nitrophenol (0.50 g, 3.59
mmol, 500 M%) and diisopropylcarbodiimide (0.600 ml, 3.84 mmol, 530 M%). After 2.5
hr, p-nitrophenol (0.22 g, 1.59 mmol, 220 M%) and DIC (0.400 ml, 2.56 mmol, 355 M%)
were added. After an additional 5.5 hr, the reaction mixture was concentrated to dryness.
The residue was dissolved in CH2C12 (50 ml) and washed with NaHCO 3 (sat) (20 ml) and
NaCl(sa) (20 ml). The organic solution was dried with NaSO4, filtered and concentrated.
The residue was suspended in CH2C12 and the diisopropylurea was filtered. The resulting
soultion was used without purification.
2'-Deoxy-5'--(4,4'-dimethoxytrityl)-7,8-dihydro-N 2-acetylguanosin-8-one 3'-succinate-
LCA resin (11).
2'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-7,8-dihydro-N 2 -acetylguanosin-8-one 3'-succinate p-
nitrophenyl ester (10) was added to long chain amine (LCA) control pore glass (2.00 g)
suspended in pyridine (5 ml). After 4 hr, the reaction mixture was filtered, washed with
DMF, MeOH, and CH2C12, and then suspended in pyridine (5 ml) and treated with acetic
anhydride (1.0 ml) and DMAP (0.51g). After 2 hrs, the reaction was filtered and washed
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with DMF, MeOH, and CH2C12. Dimethoxytrityl quantification was done by treating a
portion of the resin with 70% HC104 (5.14 ml) dissolved in MeOH (4.6 ml) and measuring
the absorbance at 498 nm. The loading was determined by using the relationship: bound
dG8-oxo° umol/g = A49 8 nm X 14.3 [volume HC104 (ml)/ mg resin]. The loading was
determined to be 4 to 5 /xmol/g.
2'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-7,8-dihydro-N 2-acetylguanosin-8-one 3'-[(2-
cyanoethyl) N,N-diisopropylphosphoramidite] (12).
2-Cyanoethyl N,N-diisopropylchlorophosphoramidite (400 /) and diisopropylethylamine
(400 td) were added to 2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-7,8-dihydro-N 2-acetylguanosin-
8-one (9) (0.745 g, 1.17 mmol) dissolved in THF (5 ml) and CH2C12 (5 ml). After 1 hr, 2-
cyanoethyl N,N-diisopropylchlorophosphoramidite (400 t/) was added. After 2 hr, the
reaction was concentrated and the 2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-7,8-dihydro-N 2 -
acetylguanosin-8-one 3'[(2-cyanoethyl) N,N-diisopropylphosphoramidite] (12) was purified
by silica gel chromatography (20 g) eluting with CH2Cl 2/MeOH (96:4). (TLC rf =0.29
MeOH/ CH2C12 97:3).
5-Hydroxy-2'-deoxyuridine (13).
A bromine saturated aqueous solution (150 ml) was added to deoxyuridine (5.29 g, 23.2
mmol) dissolved in 50 ml H20 until a persistent yellow color developed. After 10 min, the
excess bromine was quenched with Na2SO3 until the reaction mixture became clear and
156
colorless. The aqueous solution was then poured into pyridine (200 ml) chilled to 0 C.
The ice bath was removed after 10 min, and the reaction mixture was allowed to stir at
room temperature. After stirring overnight, the solvents were removed under vacuum in a
rotary evaporator. The residue was redissolved in H20 (50 ml) and washed with CH2C12 (2
x 50 ml). The aqueous solution was concentrated and the resulting viscous syrup was
purified by silica gel chromatography by eluting with 20 to 80% MeOH/CH 2Cl2. The
slightly yellow solid obtained was crystallized from MeOH at 4 'C. The yield was
determined to be 41% (2.26 g, 9.28 mmol). H (CD 3OD): 7.45 (1H, s, H6), 6.30 (1H, t,
H1'), 4.37 (1H, d, H3'), 3.88 (1H, d, H4'), 3.74 (2H, m, H5' and H115"), 2.19 (2H, m,
H2' and H2").
5 '-O-(4,4'-Dimethoxytrityl)-5-hydroxy-2-'deoxyuridine (14).
5-Hydroxy-2-'deoxyuridine (13) (1.08g 4.43 mmol) and dimethoxytritylchloride (2.25g 6.64
mmol) were dissolved in pyridine (20 ml) and stired at room temperature. After 4 hr, the
solvent was removed in vacuo, and the residue redisolved in CH2C12 (50 ml) and washed
with NaHCO3 (sa) (20 ml) and NaCl(sat) (20 ml). The organic solution was dried with NaSO4,
filtered and concentrated. The residue was purified by silica gel chromatography by eluting
with 4% MeOH/CH 2Cl 2 to yield 1.44g 2.59 mmol of 5 '-O-(4,4'-dimethoxytrityl)-5-
hydroxy-2'-deoxyuridine (14). (TLC rf 0.15 CH 2CI2/MeOH 90:10) H NMR (CDC13):
7.90 (1H, s, H6), 7.40-7.20 (9H, m, DMT), 6.83 (4H, d, DMT), 6.36 (1H, t, H1'), 4.60
(1H, br, H3'), 4.06 (1H, br, H4'), 3.80 (6H, s, DMT-OCH 3), 3.34 (2H, s, H5' and H15"),
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2.50-2.27 (2H, m, H2' and H2"). HRMS calculated for C30H30N20 8 (M+) 546.2002,
found 546.1999.
5 '-0-(4,4'-dimethoxytrityl)-5-acetoxy-2-'deoxyuridine (15).
Acetic anhydride (200 /l, 2.12 mmol, 120 M%) was added to 5 '-O-(4,4'-dimethoxytrityl)-
5-hydroxy-2'-deoxyuridine (14) (0.97 g, 1.74 mmol) dissolved in pyridine (10 ml). After
1.5 hr at room temperature, the reaction mixture was concentrated and the residue was
resdissolved in C112C12 (100 ml) and washed NaHCO 3(sa) (40 ml) and NaCl(,t) (40 ml). The
organic solution was dried with Na 2SO4, filtered and concentrated. The 5'-O-(4,4'-
dimethoxytrityl)-5-acetoxy-2-'deoxyuridine (15) was purified by silica gel chromatography
(25 g) by eluting with 4 % MeOH/CH 2Cl2. (TLC rf 0.35 CH2Cl2/MeOH 95:5) 11H NMR
(CDC13): 7.90 (1H, s, H6), 7.40-7.20 (9H, m, DMT), 6.83 (4H, d, DMT), 6.36 (1H, t,
Hi'), 4.60 (1H, br, H3'), 4.06 (1H, br, H4'), 3.80 (6H, s, DMT-OCH3), 3.34 (2H, s, H5'
and H5"), 2.50-2.27 (2H, m, H2' and H2"), 1.89 (3H, s, Ac). 13C NMR (CDCl3):
168.26, 158.61, 158.12, 149.31, 149.29, 144,29, 135,47, 135.29, 131.23, 129.94, 129.83,
128.04, 127.96, 127.92, 127.59, 127.04, 123.82, 113.33, 87.06 (RO-OC-(Ph)3), 86.39
(C'), 85.29 (C4'), 72.08 (C3'), 63.36 (C5'), 55.23 (DMT-OCH3), 41.35 (C2'), 19.83
(Ac). HRMS calculated for C32H32N20 9 (M+) 588.21078, found 588.2108.
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5-Acetoxy-2-'deoxyuridine (16).
Acetic anhydride (60 tl, 0.64 mmol, 100 M%) was added to 5'-O-(4,4'-dimethoxytrityl)-5-
hydroxy-2'-deoxyuridine (14) (0.35 g, 0.63 mmol) dissolved in pyridine (5 ml). After 1.5
hr at room temperature, the reaction mixture was concentrated and the residue resdissolved
in CH2C12 (5 ml). Three successive aliquots of a trichloroacetic acid solution (200 11l, 200
tdl, and 1.0 ml, respectively) (ABI reagent) were added at 15 min intervals before complete
deprotection of the dimethoxytrityl group occurred. The organic solution was concentrated
to dryness in vacuo. The 5-acetoxy-2-'deoxyuridine (16) was purified by silica gel
chromatography (10 g) eluting with 8 % MeOH/CH 2Cl 2. (0.15 g, 0.52 mmol, 83% yield)
(TLC rf 0.34 CH2C12/MeOH 90:10) H NMR (CDC13): 8.02 (1H, s, H6), 6.19 (1H, t,
H1'), 4.34 (1H, d, H3'), 3.88 (1H, d, H4'), 3.72 (2H, m, H5' and H5"), 2.26 (1H, m,
H2'), 2.18 (3H, s, Ac), 2.14 (1H, m, H2").
5'-O-(4,4'-Dimethoxytrityl)-5-acetoxy-2-'deoxyuridine 3'-[(2-cyanoethyl) N,N-
diisopropylphosphoramidite] (17).
2-Cyanoethyl N,N-diisopropylchlorophosphoramidite (35 tl) and triethylamine (35 L1l) are
added to 5'-O-(4,4'-dimethoxytrityl)-5-acetoxy-2-'deoxyuridine (15) dissolved in CH2C 2.
After 1.5 hr, the reaction was purified by silica gel chromatography (8 g) eluting with 2%
MeOH/CH 2C12 and trace triethylamine. (85 mg, 0.110 mmol, 91% yield).
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5 '-d(G°hSUAGC)
The oligodeoxynucleotide sequence of d(G°hSUAGC) was synthesized on a Applied
Biosystems DNA synthesizer by using the modified phosphoramidite (17). The modified
trimer sequence, d(AGC), was accomplished by interrupting the normal oligonucleotide
preparation prior to addition of the modified phosphoramite (17). The modified
phosphoramidite was then added manually. The oligonucleotide synthesis was continued at
the wash step in the standard synthesis program and the final phosphoramidite added. The
coupling efficiency of the modified phosphoramidite was determined to be 65 % (not
optimized) as determined by dimethoxytrityl quantification. The oligodeoxynucleotides were
deprotected in concentrated aqueous ammonia overnight at 60 °C and subsequently purified
by RP-HPLC.
The base composition of the oligonucleotide was determined by reversed phase HPLC after
digestion of the compounds with bacterial alkaline phosphatase and snake venome
phosphodiesterase. Peak area analysis of the chromatogram obtained from the adducted
molecule, 5 '-d(Gc°hUAGC) indicated that this compound contained dC, dG, and dT in the
same relative proportions as d(GCAGC), synthesized and purified at the same time as a
control. Unlike the latter oligonucleotide, however, the adducted pentamer contained a
compound with identical retention time and UV spectrum to a oh5dU standard.
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5-Hydroxy-2 '-deoxycytidine (18).
A bromine saturated aqueous solution (150 ml) was added to deoxycytidine (5.29 g, 23.2
mmol) dissolved in 50 ml H20 until a persistent yellow color developed. After 10 min, the
excess Br2 was quenched with Na2SO 3 until the reaction mixture became clear and colorless.
The aqueous solution was then poured into pyridine (200 ml) chilled to 0 C. The ice bath
removed after 10 min, and the reaction mixture was allowed to stir at room temperature.
After stirring overnight, the solvents were removed under vacuum in a rotary evaporator.
The residue was redissolved in H20 (50 ml) and washed with CH 2C12 (2 x 50 ml). The
aqueous solution was concentrated and the resulting viscous syrup was purified by silica gel
chromatography by eluting with 20 to 80% MeOH/CH 2Cl2. The slightly yellow solid
obtained was crystallized from MeOH at 4 C. The yield was determined to be 41% (2.26
g, 9.28 mmol). 'H (CD 3OD): 8.62 (1H, s, H6), 6.20 (1H, t, Hi'), 4.39 (1H, d, H3'),
3.98 (1H, d, H4'), 3.79 (2H, m, H5' and H5"), 2.19 (1H, m, H2'), 2.10 (1H, m H2").
3' ,5',5-Triacetyl-2 '-deoxyuridin-5-one (19).
Acetic anhydride (4.00 ml, 42 mmol) and dimethylaminopyridine (35 mg, 0.28 mmol) were
added to 5-hydroxy-2-'deoxyuridine (13) dissolved in pyridine (40 ml). After 5 hr at room
temperature, the reaction mixture was concentrated, and the residue was resdissolved in
CH2C12 (100 ml) and washed with H20 (50 ml), NaHCO 3 (,at) (50 ml), and NaCl(at) (50 ml).
The organic solution was dried with Na2SO4, filtered and concentrated. The 3'',',5-
triacetyl-2'-deoxyuridin-5-one (19) was purified by silica gel chromatography (40 g) by
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eluting with 4 % MeOH/CH 2Cl2. (rf 0.65 CH2CI2 : MeOH 95:5) 'H NMR (CDC13): 9.13
(1H, br, NH), 7.52 (1H, s, H6), 6.35 (1H, t, Hi'), 5.18 (1H, d, H3'), 4.4-4.2 (3H, m,
H4',H5'), 2.54 (IH, m, H2'), 2.28 (3H, s, Ac), 2.15 (1H, m, H2'), 2.10 (3H, s, Ac),
2.08 (3H, s, Ac). HRMS calculated for C,5sH8N20o (M+) 370.10123, high resolution
result for m/z 370 (370.1010)
3 ' ,5' ,5-Triacetyl-4-0-(2,4,6-trimethylphenyl)-2 '-deoxyuridin-5-one (20).
Triisopropylsulfonyl chloride (2.00g, 6.62 mmol, 180 M%) and triethylamine (2.00 ml,
14.38 mmol, 390 M%) were added to 3',5',5-triacetyl-2 '-deoxyuridin-5-one (19) (1.37 g,
3.70 mmol) dissolved in CH2C12 (12 ml). After 1.5 hr, additional triisopropylsulfonyl
chloride (2.00g, 6.62 mmol, 180 M%) was added. After 6 hr, trimethylphenol (3.00 g,
22.06 mmol, 600 M%) and trimethylamine (approximately 2 ml). After 20 min, the
reaction mixture was concentrated to dryness, and the residue was resdissolved in CH2CI2
(100 ml) and washed with NaHCO3 (sat) (50 ml), and NaCl(sat) (50 ml). The organic solution
was dried with Na 2SO4, filtered and concentrated. The 3',5',5-triacetyl-4-0-(2,4,6-
trimethylphenyl)-2'-deoxyuridin-5-one (20) was purified by silica gel chromatography (100
g) eluting with 2 % MeOH/CH2CI2. (1.00 g, 2.05 mmol, 55 M%). (TLC rf 0.44
CH2C12/MeOH 98:2) H NMR (CDC13): 7.79 (1H, s, H6), 6.80 (2H, s, Ar), 6.18 (1H, dd,
H1'), 5.18 (1H, m, H3'), 4.33-4.28 (3H, m, H4', H5', H5"), 2.74 (1H, m, H2'), 2.28
(3H, s, OAc), 2.21 (3H, s, OAc), 2.14 (1H, m, H2"), 2.06 (6H, s, ArCH3), 2.02 (3H, s,
ArCH3). ' 3C NMR (CDC13): 170.38, 170, 26, 168. 64, 163.93, 153.70, 146.37, 135.61,
134.37, 129.62, 129.38, 121.94, 87.28, 83.02, 74.17, 63.73, 38.89, 20.87, 20.74, 20.67,
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20.23, 12.28. HRMS calculated for C24H 28N 2 09 (M+) 488.1795, high resolution result for
m/z 488 (488.1797)
4-0-(2,4,6-trimethylphenyl)-2 '-deoxyuridin-5-one (21).
Ammonia saturated MeOH (5 ml) was added to 3',5',5-triacetyl-4-0-(2,4,6-
trimethylphenyl)-2 '-deoxyuridin-5-one (0.75 g, 1.53 mmol) dissolved in MeOH (5 ml).
After stirring overnight at room temperature, the reaction was concentrated to dryness. The
4-0-(2,4,6-trimethylphenyl)-2'-deoxyuridin-5-one (21) was purified by silica gel
chromatography (40 g) by eluting with 8 % MeOH/CH 2Cl 2. (0.55 g, 1.51 mmol, 100 %
yield) (rf 0.36 CH 2C12/MeOH 90:10). H NMR (CD 3OD): 8.04 (1H, s, H6), 6.80 (1H, s,
Ph H), 6.22 (1H, t, Hi'), 4.38 (1H, m, H3'), 3.98 (1H, m, H4'), 3.78 (2H, m, H5'), 2.40
(1H, m, H2'), 2.25 (3H, s, p-Ph-CH3), 2.1 (1H, m, H2'), 2.08 (6H, s, o-Ph-CH3). HRMS
calculated for C181122N206 (M+) 362.14779, high resolution result for m/z 362 (362.1477)
163
III. FATAL ENGINEERING 4
A. Introduction
The following sections of this dissertation describe the design, synthesis and
preliminary biological results obtained during the development a new class of compounds
that hopefully will prove useful for the treatment of cancer. The candidate chemotherapeutic
agents have been designed to exploit biochemical differences between tumor and normal
cells with the ultimate aim of selectively increasing the cytotoxicity for the tumor cell
population. The new compounds consist of a chemically reactive DNA damaging domain
linked to a protein recognition group. By choosing a protein recognition domain that
attracts proteins uniquely or selectively expressed in tumor cells, we postulate that it will be
possible to block the repair of a cytotoxic adduct selectively in those cells, sensitizing them
to the genotoxic agent. A key feature of this strategy is the ability to control the specificity
and affinity of the molecular recognition groups in these drugs. We have termed this
strategy for the design of programmable drugs "Fatal Engineering."
My efforts as part of the Essigmann laboratory to develop and validate this new
strategy for the treatment of cancer is described below. The first section establishes the
background and basis for a drug design strategy based on the inhibition of DNA repair as an
4 Portions of this section have been taken verbatim from Chen, Z.-H., Morningstar, M.L., Croy,
R.G., and Essigmann, J. M. (1993) Fatal Engineering: A new strategy for the rational design of antitumor
drugs. MIT Technology Disclosure, August 16, 1993.
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effective means to target tumor cells. The second section examines in detail the DNA
damaging domains and protein recognition groups utilized in the developed compounds.
The third section details the method of synthesis and any biological results thus far obtained
on the designed compounds.
B. Background and Basis of Fatal Engineering
Drugs that damage DNA are important therapeutic tools used in cancer treatment
(Holland and Frei, 1982). Damage inflicted on the genomes of cancer cells can destroy
genetic information essential for their growth and survival. The toxic effects of such drugs
unfortunately also affects normal, non-cancerous cells. As a result severe dose-limiting
toxicity can arise. The ability of cancer cells to become drug resistant also limits the
efficacy of many chemotherapeutic agents used to treat human malignancies (Holland and
Frei, 1982). The mechanisms by which a tumor cell becomes resistant to chemotherapeutic
agents include diminished drug uptake, changes in drug metabolism and, in the case of
agents that act by damaging DNA, enhanced DNA repair. One approach to increase the
therapeutic effectiveness of DNA damaging compounds is to prevent abnormal cells
selectively from repairing and recovering from genetic damage as a consequence of a DNA
damaging agent. We are attempting to exploit the interaction of cellular proteins with DNA
lesions as a means to achieve this objective. The rationale for this study comes from two
independent biochemical observations: a) DNA repair rates affect the toxicity of a DNA
damaging agent; and b) cellular proteins can influence DNA repair rates by shielding the
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DNA damaging agent after it has been allowed to react with the genome of a cell. These
two observations are examined in detail in the following two sections.
a. The rate of repair affects the toxicity of a DNA damaging agent
The study of repair defective cell lines and cells from humans with inherited DNA
repair disorders demonstrates that diminished DNA repair rates enhance the toxicity of a
DNA damaging agent. In patients with defects in the repair of certain types of DNA
damage (two examples include Fanconi's anemia and Xeroderma pigmentosum), the lethality
of DNA damaging drugs is substantially increased when compared to cells with normal
abilities to repair DNA damage. Treatment of Fanconi's anemia cells, for instance, with
drugs that crosslink DNA cause a ten-fold increase of genotoxic effects as compared to
repair proficient cells (Ishida et al., 1982). The rate of repair of the damaged sites in DNA
in Fanconi's anemia cells occurs at about one half the rate of normal cells. Thus, a
reduction in the repair rate by a factor of two results in a ten-fold enhancement of lethality.
Treatment of Fanconi's anemia and Xeroderma pigmentosum cells with cisplatin similarly
causes a four fold increase in the sensitivity to the drug in both repair defective cell types
(Dijit et al., 1988'). Studies with repair deficient rodent cells also demonstrate that
heightened sensitivity to DNA alkylating drugs correlates with the inability to repair DNA
damage caused by, bifunctional alkylating agents (Hoy et al., 1985). These results
underscore the important role that DNA repair plays in cell survival and suggest that drugs
that are capable of inhibiting repair processes can enhance lethality.
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b. Shielding of DNA adducts by proteins affects DNA repair
The proposition that the shielding of DNA adducts increases the genotoxic effects of a
DNA damaging agent comes from recent studies of the antitumor drug cis-
diamminedichloroplatimum(II) (cisplatin). It is widely believed that cisplatin achieves
antitumor activity by covalently binding to DNA, forming adducts that inhibit DNA
polymerases (Bruhn et al., 1992). The principal adducts are the cis-[Pt(NH 3)2{d(GpG)-
N7(1),-N7(2)}] and cis-[Pt(NH3)2{d(ApG)-N7(1),-N7(2)}] intrastrand crosslinks (reviewed in
Sherman and Lippard, 1987). The cis-[Pt(NH3)2{d(GpNpG)-N7(1),-N7(3)}] intrastrand
crosslink, cisplatin interstrand crosslinks and monoadducts also form at a lower frequency.
The genotoxicity of the cisplatin DNA adduct, cis-[Pt(NH3)2{d(GpG)-N7(1),-N7(2)}] was
demonstrated in E. coli by Bradley et al. (1993). The survival of a constructed double
stranded genome containing this adduct decreased to 22% as compared to an unplatinated
control genome. A similar study of the same cisplatin lesion using a single stranded genome
revealed that the same cisplatin lesion decreases survival to only 5 % of a control (Yarema,
1994). These results indicate that as few as one DNA lesion can affect survival. It is not
surprising, therefore, that the 1,000-10,000 cisplatin adducts per chromosome that form in
cancer patients undergoing chemotherapy (Reed et al., 1993) are highly toxic to a tumor
cell.
Recent findings indicate that binding by cellular proteins to the cisplatin-DNA adducts
may increase the genotoxic effects of this drug for tumor cells. Specifically, a group of
proteins has been identified that bind expressly to DNA containing the cisplatin cis-
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[Pt(NH3)2 {d(GpG)-.N7(1),-N7(2)}] and the structurally similar cis-[Pt(NH3)2{d(ApG)-N7(1),-
N7(2)}] intrastrand crosslinks (Donahue et al., 1990; Pil and Lippard 1992; Bruhn et al.,
1992; Clugston et al., 1992; Hughes et al., 1992). A common DNA binding motif, the high
mobility group (HMG) box has been revealed in most cisplatin binding proteins discovered
so far. The HMG proteins, however, do not bind to DNA modified with the
chemotherapeutically inactive trans-diamminedichloroplatimum(II) and monofunctionally
coordinated platinum complexes. Recognition of the cis-[Pt(NH3)2{d(GpG)-N7(1),-N7(2)}]
and the cis-[Pt(NH3)2{d(ApG)-N7(1),-N7(2)}] intrastrand crosslinks by HMG proteins results
from a specific DNA conformation that arises as a consequence of cisplatin adducts in the
DNA. These adducts cause unwinding of the DNA duplex by 13' and induce bending of
32-35' (Bellon et al., 1991). Based on the specific binding of protein to only the clinically
active forms of cisplatin, Donahue et al. (1990) speculated that a protein-cisplatin adduct
complex could be responsible for the clinical efficacy of cisplatin. Two mechanisms were
proposed for the role of the protein complex in effecting the cytotoxicity of cisplatin: 1) the
blocking of repair by the bound protein, and 2) the diversion of the bound protein from its
normal cellular function. The first model would result in cisplatin lesions persisting in the
genome of a cell and, as a consequence, DNA replication and transcription could be
blocked. The second model would result in metabolic imbalances, especially if the bound
protein were a crucial regulatory protein. Both models lead to eventual cell death. The
models are not mutually exclusive.
Both models are supported by the work of Brown et al. (1993) and Treiber et al.
(1994). Treiber et al. determined that the cis-[Pt(NH3)2{d(GpG)-N7(1),-N7(2)}] intrastrand
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crosslink acts as a high affinity binding target for the human upstream binding transcription
factor, hUBF. The binding of hUBF to the cisplatin adduct was proposed to disrupt the
regulation of rRNA synthesis by titrating the hUBF from its normal binding site, the
ribosomal DNA promoter. The binding of hUBF to the DNA lesion would have the
additional effect of shielding the adduct from repair enzymes, in support of the first model.
In yeast, recent findings by Brown et al. (1993) provide the most direct evidence to
date that the binding and possible shielding of cisplatin lesions from repair by HMG proteins
can impact cell survival. These workers report that the elimination of one of four detected
yeast proteins that bind to cisplatin-damaged DNA results in a two-fold decrease in the
toxicity of cisplatin. This finding indicates that the binding of a protein presumably not
responsible for the repair of cisplatin lesions significantly affects the toxicity of the drug.
C. The Fatal Engineering Concept
The proposed mode of action of a Fatal Engineering compound is depicted in Figure
20. The initial step is covalent modification of DNA by the warhead portion of a Fatal
Engineering compound. At this stage, both cancer and noncancerous cells would be
damaged. In normal cells, the natural repair process would remove the lesion from DNA
(Figure 20A), resulting in the diminished toxicity of the lesion. In contrast, in cancerous
cells (Figure 20B), tumor specific proteins would associate with the molecular recognition
domain of the DNA associated genotoxic compound. The complex formed between the
Fatal Engineering compound and the tumor specific protein would, in principle, slow the
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rate of repair of the lesion. The end result would be the higher relative toxicity of the drug
in the cancer cell than in the noncancerous cell. Thus, a favorable therapeutic index would
be achieved.
A key feature of Fatal Engineering is the ability to control the specificity and affinity of
the protein recognition domain in these candidate drugs. This ability should allow us to
exploit the different molecular changes that are characteristic of various malignancies,
including the expression or overexpression of oncogene-encoded or suppressor gene-encoded
proteins. Although our research has focused on developing a new cancer therapy, this
approach could also be applied to any disease that results in the expression of foreign or
unique proteins in the nucleus of a cell (e.g., viral infections, including that caused by
human immunodeficiency virus). My contribution to this research has involved the design
and synthesis of trifunctional Fatal Engineering compounds to validate this approach. The
compounds that were made utilized either a psoralen or an aryl nitrogen mustard as
cytotoxic warheads. The protein recognition domains that were used include: a ss DNA
aptamer, biotin, and estradiol. The key features of each domain and the chemical properties
of the molecules utilized are detailed in the following section.
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Figure 20. The conceptual basis for Fatal Engineering. Fatal Engineering attempts to
exploit the differential repair of lethal DNA damage by the selective shielding of DNA
damage. The specific shielding arises from the binding of proteins either selectively
expressed or specifically present in abnormal cells to a complementary recognition domain
of a Fatal Engineering compound. As a consequence of this shielding, the repair of the
damaged segment of DNA is hindered resulting in increased genotoxicity.
A Fatal Engineering compound has three domains: 1) a DNA damaging domain or
warhead; 2) a linker arm; and 3) a protein recognition domain. The DNA damaging
domains so far explored as Fatal Engineering compounds are psoralen and an aryl nitrogen
mustard. A ss DNA thrombin aptamer, biotin and estrogen have been tested as recognition
domains for thrombin, streptavidin, and estradiol receptor proteins, respectively.
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D. Design of Fatal Engineering Compounds
a. DNA Damaging Domains
The selection of the DNA warhead is limited to compounds that form repairable
lesions. This requirement arises because the compounds under development exploit
differential repair as a means to induce selective genotoxicity in tumor cells. Consequently,
a chemical could be an effective warhead if: 1) the chemical can be activated by cellular
metabolism or other means to a reactive species that covalently links the drug molecule to
cellular DNA; and 2) the DNA adduct thus formed can be efficiently repaired by cellular
enzymes. Fortunately, a large number of DNA damaging agents exist that meet these
criteria (Holland and Frei, 1982; Brednel et al., 1984; Nielsen et al., 1991).
We postulated that by comparing the effects of two differing mechanisms for DNA
adduct formation, we could determine which factors, such as reactivity, sequence selectivity
and stability are important determinants of therapeutic efficacy. The two DNA damaging
agents investigated as part of a Fatal Engineering compound were trimethylpsoralen and an
aryl nitrogen mustard. The general chemical properties of these two warheads are discussed
in detail in the following two sections.
i. Psoralen
Psoralens are bifunctional photoreagents that form covalent bonds with the pyrimidine
bases of nucleic acids in the presence of near UV light (Song et al., 1979; Hearst et al.,
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1984). In Figure 21, the specific chemical reactions involved are illustrated along with a
macroscopic view of the crosslinking process. The mechanism of the photoaddition of a
psoralen to a DNA helix involves several steps. The initial step is the intercalation of the
psoralen into the nucleic acid helix in the absence of near UV light. The necessity for
intercalation before photochemical reactivity forbids the formation of intrastrand
crosslinking. The intercalation step is reversible and normally does not lead to stable DNA
lesions. When an intercalated psoralen absorbs a photon of wavelength between 300 and
400 nm, it is sensitized to react by cycloaddition at either the 3,4 double bond of the pyrone
ring or the 4',5' double bond of the furan ring. If an adjacent pyrimidine is correctly
positioned, a cyclobutane ring results from reaction with the 5,6 double bond of the
pyrimidine (Straub et al., 1981; Kanne et al., 1982). Subsequent formation of a DNA
crosslink to the opposite strand of DNA occurs only if two conditions are met (Hearst,
1989). First, the monoadduct formed must be a furan-side monoadduct. Second, a
pyrimidine must be adjacent to the psoralen monoadduct on the opposite strand. The
resulting mono- and crosslinked adducts are chemically stable (Cimino et al., 1985) and can
result in inhibition of DNA replication and cellular proliferation (Cimino et al., 1985; Ben-
Hur et al., 1984).
The molecular mechanism involved in the removal of the psoralen damage is fairly well
understood (Brendel and Ruhland ,1984). Repair of psoralen monoadducts occurs via an
excision repair pathway whereas repair of interstrand crosslinks occurs by a combination of
excision and recombination (Cole et al., 1978; Cole and Sinden 1975). Although a crosslink
is more effective in cell killing, the monofunctional adducts also result in genotoxicity (Cole
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Figure 21. Mechanism of the photoreaction of psoralen with DNA. The first step is a
thermal reaction involving the intercalation of the psoralen in the helix. In the second step,
a cyclobutane ring can form with the pyrone or furan sides of psoralen after the absorption
of a photon. The third step is the formation of the second cyclobutane ring upon absorption
of a second photon. Covalent crosslinking between two strands of the DNA helix only
occurs if the first cyclobutane ring formed is between the furan side of the psoralen.
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et al., 1978). The repair of psoralen damage, however, does not occur in cells deficient in
DNA repair (e.g., Fanconi's anemia and Xeroderma pigmentosum) (Brendel and Ruhland,
1984). In the absence of repair, these cells are rapidly killed. In fact, in a bacterial double-
mutant uvrArep, a single crosslink on average results in cell killing (Bridges, 1983).
Therefore, a psoralen DNA damaging domain would fulfill the primary requirement of a
Fatal Engineering warhead - the formation of a repairable lethal DNA lesion.
ii. Nitrogen Mustards
The other warhead utilized in our experiments was an aryl nitrogen mustard. All
mustards contain at least one 2-chloroethyl group attached to a nucleophilic sulfur or
nitrogen atom. Sulfur and nitrogen mustards can be synthesized with up to two or three 2-
chloroethyl groups, respectively. By varying the substituents attached to the sulfur or
nitrogen, chemicals with different selectivity and/or chemical stability have been synthesized
(Wilman and Connor, 1983). Mustards that have two or more reactive arms can covalently
crosslink DNA. One advantage of the nitrogen mustards as compared to the sulfur mustards
is that a third substituent other than 2-chloroethyl can be added while retaining the ability to
crosslink DNA. Mustards, however, are generally non-selective in their attack on biological
material, reacting with structural proteins, enzymes, and DNA (Warkwick 1963; Wheeler
1967). The mustards are primarily activated to react by the process of entering a cell due to
the difference between intracellular and extracellular chloride ion concentration.
The major lesions resulting from alkylation of nucleic acids by nitrogen mustards
form through their reaction with the N7 position of guanine (Figure 22). Less extensive
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reaction occurs at the N1 position of cytosine and the 06 position of guanine (Lawley, 1966;
Lawley and Thatcher, 1970). Crosslinking of two strands of DNA commonly results with
polyfunctional mustards through the N7 position of guanine in one strand of DNA and the
N7 position of guanine in the other strand (Lawley, 1966) (Figure 22). For almost 30
years, this product was thought to arise from the sequence 5'-d(GC). The distance between
N7 guanine atoms in this dinucleotide pair appeared to be optimal for reaction with both
arms of the nitrogen mustard. Recently it has been demonstrated that the crosslink in fact
arises from the sequence 5'-d(GpNpC) (Grueneberg et al., 1991; Hopkins et al., 1991).
This finding was unexpected because the tether that links the N7 atoms of the guaninyl
crosslink is several angstroms too short to accommodate the spacing of the N7 atoms in the
normal duplex DNA sequence 5'-d(GpNpC). This result suggests that distortion of the
double helix must accompany formation of such a crosslink.
The reaction mechanism of adduct formation by aryl nitrogen mustards has also been
subjected to several revisions. A variety of mechanisms (SN1, SN2, 'internal SN2') have
been proposed (Wilman et al., 1983) (Figure 22). The currently accepted mechanism of
reaction of aryl nitrogen mustards involves two competitive pathways (Benn et al., 1970).
One pathway involves direct SN2 displacement of chloride by a nucleophile. The second
pathway involves a reactive aziridinium ion intermediate. The aziridinium ion is preferred
except in the case of very powerful nucleophiles. Because the aziridinium pathway of
activation is reversible, the relatively high chloride concentration present in blood decreases
the in vivo rate of alkylation by aryl nitrogen mustards. Inside cells, however, the chloride
concentration decreases whereby both methods of activation occur. As a result, aryl
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nitrogen mustards are useful chemotherapeutic agents because of their increased reactivity in
the intracellular environment.
The ability to crosslink DNA appears to be essential to the effectiveness of many
nitrogen mustards (Colvin, 1982; Hemminki et al., 1984; Kohn, 1981). Although the
interstrand crosslink might be considered the most dangerous lesion, the removal of the
intrastrand and monofunctional lesions appear to be equally important for cell survival (Hoy
et al., 1985). As a consequence, the ability of a nitrogen mustard to form a crosslink in
DNA does not appear to be a critical requirement for the purpose of designing a Fatal
Engineering compound.
b. Introduction to Protein Recognition Domains
Three properties are likely to be necessary for a protein recognition domain to
function effectively as part of a Fatal Engineering compound. The first property is that the
protein recognition domain must selectively attract a tumor specific protein. The second
property is that the protein-DNA adduct complex must be sufficiently stable to prevent
displacement of the protein by repair enzymes. The third property is that the protein-DNA
lesion must be sufficiently large to prevent access of DNA repair enzymes to the DNA
lesion.
In order to determine the optimal parameters for these three factors, our initial studies
examined the interaction of model proteins with known recognition domains. The synthesis
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Figure 22. Mechanism of the crosslinking by aryl nitrogen mustards with DNA. Two
competitive pathways of reaction result in reaction with DNA. One pathway involves direct
SN2 displacement while the second pathway involves SN1 displacement and formation of a
aziridinium species. Reaction with DNA can result in the alkylation of N7 of guanine. A
common crosslink found with DNA occurs between guanines in the sequence 5'-d(GpNpC).
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and study of compounds containing model protein recognition domains has allowed the in
vitro testing and optimization of spacer arm length, warhead reactivity, solubility, stability,
and - the crucial test - DNA repair. These initial findings have facilitated the design and
development of a second generation of compounds to undergo biological evaluation. The
following sections discuss some of the advantages of the three protein recognition domains
that have been under study: a ss DNA aptamer, biotin, and estrogen.
i. Aptamers
The first recognition domain we examined as part of a Fatal Engineering compound
was the anti-thrombin aptamer. The term "aptamer" is derived from the Latin word aptus
meaning to fit. The term was introduced by Ellington and Szostak (1990) when they
reported on the preparation of ss RNA molecules that bind with high affinity to organic
dyes. Starting with a large random pool of oligonucleotides (103 molecules), this
technology selects for ss DNA or RNA that can bind specifically to, at least in theory, any
target molecule. The selection cycle is a reiterative process involving isolation of DNA or
RNA sequences that bind to the desired protein or target molecule and amplification of those
sequences by polymerase chain reaction (PCR). Recently, these and other researchers have
generated high affinity complexes between ss DNA or RNA and proteins such as thrombin
(Bock et al.,1992) and U1-snRNP-A (Tsai et al., 1991), or small molecules such as
tryptophan (Famulok et al., 1992).
One goal of ongoing research in our laboratory is the selection of an aptamer with high
affinity for a mutated or overexpressed tumor encoded protein. A complex between such
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an aptamer incorporated into a Fatal Engineering compound and its target protein could
result in selective interference with repair of DNA lesions in tumor cells. As a test for this
strategy, a Fatal Engineering compound was designed and synthesized using a known
aptamer. The aptamer chosen was a ss DNA that bound to human thrombin which is
admittedly a non-tumor specific protein. Our goal was to test for the ability of a thrombin
aptamer linked to a DNA adduct to block repair in vitro in the presence and absence of
thrombin.
ii. Biotin
As a second method to test the concept of Fatal Engineering, two Fatal Engineering
compounds were designed with biotin, a small molecule, as the protein recognition domain.
Biotin is a prosthetic group that acts as a carrier of activated CO2 for various enzymes that
catalyze the fixation of CO2 into cellular metabolites. Avidin is a tetrameric glycoprotein
found in egg white that has exceptionally high affinity for biotin. Avidin or streptavidin, the
unglycosolated form of avidin, binds one biotin molecule per subunit with a Kd = 10-' 5 M.
This dissociation constant is five orders of magnitude smaller (i.e., tighter binding) than
typical protein-nucleic and protein-protein interactions. As a consequence of this tight
binding, the avidin-biotin system has provided the basis for a number of sensitive and
specific detection methods (Green, 1975; Guesdon et al., 1979; Bayer and Wilchek, 1980).
This ligand-protein recognition complex was of value to validate the Fatal Engineering
approach. Although the resulting Fatal Engineering compound would have no activity in
tumor cells since its molecular target, avidin, is not present in any human cells, the biotin-
avidin system would allow us to examine in vitro whether avidin, a 60 KD protein, is
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sufficient to block access to a DNA lesion by cellular repair enzymes. Furthermore,
derivatives of biotin with differing affinities for avidin are known (Green, 1975) that would
allow us to determine what affinity is required for a protein-DNA lesion to prevent DNA
repair.
iii. Estrogen
The high affinity of the estrogen receptor (ER) for estradiol and other estrogenic
compounds served as our third ligand-protein recognition complex. In contrast with the
biotin-avidin system, this ligand-protein combination would provide a clinically relevant
model with which to test the Fatal Engineering strategy for drug design. Estradiol is the
most potent of the naturally occurring estrogens. In mammals, endogenous estrogens are
formed primarily by the ovaries, placenta, testes and adipose tissue acting to stimulate
estrus, secondary sexual characteristics, and systemic effects such as growth and maturation
of bones. Key to utilizing this system as part of a Fatal Engineering compound is that
estrogens function in vivo by binding to a nuclear receptor protein. Proteins of this family
of transcriptional regulators are activated by the binding of small lipophilic ligands such as
steroid and thyroid hormones, retinoids and vitamin D3 (Green et al., 1988; Evans, 1988;
Beato 1989; Gronemeyer, 1991). In the case of the ER, binding of estradiol which can
freely diffuse across the cell membrane to the ER leads to ER dimerization and subsequent
tight binding of the ER dimer to its specific DNA target, the estrogen responsive element
(Parker, 1993; Gronemeyer, 1993; Baniahamad and Tsai, 1993). A DNA lesion that
contained an estrogen recognition domain might be capable of interacting or "hijacking" the
estrogen receptor resulting in the targeting of the protein to a DNA lesion. By exploiting
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the differential expression of the ER in breast cancer patients described below, the designed
compound could produce a DNA lesion with increased toxicity to breast cancer cells.
In breast cancer patients, the expression of estrogen receptor can vary significantly.
Breast cancers having receptor levels greater than 10 fmol/mg protein are classified as
estrogen receptor positive (ER+) and considered candidates for hormonal therapy (Pollow et
al., 1990). The reported range of ER concentration in breast cancers varies between
undetectable levels (ER-) to 4,000 fmol/mg protein (ER+). Of ER+ patients, 50-60% of
the patients respond positively to endocrine therapy (DeSombre et al., 1979).
Unfortunately, the patients with the highest ER levels (> 108 fmol/ mg), comprising 47 % of
the ER+ breast cancers do not respond to endocrine therapy. These ER+ patients have as
poor a prognosis as ER- patients (Thorpe et al., 1993). Therefore, a drug that targeted the
overexpression of ER as a means of enhanced genotoxicity would be an effective treatment
for these unresponsive ER+ patients.
One very important advantage of this strategy beyond the ability target ER+ breast
cancer cells is that systemic toxic side effects should be minimal. ER levels are very low in
hematopoietic tissues such as the spleen and bone marrow. Consequently, a Fatal
Engineering compound would be repaired in these cells. This finding means that the bone
marrow toxicity that limits the dose of many anticancer drugs would not occur with an
estrogen-Fatal Engineering compound. In terms of normal estrogen responsive tissues such
as the uterus and ovaries, the mean concentration of ER in tumors in older patients (> 50
years of age) is two- to ten-fold greater. Therefore, a drug that targeted the overexpression
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of ER as a means of enhanced genotoxicity would not adversely effect normal estrogen
responsive tissues. Consequently, a compound that selectively utilized the overexpression of
ER as a means to block the repair of DNA damage might have enhanced toxicity only in
tumor cells.
Useful to the testing of the Fatal Engineering concept in vivo is the availability of cell
lines that either overexpress or do not express the estrogen receptor. These cell lines can
allow us to compare in vivo the toxic effects of our designed drugs in the presence and
absence of ER. The effectiveness of the proposed drugs should not be affected by the
possible abnormal function of the overexpressed ER. The Fatal Engineering strategy only
requires that the overexpressed ER retain its ability to bind with estrogen tightly. By
retaining the ability to bind with estrogen, the resulting protein-drug-DNA complex would
function as the desired block to repair.
c. Introduction to Linker Arms
The function of the linker arm is to connect the DNA warhead to the protein
recognition domain. The ideal linker arm would function to balance the protection of the
DNA lesion against the binding of each domain with their respective targets. Factors such
as how far the protein recognition domain is presented away from the DNA helix are
expected to effect the affinity of the protein for the protein recognition domain. If the
linker arm is not of sufficient length, the DNA helix may adversely affect protein binding by
steric hindrance or electrostatic repulsion and as a consequence the protein-drug-DNA
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complex may not be of sufficient stability to block repair. In addition to an optimal distance
for presenting the recognition domain, the spanning residues should be designed to increase
the binding affinity of the tumor specific protein to the Fatal Engineering DNA lesion.
Other factors affecting the choice of linker include the ability to position correctly the
protein recognition domain for subsequent binding by the tumor specific protein, stability to
cellular enzymes, and the ability to help target our compounds to DNA. Preliminary studies
using DNA models and molecular modeling have been used to guide us in the design of an
optimal linker arm. Our present studies however have focused first on determining an ideal
recognition domain and DNA warhead then developing an optimal linker. The following
section details one approach we undertook to understand the constraints of the linker arm.
Sulfur-Mercury as a Method of Linking
The approach we took to examine the linker requirements was to form a linker between
a pre-existing DNA lesion and a protein recognition domain. If a covalent link could be
formed between the warhead, already bound to DNA, and the recognition domain, the
requirements such as length, positioning, and linker composition could be determined and
later optimized. This modular synthetic approach would additionally allow the attachment
and testing of different protein recognition domains attached to the same DNA adduct. As a
result, the optimal recognition domain for a particular DNA lesion could more rapidly be
joined and tested. The only requirement the DNA warhead would have in addition to the
ability to damage DNA would be that it contained a functional arm that could later be used
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to link to the protein recognition domain. The method studied as the chemical link involved
a sulfur-mercury coupling chemistry.
This strategy was based on previous studies using the affinity of mercurated
oligonucleotides for sulfur as a means of purification (Dale et al., 1975). Dale et al.
showed that the introduction of as few as one mercury atom per 200 bases permits the
selective and quantitative retention of the mercurated polymer probe on columns of
sulfhydryl-agarose. In our work, a derivatized psoralen with a free thiol was chosen as the
chemical warhead and a mercurated aptamer as the recognition domain. As depicted in
Figure 23, the strategy involved 1) the photo-crosslinking of DNA with a thiol-psoralen, and
2) the attempted coupling of a mercurated aptamer recognition domain to the DNA lesion.
The advantages of this strategy are threefold. First, a psoralen warhead would fulfill the
requirement of a repairable lesion. Second, a variety of psoralens could be synthesized with
different side chains that would allow us to determine the optimal length and chemical
composition of the spacer arm needed to form a mercury sulfur couple. Third, the site of
attachment of the mercury linkage to the aptamer could be changed, allowing us to optimize
the site of coupling to the protein recognition domain. We postulated that the knowledge
gained from this two step approach of forming a Fatal Engineering lesion could be
subsequently used in the design and synthesis of a second generation of bifunctional Fatal
Engineering compounds.
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Figure 23. Sulfur-mercury as a method of coupling the recognition and DNA damaging
domains together. The first step involved photo-crosslinking of a psoralen DNA damaging
domain to ds DNA. The second step would involve coupling of a ss DNA aptamer to the
psoralen lesion via a thiol side chain on the psoralen and a mercurated nucleotide
specifically located in the DNA aptamer.
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E. Design and Synthesis of Candidate Fatal Engineering Drugs
a. Introduction
The following sections describe in detail the design and synthesis of several DNA
modifying compounds designed to block their own repair only in the presence of specific
proteins. The compounds include a) one psoralen-ss DNA aptamer, b) three thiol-psoralens,
c) two psoralen linked biotins, d) one psoralen linked estrogen, and e) three nitrogen
mustard linked estrogens. Biological results, when available for a specific compound, are
also presented.
b. Psoralen Linked Thrombin DNA Aptamer
The recognition domain for the first Fatal Engineering compound utilized the unusual
ability of some ss DNA or RNA molecules, aptamers, to bind selectively to proteins or
small molecules. Our work attempted to exploit this ability as a means to cause a DNA
adduct to interact selectively with a tumor specific protein. In the synthesized molecule, the
DNA damaging warhead was psoralen, a repairable lesion. The resulting aptamer-psoralen
was designed to form a ds DNA lesion that presented a recognition domain for subsequent
protein binding (Figure 20). The Fatal Engineering effect would arise if repair were
selectively blocked only in the presence of the protein complementary to the recognition
domain. In order to evaluate this approach quickly, we started with a known aptamer-
protein combination.
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The earlier studies of Bock et al. (1992) had determined the necessary ss DNA
sequence for binding to human thrombin. Sequence data from 32 thrombin aptamers
(selected from an initial pool of approx 1013 molecules) showed a highly conserved 14-17
base region. Several of the selected DNA sequences had binding affinities of K = 200 nM
for thrombin. In contrast, the original pool of DNA showed little affinity for thrombin.
The sequence chosen for our oligonucleotide, 5'-CAG GTT GGT GTG GTT GGG-3',
contains the consensus sequence determined by Bock et al. of GGT TGG (N)3 GGT TGG.
In addition to the consensus sequence of Bock et al., a 5 '-dinucleotide "linker," CpA, was
added to our compound in an attempt to keep the attached DNA warhead from interfering
with the aptamer structure.
Part of the rationale behind the use of psoralen as the warhead for a DNA aptamer
stems from the wealth of knowledge available on the synthesis of DNA with attached
molecular reporters. A large number of oligonucleotides has been synthesized with attached
intercalators, photoreactive and cleavage agents (Thuong et al., 1991; Uhlmann et al., 1990;
Englisch et al.,1991). These DNA conjugates can result in site specific covalent
modification of DNA if designed to act as a second strand in a DNA duplex or as a third
strand in a triple helix. In the case of our compound, we sought to allow it to react
randomly with ds DNA. Therefore, we intentionally designed our molecule not to have
either of these means to react with DNA in a sequence-specific manner.
Synthesis of the first candidate Fatal Engineering drug was based on a literature method
(Pieles et al., 1989). This procedure results in an oligonucleotide with a 5 '-terminal
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psoralen (5) (Figure 24). The starting material for the molecular warhead was 4,5',8-
trimethylpsoralen (1). Side chains were appended onto the psoralen core via a literature
procedure by Isaacs et al. (1977) involving chloro- or bromomethylation. The resulting 4'-
chloro- or 4'-bromomethyl-4,5',8-trimethylpsoralens (2) are unstable and hydrolyze rapidly.
The crude 4'-bromomethyl-4,5',8-trimethylpsoralen (2), if used immediately, reacts in high
yields with a variety of sulfur, nitrogen, and oxygen nucleophiles (e.g., ethylene glycol,
pentanedithiol, pentanediol, and dimethyl ethylene diamine). The linking arm of ethylene
glycol was appended by heating the 4'-bromomethyl-4,5 ',8-trimethylpsoralen (2) in neat
glycol. The resulting glycol-psoralen (3) was synthesized in greater than 80% yield for two
steps. Next, the necessary phosphoramidite (4) was formed by reaction of the glycol-
psoralen (3) with 2-cyanoethyl N,N-diisopropyl chlorophosphoramidite. The yields
determined for each step did not vary from literature values.
The desired aptamer-psoralen (5) was synthesized by modified solid phase DNA
synthesis. The synthesis procedure involved first preparing the 3' resin linked
oligonucleotide, 5 '-CAG GTT GGT GTG GTT GGG-3', by normal solid phase DNA
synthesis (Gait 1984). The phosphoramidite (4) was then added by manual coupling.
Manual coupling involved the removal of the column containing the resin bound
oligonucleotide and manual injection of the phosphoramidite (4) in the presence of tetrazole /
CH3CN. Following manual coupling, the column was placed again on the Applied
Biosystems DNA synthesizer and subjected to an abbreviated coupling routine that did not
include a trichloroacetic acid treatment. The oligonucleotide-psoralen was then cleaved from
the resin and deprotected by heating the resin to 50-60 C overnight in concentrated
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Figure 24. Method of synthesis of thrombin aptamer. The phosphoramidite (4) necessary
for solid phase DNA synthesis was synthesized in three steps from trimethylpsoralen
occurring to the procedure of Pieles et al. (1989).
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i.
ammonium hydroxide. The resin was filtered and the ammonia solution evaporated
yielding crude aptamer-psoralen (5). The resulting oligonucleotide-psoralen (5) was purified
by polyacrylamide gel electrophoresis by Z. Chen. The presence of the psoralen was
determined by digestion of the DNA by snake venom phosphodiesterase I and alkaline
phosphatase. The resulting aptamer digest was separated by HPLC and the presence of the
psoralen verified by comparison to a known standard (Z. Chen, personal communication).
With the purified oligonucleotide-psoralen (5) in hand, the first question we sought to
answer was whether the attachment of the psoralen to the 5' end of aptamer would interfere
with the ability of the aptamer to interact with thrombin. Block et al. (1992) had shown
previously that binding of a thrombin selected aptamer to thrombin slowed the catalytic
activity of this enzyme. In the case of an unselected aptamer or a scrambled consensus
sequence control, no inhibition of thrombin activity was seen by Block and coworkers.
Fibrin formation, however, was six times slower in the presence of the selected aptamer.
The assay done in our lab by K. Fu showed that similar inhibition to clotting occurred in the
presence of the psoralen-aptamer (5). This result indicated that the 5' attachment of the
psoralen warhead to the thrombin aptamer did not functionally alter the aptamer structure.
Since the recognition domain was still intact, the next question we sought to answer was
whether the psoralen-oligonucleotide would react with ds DNA. A ds DNA that contained
only one site suitable for DNA crosslinking was chosen as a target for intercalation and
photo-crosslinking with the aptamer-psoralen (5). Unfortunately, under a variety of reaction
conditions, no covalent attachment occurred (Z. Chen, personal communication).
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There are several possible explanations for this initial failure to form a Fatal
Engineering lesion. It is possible that compound (5) failed to react with DNA because of
unfavorable interactions between the psoralen-aptamer and ds DNA, possibly due to
electrostatic repulsion between the aptamer and the DNA target. Previously, Takasugi et al.
(1991) showed greatly decreased crosslinking ability if a single mismatch were introduced in
to the triple helix binding site of a triple helix forming psoralen-oligonucleotide. In fact,
under conditions of high salt where triple helix formation was abolished or when the triple
helix recognition site had a five base pair change, no reaction occurred between the ds DNA
target and their psoralen-oligonucleotide. This last result clearly indicates the need to have a
driving force to bring and to hold the ds DNA and reactive oligonucleotide together. Even
in the case where the aptamer and ds DNA might bind well, the psoralen might be
positioned such that it is unable to intercalate and/or to crosslink. As discussed previously,
the ability of psoralen to crosslink is dependent on it achieving a specific orientation in the
ds DNA. Alternatively, the intercalation of the psoralen may have occurred into the
aptamer structure making the psoralen unavailable. As a consequence, the psoralen would
again be unavailable to interact with the target. Because it was our long term goal to use a
DNA aptamer as a protein recognition domain, we subsequently tried to form the same type
of lesion by a two-step approach using a mercury sulfur bond.
c. Thiol-Psoralens and Mercurated DNA
The inability of the psoralen-aptamer combination to intercalate and crosslink ds DNA
productively led us to develop our next compound. We postulated that if the initial
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intercalation step where the warhead is allowed to form a DNA adduct were done in the
absence of the aptamer, a DNA lesion would form. We additionally postulated that we
could attach the desired recognition domain to the initial adduct to yield the desired Fatal
Engineering lesion. The strategy chosen to link the two components together was by way of
a mercury-sulfur bond (see discussion on linkers) (Figure 23). With this strategy, the first
step would be to photo-crosslink the target ds DNA with a psoralen containing a side chain
with a terminal sulfur. Following modification of DNA, a mercury-sulfur bond could link
the mercurated aptamer recognition domain to the psoralen lesion. The advantages of this
strategy would include: 1) the easier optimization of the initial psoralen warhead, 2) the
ability to optimize the psoralen-aptamer link by moving a mercurated nucleotide to different
places on the aptamer structure, and 3) characterization of linker requirements, such as
length and chemical nature.
To test the approach described above, four psoralens were synthesized with side chains
of varying length and composition but always ending in sulfur. The first thiol psoralen
synthesized was the 4'-(thioxypenthioxymethyl)-trimethylpsoralen (6) (Figure 25). This
psoralen was synthesized in one step by heating for 90 min 4'-bromomethyl-4,5',8-
trimethylpsoralen (2) in neat 1,5 pentanedithiol. In order to ensure that the DNA
crosslinked thiol-psoralen would react with a mercurated aptamer, reaction of the
uncrosslinked thiol-psoralen (6) with a mercurated nucleoside, 5-mercuri-2'-deoxycytidine
(Hg-dC) (7) was tested first. The extent of reaction between an equal molar solution of thiol
psoralen (6) and Hg-dC (7) in 1:1 CH 3CN: H20 at room temperature was monitored by
reversed phase HPLC by using a diode array UV detector. A gradient starting with 10%
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acetonitrile / 0.1 M ammonium acetate buffer and increasing to 100% acetonitrile over 50
min was used. With this gradient, the mercurated nucleoside eluted in the void volume after
injection, whereas, the thiol psoralen (6) did not elute until the gradient had reached 100%
acetonitrile. Examination of the reaction by HPLC after just a few minutes of reaction
showed the presence of only one new peak of intermediate retention time (approximately 40
min). The UV profile of this new peak showed absorbances expected for both the psoralen
and mercurated nucleoside. Isolation of the peak from the HPLC eluent and examination of
the effluent by atomic absorption spectroscopy indicated that this new peak contained
mercury. This preliminary data tentatively established that the free thiol psoralen (6) could
react with a mercurated nucleoside as monomers in an acetonitrile/water solution to generate
compound (8).
The next question was whether the thiol psoralen (6) could crosslink DNA. Using a
DNA probe containing a single AT site, the thiol psoralen (6) in the presence of near UV
light could crosslink ds DNA but with ten-fold less efficiency at equimolar concentration
than the unmodified parental psoralen (Z. Chen, personal communication). The crosslinked
material was then tested for reaction with a mercurated nucleotide, Hg-dCTP.
Unfortunately, under all the conditions studied, no reaction was observed (Z.Chen, personal
communication). We attributed this disappointing result to either or both of the following:
1) electrostatic repulsion of the nucleotide triphosphate and the ds DNA, or 2) a non-optimal
linker arm.
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Figure 25. Thiol psoralen reaction with 5-mercuri-2'-deoxycytidine. The thiol (6) was
synthesized in one step from the activated 4'-bromo-4,5',8-trimethylpsoralen (2) in neat 1,5
pentanedithiol. Reaction of the thiol-psoralen (6) with 5-mercuri-deoxycytidine (Hg-dC)
resulted in the formation of a new peak as detected by HPLC.
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In order to determine if the previous negative result were due to the length of the linker
arm, three new psoralens with differing arm lengths and compositions were designed and
synthesized (Figure 26): 4'-[[[(methylamino)ethyl]methylamino] methyl]trimethylpsoralen
cysteaminyl succinate ester (13), 4'-[[[(methylamino)ethyl]
methylamino]methyl]trimethylpsoralen 6-[3-(2-pyridyldithio) propionamido]hexanoate ester
(17), and 4'-[[[(methylamino)ethyl]methylamino]methyl] trimethylpsoralen) succinimidyl 3-
(2-pyridyldithio)propionate (15). The starting material for all three compounds was the
unstable 4'-bromomethyl-trimethylpsoralen (2). In order to increase the water solubility of
the warhead, a new linker arm was added to the psoralen warhead: N,N-dimethyl ethylene.
The [[[(Methylamino)ethyl]methylamino]methyl] trimethylpsoralen (9) had been synthesized
previously and had showed greater solubility in water (Goldenberg et al., 1988).
Using the dialkylamine psoralen (9), the 4'-[[[(methylamino)ethyl]methylamino]
methyl]trimethylpsoralen cysteaminyl succinate ester (13) was synthesized in three steps.
Treatment of the dialkylamine-trimethylpsoralen (9) with succinic anhydride, DMAP and
pyridine resulted in the dialkylamine-trimethylpsoralen succinate (10). Unprotected
cysteamine (2-mercaptoethylamine) could not be coupled directly to the terminal carboxylic
acid of the psoralen (10) because a thiol ester would result instead of the desired amide with
terminal thiol. To prohibit this reaction, the thiol of cysteamine was blocked with a
dimethoxytrityl (DMT) group. Coupling of the DMT-cysteamine (11) with the psoralen (10)
was done via a DIC activated ester. The final product, 4'-[[(methylaminoethyl]methyl]
trimethylpsoralen cysteaminyl succinate ester(13), was obtained by treating the DMT-
psoralen(12) with TCA/CH2.
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Figure 26. Synthesis of thiol psoralens varying in chemical composition and length.
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The synthesis of 4'-[[[(methylamino)ethyl]methylamino]methyl] trimethylpsoralen 6-[3-
(2-pyridyldithio) propionamido] hexanoate ester (17), and 4'-
[[[(methylamino)ethyl]methylamino]methyl]trimethylpsoralen) succinimidyl 3-(2-
pyridyldithio)propionate (15) utilized a similar coupling strategy as done for 4'-
[[[(methylamino)ethyl]methylamino]methyl]trimethylpsoralen cysteaminyl succinate ester
(13). The SPDP and LC-SPDP linker arms were appended to the dialkylamine-psoralen (9)
by using the activated N-hydroxysuccinimide esters of SPDP and LC-SPDP available from
Pierce (Carlsson et al., 1978). The products from acylation, psoralens 14 and 16, yielded
the free thiol psoralen (15) and (17) after reducing the disulfide linkage with 25 mM
dithiothreitol, pH 4.5 (R. Croy, personal communication).
In a series of HPLC experiments conducted by R. Croy, the ability to form a mercury-
sulfur couple between the three new thiol-psoralens and Hg-dC (7) was studied. The thiol-
psoralens (13,15,17), when mixed with Hg-dC (7), resulted in a coupled product as
monitored by reversed phase HPLC and UV detection. However, before in depth studies
were conducted on these molecules, R. Croy noted that the new peaks formed from reaction
of the thiols with the mercurated nucleoside were not stable over time. In fact, prolonged
exposure of the mercurated nucleoside products to an excess of thiol-psoralens resulted in
their decomposition. This problem with reductive demercuration in the presence of excess
thiols had been seen earlier with other mercurated nucleosides (Dale et al., 1975). If the
coupled mercurated aptamer-thiol psoralen crosslinked DNA also underwent decomposition,
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the ability to test for repair of lesion would be problematic. As a result of the poor stability
of the coupling products, no further study was done with these compounds.
This failure to validate the Fatal Engineering concept with an oligonucleotide based
strategy led us to reconsider our overall strategy. We decided that a simpler recognition
domain was needed to validate the Fatal Engineering approach. The new strategy used
biotin as the recognition domain. It was envisioned that attachment of biotin to the same
trimethylpsoralen warhead would yield a compound with which to test the Fatal Engineering
strategy in vitro.
d. Psoralen Linked Biotins
The first biotin-psoralen Fatal Engineering compound utilized a pentanediol linking arm
between the trimethylpsoralen warhead and the carboxylic side chain of biotin (Figure 27).
The derivatized pentanediol-psoralen (18) was synthesized by allowing 4'-bromomethyl-
4,5',8-trimethylpsoralen (2) to react with 1,5-pentanediol according to a procedure by Pieles
et al. (1989). The reaction of the pentanediol-psoralen (18) with biotin-NHS in DMF
yielded our first biotin-psoralen (19). Owing to the poor water solubility of this molecule,
reaction of biotin-psoralen (19) with ds DNA resulted in negligible crosslinking (Z. Chen,
personal communication). Although co-solvents such as DMSO or DMF increased the
solubility of the biotin-psoralen, the addition of these co-solvents resulted in increased
denaturation in the target ds DNA. Consequently, insufficient crosslinked material was
made for biological studies. Therefore, a new more polar psoralen-biotin was needed.
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Figure 27. Synthesis of psoralen biotins.
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The new compound was specifically designed to include a polar spacer arm. The
dialkylamine-psoralen (9), which had previously be shown to have exceptional water
solubility and reactivity with DNA (Goldenberg et al., 1988), appeared to be ideal as a
warhead and linker. The biotin-linked psoralen (20) was prepared by allowing the
dialkylamine-psoralen (9) to react with the biotin p-nitrophenyl ester (Figure 27). A similar
synthesis was used by Saffran et al. (1988) to make the same biotin-linked psoralen in order
to detect DNA concentrations by an ELISA based detection assay.
This second biotin-psoralen (20) was subsequently tested in a series of biological
experiments for its ability to function as a potential Fatal Engineering drug. The ability to
crosslink DNA was tested by exposing DNA and the biotin-psoralen to near UV light. As
determined by denaturing gel electrophoresis, the extent of crosslinking was decreased by a
factor of ten as compared to that seen for the underivatized psoralen, trimethylpsoralen (Z.
Chen, personal communication). Accompanying this decrease in crosslinking was an
increase in the amount of monoadducts formed. This change in reactivity could have
resulted from the influence of the molecular structures of the derivatized psoralen on their
solubilities, their photochemical reactivities, and the photodestruction of the compounds
themselves (Isaacs et al., 1977). Even with this diminished yield of crosslinked DNA,
adequate material was synthesized for the biological studies described below.
Through the use of denaturing gel electrophoresis, biotin-psoralen crosslinked DNA
was isolated to test for the binding of streptavidin to the lesion. Of the purified psoralen-
biotin crosslinked DNA, only 10-20% could bind to streptavidin as determined by an
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electrophoretic mobility shift experiment (Z. Chen, personal communication). The band of
retarded electrophoretic mobility corresponding to streptavidin-biotin-psoralen DNA was
reversed by the addition of free biotin. This ability to titrate the binding of the streptavidin
away from the DNA sample supported the role of biotin-streptavidin interactions as the
reason for the band shift.
Since the psoralen damaged DNA population successfully interacted with streptavidin,
this material was subsequently tested for the ability to repair DNA in the presence and
absence of streptavidin. Instead of testing for the removal of the psoralen DNA lesion, the
DNA was tested as a substrate for the removal of another DNA lesion incorporated into the
DNA prior to crosslinking. Specifically, a 2'-deoxyuracil was incorporated into the DNA
three bases away from the site of crosslinking. The removal of uracil from the DNA can be
accomplished in vitro by uracil glycosylase, a DNA repair enzyme that protects cells from
genetic instability that arises from either cytosine deamination or misincorporation of uracil
from the nucleoside triphosphate pool. It was determined that the removal of the nearby
uracil base from our psoralen crosslinked DNA by uracil glycosylase was inhibited only in
the presence of streptavidin (Z. Chen, personal communication). This inhibition was
reversed, although not completely, when free biotin was added. This experiment provided
our first conclusive evidence that binding of a protein to a designed DNA lesion can inhibit
DNA repair.
To examine further the shielding by streptavidin of the psoralen-biotin DNA lesion, a
DNase I protection assay was done. DNase I is an endonuclease capable of digesting DNA
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to mononucleoside fragments. Experiments indicate that the entire target psoralen-biotin
crosslinked oligonucleotide was protected from DNase cleavage only in the presence of
streptavidin (Z. Chen personal communication). In the absence of streptavidin, only a small
region on the 3' side of the crosslink was resistant to DNase cleavage. This result clearly
indicates that the binding of a protein to a designed DNA lesion can interfere with the
function of repair enzymes.
In summary, a biotin-containing psoralen derivative (20) was synthesized in a simple
one-step procedure from the readily available psoralen (9) and biotin p-nitrophenyl ester.
The synthesized compound (20) is a bifunctional nucleic acid- and avidin-binding reagent
that combines the properties of psoralen, in its specific photoreaction with DNA, and of
biotin, in its strong interaction with avidin. This reagent binds covalently to DNA in a UV-
dependent reaction and produces interstrand crosslinks. The biotin recognition domain of
the compound (20) retains its affinity for avidin, even after photoaddition to DNA. Most
importantly, only in the presence of streptavidin was the resulting DNA lesion able to inhibit
the repair of a nearby uracil lesion or to prevent a DNA exonuclease from degrading the
modified DNA.
e. Psoralen Linked Estrogens
Since the previous experiment validated in vitro that directed protein binding to a DNA
lesion could inhibit DNA repair systems that ordinarily protect cells, we turned to the
synthesis of compounds that might validate the approach in vivo. A successful test of the
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strategy in vivo would have to include a protein recognition domain that would attract a
biologically relevant protein. The protein we chose to target was the estrogen receptor
which, as indicated earlier, is overexpressed in many breast tumors. Fortunately, a number
of steroidal and non-steroidal compounds have been synthesized that show high affinity
binding to the estrogen receptor protein which could serve as a protein recognition domain
for our compounds (Bucourt et al., 1978; Poirier et al., 1991; Jordan et al., 1984).
Derivatives at the 17-hydroxyl of estrogen were initially viewed as the most promising
candidates as the molecular magnet to attract the estrogen receptor. Three criteria were
used in the selection of derivatives at this site. First, Bucourt et al. (1978) showed that
estrogen derivatives with a variety of spacer arms attached to the 17 position are bound
tightly by the estrogen receptor. Derivatives at the 2, 3, and 4 position of estrogen, by
contrast, have greatly decreased affinity for the estrogen receptor. Second, the same
workers have shown that the 17-hydroxyl linked estradiols, even when attached to a polymer
resin (e.g., polyacrylamide, agarose, and polystyrene), bind the estradiol receptor. We
postulated that the polymer resin to a first approximation offered a comparable steric
hindrance to the estrogen receptor as would DNA in our specific example. Third, a variety
of linker arms can be attached to the 17 hydroxyl via ether, ester, carbonate, or carbamate
bonds.
In choosing the optimal side chain length between the psoralen warhead and the
estrogen recognition domain, the work of Bucourt et al. with polymer bound estrogen
indicates that a spacer chain containing more than 14 atoms is necessary for binding of the
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estrogen receptor to occur. We chose a succinate-glycyl-glycyl-dialkylamine as a 14 atom
bridge between the estrogen recognition domain and the psoralen warhead. By incorporating
at least two amide groups, the poor water solubility encountered in our earlier compounds
and in the estrogen analogs of Bucourt et al. would be avoided. We chose to use a
succinate linker to the estrogen core because Bucourt et al. had already shown that succinate
linked estrogens could bind with high affinity to the estrogen receptor.
The approach used to synthesize estradiol-succinate-gly-gly-dialkylamine psoralen (24)
was 1) to synthesize the two domains separately and 2) to couple the domains together with
an amide bond (Figure 28). Based on the commercial availability of 17-hemisuccinate
estrogen diol, the only domain that needed to be synthesized was the gly-gly-dialkylamine-
psoralen. The necessary gly-gly-dialkylamine-psoralen could be synthesized by dipeptide
coupling to the dialkylamine psoralen (9) used previously. The BOC-gly-gly was coupled
to the dialkylamine psoralen (9) by in situ activation of the terminal carboxylic acid of the
dipeptide with DIC. The BOC-gly-gly-dialkylamine-psoralen (21) was obtained in 77%
yield after chromatography. Deprotection of the BOC group was achieved by treating the
BOC-gly-gly-dialkylamine-psoralen (21) with TFA. The purified gly-gly-dialkylamine-
psoralen (22) was obtained in 100% yield. The estradiol portion was coupled to the
psoralen (22) by mixing the gly-gly-dialkylamine-psoralen (22) with the NHS activated
succinate estradiol ester (22). The identity of the coupled product (24) was obtained by
FAB-MS and NMR.
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Preliminary biological testing of this compound as a candidate Fatal Engineering drug
was conducted by R. Croy. A competition assay was used to determine the dissociation
constant for the binding of the new drug in vivo. In this assay, the concentration of the
psoralen-estrogen (24) was varied to determine the required concentration necessary to
displace [3H]estradiol, the natural substrate, from the ER. The result of this assay revealed
that the psoralen-estrogen (24) bound with comparable affinity as estradiol (R. Croy,
personal communication). This result seemed fortunate, but was not expected because the
addition of side chain substituents to estrogen usually decreases the binding to the estrogen
receptor. This unexpected result seemed to indicate that our compound was not stable. A
explanation for the possible rapid break down of psoralen-estrogen (24) is hydrolysis in cell
extracts by steroid esterases (Katz et al., 1987). If the succinate bond were cleaved, the
released estradiol would compete with equal efficiency as the tritium labeled estradiol. No
studies were done to verify whether this were the problem with this compound. We chose
instead to synthesize a new estrogenic compound with a linker that would not be vulnerable
to enzymatic hydrolysis.
f. Nitrogen Mustard Linked Estrogens
Based on the results from the psoralen-estrogen (24), three changes in design were
made before synthesizing the next estrogen based Fatal Engineering compound. The
problems we believed needed to be overcome were: 1) the poor stability to hydrolytic
cellular enzymes, 2) low water solubility, and 3) low reactivity towards DNA. The
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Figure 28. Synthesis of estradiol-gly-gly-dialkylamine psoralen.
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solutions to these problems were: 1) to change the point of attachment of the linker arm to
the estrogen recognition domain, 2) to include a polar linker between the warhead and the
recognition domain, and 3) to change to the warhead used in our compounds.
The first of these changes involved attaching the linker arm to the C17-position of
estrogen via a stable carbon-carbon bond. The study by Bucourt et al. (1978), which earlier
led us to develop the 17-succinate estrogen compound (24), also indicated that 17-alkyl
estrogen derivatives are suitable for binding to the estrogen receptor. In determining the
method of attachment to the C17 position, the work by Salman et al. (1987) indicates that an
alkyne link to C17 position has greater binding affinity to the estrogen receptor than either
alkane or alkene groups.
The second change involved using a different method of linking the warhead and
recognition domain together. Since steroid esterases might hydrolyze our compounds again,
we chose a more stable, polar linker. Cho et al. (1993) recently showed that an
oligocarbamate was completely resistant to hydrolysis by proteases. This ability to resist
hydrolysis by cellular proteases made carbamates superior polar linking groups as compared
to amides or esters.
The third design change was to use a different DNA warhead in our compounds.
Although the psoralen warhead had given us selectivity in reaction with DNA, each of our
studies with a psoralen linked compound showed that the appendages on the psoralen
nucleus greatly decreased the ability of the compound to react with DNA. We chose,
217
therefore, to utilize a different warhead that would yield more abundant DNA adducts to
study. We chose chlorambucil, an aryl nitrogen mustard, as the DNA warhead (see
discussion on warheads).
Having chosen the warhead and recognition domain, the only detail left to determine
was the chemical composition of the linker arm. Based on the earlier finding that at least 14
atoms are needed for binding the estrogen receptor protein to polymers, we decided to keep
a 14 atom linker. In determining the exact chemical composition of the linker arm, two
studies by Poirier et al. (1990, 1991) indicated that five methylenes or more were necessary
for optimal binding to the estrogen receptor of 17a-alkynyl estrogens.
Based on all these considerations, the "ideal" molecule would include: 1) an estrogen
diol recognition domain, 2) a C17 alkynyl linker between the estrogen and the linker arm, 3)
at least a five methylene bridge between any other functional groups and the alkyne, 4) a
non-hydrolyzable carbamate linker to the DNA warhead side chain, 5) a 14 atom long linker
arm, and 6) a chlorambucil warhead. Retrosynthetically, the required components would be
estrone, an eight carbon long alkyne with terminal alcohol or amine group, a phosgene
equivalent and the chlorambucil amine or alcohol.
Two methods are widely used to synthesize C17 alkynyl estrogens. One method uses
estrone as starting material whereby linker arms are added via a nucleophilic carbon species
(i.e., grignards, alkyl lithiums, and lithium alkynes) (Miller and Christiansen, 1967; Garrouj
et al., 1993). The second method begins with 17-ethynylestradiol, the main ingredient in
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oral birth control pills. This method involves deprotonation of the C17-alkyne and
subsequent reaction with acyl esters or alkyl iodides and bromides (Poirier et al., 1990;
Poirier et al., 1991; Salman et al., 1987). The procedure chosen to link the alkynyl side
chain to estrogen domain was that by Miller et al. (1967). The procedure of Miller et al.
involves the alkynylation of estrone methyl ether with lithium, sodium, and potassium
derivatives of 3-butyn-l-ol.
The procedure of Miller et al. appeared ideal for our study for two reasons. First, if
7-octyn-1-ol were used instead of the 3-butyn-l-ol used in the study of Miller et al., the
desired five plus carbon methylene bridge between the alkyne and the next functional group
would result. Second, alkynylation of estrone yielded only the P-ol stereoisomer.
Although a mixture of stereoisomers would not be a problem for our studies, earlier results
by Bucourt et al. (1978) had shown that 3-ol alkynes bound tighter to the estrogen receptor
than a-ol alkynes. The only drawback of the procedure by Miller et al. was that the product
from alkynylation would be an estrone methyl ether. It was postulated that the removal of
the methyl protecting group from this product could be problematic. Therefore, we chose to
replace the methyl ether protecting group with a benzyl ether protecting group.
Benzyl estrone (26) was prepared by reaction of estrone (25) with benzyl bromide (210
M%) in THF with potassium carbonate (Figure 29). Even after stirring at room temperature
for greater than 12 hr, the protection reaction had failed to go to completion. However,
upon addition of sodium hydride, the estrone benzyl ether (26) rapidly formed. With the
estrone benzyl ether (26) in hand, the alkynylation procedure was tested with 3-butyn-l-ol.
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The procedure involved generating the bis-anion of the alkynyl alcohol with potassium metal
in liquid ammonia followed by subsequent addition with estrone benzyl ether (26). The
yield for this reaction was, however, only 20%. Instead of trying to optimize this reaction,
we decided to try the reaction with a protected alcohol and generate the mono alkynyl anion.
The longest commercially available terminal alkyne-l-ol is 5-hexyn-l-ol. By using this
alkyne, the linker arm next to the estrogen would have the desired five carbons between the
alkyne linkage to estrogen and the terminal hydroxyl. Although the total linker arm length
when linked to chlorambucil would be two atoms short of the desired 14 atom linker, the
availability of this alkyne-1-ol made this the compound ideal for testing the new synthetic
scheme. The protecting group chosen to block the primary hydroxyl of the alkyne-1-ol was
the t-butyldimethylsilyl (tBDMS). Reaction of 5-hexyn-l-ol with tBDMSCl in THF with
sodium hydride yielded the 5-hexyn-l-t-butyldimethylsilyol (29) in 82% yield. Instead of
repeating the alkynylation reaction with benzyl estrone (26), the reaction was done with
MOM-estrone (28), previously synthesized in this laboratory for other studies. The
alkynylation reaction was preformed by first generating the alkyne anion of compound (29)
in THF with hexamethylphophoramide at -78 C with BuLi/Et 2O. Subsequently, the MOM-
estrone (28) was added and the cold bath removed to yield after 6 hr at room temperature
the alkynyl-estrone (30). Deprotection of the silyl alcohol was accomplished by treating the
alkynyl-estrone (30) with HF/pyridine (70% solution). Under these conditions, the MOM
protecting group was completely stable. The alkynyl-estrone (31) was obtained after
purification in 99% yield.
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Figure 29. Alkynylation of benzyl estrone.
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Figure 30. Synthesis of 12 atom linker between aryl-nitrogen-mustard and estradiol.
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Based on our design criteria, in order to couple the alkynyl-estrone (31) with
chlorambucil via a carbamate linker, chemical modification of the terminal carboxyl group
of chlorambucil into an amine was required. Using a procedure by Gourdie et al. (1990),
the terminal carboxyl group of chlorambucil can be changed into an amine by a Curtuis
reaction. The method involves ethylchloroformate activation of the carboxyl group followed
by azide displacement and subsequent rearrangement at high temperatures to yield the
nitrogen mustard (33). Subsequent coupling of the nitrogen mustard (33) to the alkynyl-
estrone (31) can be done with a phosgene equivalent, p-nitrophenyl chloroformate.
Procedurally, either component (amine or hydroxyl) could be activated and then allowed to
react with the other component. The reaction of p-nitrophenyl chloroformate with an
alcohol would yield a p-nitrophenyl carbonate, whereas the reaction of p-nitrophenyl
chloroformate with an amine would yield a p-nitrophenyl carbamate. Because the reaction
of the p-nitrophenyl carbonate with the amine would occur more rapidly than reaction of the
p-nitrophenyl carbonate with the amine would occur more rapidly than reaction of the p-
nitrophenyl carbamate with a hydroxyl group, we chose to activate the alkynyl-estrone (31)
with p-nitrophenyl chloroformate and then couple the nitrogen mustard amine (33) to the p-
nitrophenyl carbonate intermediate.
Activation of the alkynyl-estrone (31) with p-nitrophenyl chloroformate occurs at room
temperature within two hours. The resulting p-nitrophenyl carbonate unfortunately
hydrolyses slightly when subjected to chromatography. Consequently, the crude p-
nitrophenylcarbonate isolated after aqueous workup was used without further purification.
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Reaction of the isolated alkynyl-p-nitrophenyl carbonate estrone with the nitrogen mustard
amine (33) yielded the desired estrogen-carbamate-nitrogen mustard (34) in approximately
70% yield. The desired deprotected Fatal Engineering compound, the estrogen-nitrogen
mustard (35), was obtained by treating the MOM-estrogen nitrogen mustard (34) in
methanol with HCl(con). The estrogen-nitrogen mustard (35) could be stored as its
hydrochloride salt or purified by silica gel chromatography for biological testing.
Preliminary biological evidence indicated that the estrogen-nitrogen mustard (35)
resulted in increased toxicity in estrogen receptor positive cells as compared to estrogen
receptor negative cells. Based on this result, we decided to synthesize two additional
estrogen-nitrogen mustards in an attempt to increase the biological response exhibited. The
approach we undertook to increase the biological activity was to vary the distance between
the DNA damaging domain and the estrogen receptor. Our earlier study with the biotin-
psoralen (20) had already indicated that decreased binding to the receptor domain occurs if
the linker arm were too short for proper interaction with the targeted protein. This first
estrone-chlorambucil (35) had twelve carbons between the C17 position on the estrogen and
the phenyl group of the chlorambucil. We therefore decided to synthesize estrone-
chlorambucils with 14 and 16 carbon linker arms. In order to synthesize estrogen-nitrogen
mustards with longer spacer arms, two different alkynes were needed for the initial
alkynylation reaction. Unfortunately, the longest commercially available linear alkyne with
a primary hydroxyl was the six carbon, 5-hexyn-l-ol, used for estrone-chlorambucil (35).
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In order to synthesize the necessary alkynes (7-octyn-l-ol and 9-decyn-l-ol), six and
eight carbon bromo alcohols, respectively, were allowed to react with lithium acetylide.
The method of synthesis involved protection of the primary alcohols with a silyl protecting
group and subsequent displacement of the primary bromides with lithium acetylide. As was
done with the six carbon alkyne, the TBDMS protecting group was used. Unfortunately,
without a chromophore or a method of staining to detect the reaction product, the protection
reaction conditions could not be monitored. Additionally, the purification of the reaction
mixture was difficult. Further, subsequent monitoring of the displacement with lithium
acetylide was not possible and as a result low yields were obtained for the 7-octyn-1-TBDM-
ol and 9-decyn-l-TBDMS-ol. To allow for easier monitoring and purification, the TBDMS
protecting group was replaced by t-butyldiphenylsily (TBDPS), which has two aromatic
groups that would allow monitoring by UV absorbance. Protection of 6-bromo-1-hexanol
and 8-bromo-l-octanol with TBDPS groups was done by using TBDPSCl and sodium
hydride in THF. Subsequent displacement of the alkyl bromides was done with lithium
acetylide, ethylene diamine complex (LAEDA) (Dejarlais et al., 1980; Brattesani et al.,
1973). The necessary alkynes (36,37) were obtained in greater than 70% yield for two
steps.
The coupling of the alkynes (36,37) with MOM-estrone (28) was done by the using the
procedure developed with the 5-hexyn-l-t-butyldimethylsilyol (29). Unfortunately, the
MOM-estrone starting material and the resulting MOM-estrone-alkyne products (38, 39)
have almost identical retention times which made chromatographic isolation of the MOM-
estrone-alkyne products problematic when incomplete conversion of the MOM-estrone (28)
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Figure 31. Synthesis of 14 and 16 atom linker between aryl-nitrogen-mustard and estradiol.
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occurred. As expected, treatment of the mixture of products with HF / pyridine only
resulted in the removal of the TBDPS group whereby MOM-estrone-alkynes (40, 41) could
be easily separated from the MOM-estrone (28) in 60% yield for two steps. Subsequently,
the same procedure involving p-nitrophenyl chloroformate was then used to couple the
nitrogen mustard amine (33) with the alkynyl- estrogens (40) and (41). The final
deprotection with HCl yielded the 14 and 16 atom estrogen-nitrogen mustards (44,45)
desired for biological testing.
One of the first experiments conducted with the three estrogen-nitrogen mustards (35,
44, 45) was designed to determine if there were any change in the chemical reactivity of the
mustard warhead as compared to chlorambucil. The reactivity of the mustard warheads was
determine by examining the rate of hydrolysis with different aqueous buffers (Figure 32).
Specifically, two buffers (one with and one without chloride) were examined to determine
the effect of chloride concentration on the extent of hydrolysis. The extent of hydrolysis
was determined by monitoring, at different time points, for the appearance of new peaks as
detected by reversed phase HPLC using UV detection at 254 nm and 280 nm. With the
gradient described in the Materials section, the order of elution from a C18 reversed phase
column of the parent estrogen-nitrogen mustards was compound 35, compound 44, and then
compound 45. The only difference between the three compounds was the length of their
linker arms. The earliest eluting compound (35) had the shortest linker arm (12 atoms) and
the latest eluting compound (45) had the longest (16 atoms). As expected the addition of
methylene groups increased the relative hydrophobicity of the estrogen-nitrogen mustards.
After heating (60 C), two more polar products resulted, irrespective of the method used for
230
hydrolysis. Based on the retention times, the peaks were assigned as the mono-hydroxy,
mono-chloro product, and the bis-hydroxy product.
We determined subsequently that the extent of hydrolysis depended on both the
chloride concentration and the pH of the solution. If the pH were adjusted to less than six,
the estrogen-nitrogen mustards did not undergo hydrolysis, even when heated overnight at
60 C. When the pH was subsequently adjusted to eight, the extent of hydrolysis for the
Tris-HCl buffer was only 50% after being heated overnight at 60 C. This slow rate of
hydrolysis with Tris-HCl buffer was attributed to the presence of chloride ions. As
discussed earlier, the chloride ions can react with the intermediate aziridinium ion to reverse
one pathway of reactivity. When we examined the extent of hydrolysis with a buffer
without chloride, 10 mM sodium cacodylate pH 8.0, 50% CH3CN buffer, the extent of
hydrolysis was more than 50% in less than two hours. The conclusion from these
experiments was that the nitrogen mustard-estrogens (35, 44, 45) would be stable to
conditions encountered in vivo. In fact, the high chloride concentration and lower
temperature (37 C) used for growing the estrogen receptor cells in tissue culture meant that
the estrogen-nitrogen mustards would be stable for at least two hours. Consequently, the
drug could slowly diffuse into the cells under study and possibly form DNA lesions.
The ability of the estrogen-nitrogen mustards (35, 44, 45) to react in vitro with DNA
was determined by mixing the estrogen-nitrogen mustards with DNA. Reaction with DNA
was conducted by using the same cacodylate buffer used in the hydrolysis experiments. In
order to understand the relative reactivity of the new compounds, two other nitrogen
231
Figure 32. Hydrolysis of aryl nitrogen mustards.
232
100
75
50
25
n
100
75
rA 25
0
100
75
50
25
0
0 100 200 300 400 600
Time (min)
233
._r
mustards, mechlorethamine and chlorambucil, were studied as controls. The
mechlorethamine is an alkyl mustard having only a methyl group attached to the nitrogen
mustard functionality. During these preliminary biological experiments, it was determined
that the estrogen-mustard (45) would precipitate from aqueous solution even when an
organic co-solvent (DMSO or acetonitrile) was added. As a consequence, no further DNA
crosslinking testing was done with this compound.
The largest extent of DNA damage was obtained by methchlorethamine and the least
amount of crosslinking resulted from our nitrogen mustard-estrogens (K. Yarema, personal
communication). The extent of crosslinking of chlorambucil was determined to be 20 to 100
fold lower than that caused by mechlorethamine. Crucial to our research, the extent of
DNA damage by our estrogen-nitrogen mustards was 10-100 fold lower than that caused by
chlorambucil. Ongoing studies are attempting to determine whether the DNA damage
resulting from our compounds is due to DNA crosslinking or monoadduct formation.
The efficacy of the estrogen-nitrogen mustards (35, 44, 45) to function as selective
toxins in vivo was tested by a growth inhibition assay using estrogen receptor positive and
estrogen receptor negative cells. The experiments conducted by R. Croy tested the ability of
estrogen receptor positive and estrogen receptor negative cells to grow when exposed to
increasing amounts of the estrogen-nitrogen mustards. As a control compound,
chlorambucil was used as a baseline for cell toxicity. As might be expected, the estrogen-
nitrogen mustard (45), that showed greatly decreased reactivity with DNA in vitro, was not
effective in killing cells. Although this compound did result in some cell toxicity, no
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difference in cell toxicity resulted with increasing amounts of estrogen-nitrogen mustard
(45). Two reasons were postulated for this result: 1) the estrogen-nitrogen mustard (45)
precipitated from solution at higher concentration, and 2) the compound may be sequestered
in the cell away from the DNA due to its hydrophobic nature. In either case, the estrogen-
nitrogen mustard (45) apparently does not reach the cell nucleus and consequently does not
form DNA lesions.
In contrast, the estrogen-nitrogen mustards (35,44) with a slightly shorter spacer arm
proved to be equally toxic to estrogen receptor positive cells as chlorambucil (R. Croy,
personal communication). Unfortunately, no difference was seen between the estrogen
receptor positive and estrogen receptor negative cells as would have been predicted if a Fatal
Engineering drug complex formed. This result was attributed to nonoptimal interaction of
ER with the drug lesions. An estrogen receptor binding assay later confirmed this
hypothesis. The receptor binding assay determined that the estrogen mustard drugs (35, 44)
bound 100 to 1000 fold less tightly than estradiol (R. Croy, personal communication).
In summary, three trifunctional compounds were synthesized with a nitrogen mustard
DNA damaging domain, an alkynyl-carbamate linker arm, and a complementary domain for
the estrogen receptor. The nitrogen mustard-estrogen (45) with the longest linker arm
between a DNA damaging domain and a protein recognition domain had the lowest water
solubility of the three compounds. This compound showed drastically decreased ability to
react with DNA in vitro and to induce in vivo toxicity experiments. In contrast, two
nitrogen mustard-estrogens (35,44) with shorter linker arms had increased water solubility
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and could react with DNA in vitro as determined by a DNA modification assay and in vivo
as determined by a cell killing assay. In fact, preliminary results indicate that even with the
attachment of the bulky side chain and protein recognition domain, the compounds were
equally toxic to cells as the underivatized chlorambucil. This result contrasts with our
earlier results with psoralen, where the attachment of the linker arm and recognition domain
decreased reactivity with DNA greater than ten-fold. Unfortunately, no difference was
determined between the targeted estrogen receptor positive and control estrogen receptor
negative cells. This result was attributed to the poor binding of the estrogen receptor to the
nitrogen mustard-estrogens. If the estrogen receptor protein cannot bind to the drug lesion,
no difference in selectivity would consequent result. Therefore, in order to target selectively
the estrogen receptor cells, the binding affinity between the nitrogen mustard-estrogen
needed to be increased.
During the writing of this dissertation, the next step in the evolution of the Fatal
Engineering compounds occurred. In this work, done by R. Croy with my supervision, a 2-
phenylindole moiety used to in place of estradiol. 2-Phenylindoles can bind at the same site
as estradiol and, in some case, bind even more tightly than estradiol. Preliminary biological
tests indicate that the resultant mustard showed far greater toxicity to ER positive cells than
ER negative cells (R. Croy, personal communication). Further studies are underway to
determine whether this result were due to selective non-repair of the lesion in the cells
overexpressing the tumor specific protein, as would be expected if the goals of the Fatal
Engineering project were achieved.
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F. Conclusions
This chapter has described the rationale and testing of a new approach for the treatment
of cancer. The new therapeutics under development in this laboratory involved coupling a
DNA damaging agent to a protein recognition domain that attracts a tumor specific protein.
The therapeutic efficacy of these trifunctional compounds depends on their ability to produce
lethal chemical damage in cellular DNA, and on the selective blockage of repair in the
presence of a tumor specific protein. The custom designed toxicity for cancer cells arises
from the selective inhibition of DNA repair in the tumor as a consequence of a tumor
specific protein binding to the DNA damage. The selective binding of proteins to the DNA
damage in tumor cells arises either by the expression of oncogene-encoded or mutated
suppresor gene-encoded proteins or by the overexpression of normal cellular proteins.
Binding of the targeted protein to its recognition domain at the damaged site intentionally
obstructs DNA repair enzymes. Consequently, the repair of the damaged segment of DNA
would occur less efficiently and the lethal effect of the drug should be enhanced. In
contrast, in the absence or with the low expression of the tumor specific protein in normal
cells, repair enzymes would have free access to the damaged DNA site. Under such
conditions, DNA repair could take place unobstructed and the cell would suffer far less
toxicity.
Our initial objective of synthesizing compounds that were capable of both reacting with
DNA and binding to a cellular protein has been accomplished. The first designed drug that
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validated the Fatal Engineering concept took advantage of the high affinity of biotin for the
protein streptavidin and the ability of psoralen to photo-crosslink ds DNA when irradiated
with near UV light. To summarize the experiment, biotin-psoralen (20) was crosslinked to
ds DNA by irradiation with near UV light. Subsequently, a nearby DNA lesion, uracil, was
tested for repair in the presence and absence of streptavidin. In the presence of streptavidin,
a protein-DNA lesion complex formed as evidenced by the inhibition of DNA repair of the
nearby lesion and the diminished ability of the DNA to be degraded by an endonuclease.
Although streptavidin is not expressed in mammalian cells, this system nevertheless
demonstrated that proteins attracted to a DNA lesion can inhibit DNA repair.
Estrogen, a more biologically relevant recognition domain suitable for therapeutic
applications, was subsequently incorporated into candidate Fatal Engineering drugs. Four
compounds were synthesized and tested to various degrees in order to understand their
ability to act as potential Fatal Engineering drugs: one psoralen linked estrogen and three
nitrogen mustard linked estrogens. The instability of the psoralen linked estrogen, possibly
due to steroid esterases, led to the development of non-hydrolyzable compounds for testing.
The three nitrogen mustard-estrogens (35,44,45) differed only in the length of the spacer
arm connecting the protein recognition domain to the DNA warhead: 12, 14 and 16 atoms,
respectively. The nitrogen mustard-estrogen(45) with the longest linker arm had the lowest
water solubility of the compounds tested. In addition, this compound showed greatly
decreased DNA damaging ability in vitro. The nitrogen mustard-estrogens (35 and 44)
were more water soluble and could react with DNA in vitro, although not as well as the
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underivatized DNA warhead. Unfortunately, no difference in cell toxicity was determined
between the targeted and the control cells.
Although the "magic bullet" was not developed in the studies described in detail here,
the data gained from these early studies has been useful in our continuing investigation of
this novel approach to treat cancer. My work has shown that one factor to incorporate into
a new compound would be a protein recognition domain showing higher binding affinity to
the ER. The current estrogen mustards (35, 44, 45) bind 100 times less tightly to the ER
than estradiol. This binding affinity may not be strong enough to allow a stable protein-
DNA lesion to form. One way to improve the binding to the ER would be to use other
steroid and non-steroid analogs that have shown tighter affinity to the ER. Experiments are
now underway by R. Croy, K. Yarema, and myself to manipulate the structure of the
estrogen compounds to enhance the likelihood of interaction between the Fatal Engineering
compounds and the estrogen receptor. Initial biological experiments with a 2-phenylindole-
aryl nitrogen mustard drug indicate that the Fatal Engineering strategy may work as
propossed.
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G. Experimental
a. General Procedures and Materials
Unless otherwise specified, all chemicals were bought from Aldrich or Sigma chemical
companies. N-succinimidyl 3-(2-pyridyldithio)propionate and N-succinimidyl 6-[3-(2-
pyridyldithio) propionamido] hexanoate were purchased from Pierce. All reactions were
performed under argon atmosphere except when performed in aqueous media. Silica gel
TLC plates were visualized with UV illumination followed by charring with 5 %
anisaldehyde in (95:5:1) ethanol-acetic acid-sulfuric acid. Silica gel (230-400 mesh) was
used for normal phase chromatographic separations. All reactions were performed under an
argon atmosphere except when working in aqueous media.
The purity of the thiol-mercury (8), psoralen-biotin products (19, 20), and estrogen-
aryl mustard products (35, 44, 45) were examined by reverse phase chromatography with a
Beckman Ultrasphere C18 column using a Beckman 114M solvent delivery system, Beckman
421A controller, and Hewlett Packard model 1040A photodiode array detector or using an
Nec PC-8300 controller, Beckman Analog interface Module 406, Beckman 110B solvent
Delivery Module, Nelson Analytical 760 series interface and Gateway 2000 computer. The
compounds were monitored at 280 and 254 nm. The follow rate was 1 ml/min. Gradient I:
a linear gradient of 0 -100% B over 50 minutes where solvent A = CH3CN/H 2O (90:10)
and solvent B = CH3CN. Gradient II: a linear gradient of 0-20% B over 40 min where
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solvent A = acetonitrile/water (1:1) and B = acetonitrile; Gradient III: isocratic elution
with 60% B where solvent A = MeOH/0.1 M NH4OAc (20: 80) and solvent B = MeOH.
Gradient IV: a linear gradient of 70 -100% B over 20 min where solvent A = 0.1 M
NH 4OAc, 1 mM triethylamine, 1 mM hexane bisulfonic acid, 10% acetonitrile and solvent
B = methanol.
GC-MS analyses were performed with a Hewlett-Packard 5971 mass spectrometer
equipped with a Hewlett-Packard 5890 gas chromatograph. Fast atom bombardment (FAB-
MS) was obtained with 2-nitrobenyzl alcohol as the matrix on a Finnigan 8200 mass
spectrometer. High-resolution mass spectral (HRMS) data are reported in units of m/z for
M+ or the highest mass fragment derived from M+. H and '13C NMR were recorded on
Varian VXR-300, VXR-301, or Bruker AC-250 MHz spectrometers. Chemical shifts are
expressed in parts per million downfield from CDC13 (7.24 ppm or 77.00 ppm) or CD3OD
(3.30 ppm and 35.00 ppm) for H and 3C, respectively. Data are reported as follows:
chemical shift, integration, multiplicity, and regiochemical assignments.
b. Methods
4'-Bromomethyl-4,5 ',8-trimethylpsoralen (2)
Bromomethyl methyl ether (1.00 ml, 12.65 mmol, 14,000 M%) was added to
trimethylpsoralen (1) (0.200 g, 0.876 mmol) that was partially dissolved in AcOHcacal) (10
ml). After 1.5 hr at room temperature, additional bromomethyl methyl ether (1.00 ml) was
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added to the clear yellow reaction. After 3 hr, a solid precipitate formed. At 4.5 hr, the
precipitate was filtered and washed with AcOHglacial) (3 x 10 ml). The filter cake was
dissolved with a minimum of CH 2CI2 and concentrated in vacuo to an off-white solid. 11H
NMR (CDC13): 7.57 (1H, s, H5), 6.25 (1H, s, H3), 4.61 (2H, s, CH2Br), 2.55 (3H, s,
CH3), 2.52 (3H, s, CH3), 2.48 (3H, s, CH3).
4'-(Hydroxyethoxymethylether)-4,5 ',8-trimethylpsoralen (3)
4'-Bromomethyl-trimethylpsoralen (2) (0.36 g, 1.2 mmol) was suspended in ethylene glycol
(8.00 ml) and heated (100 C). After 2 hr, the reaction was diluted with H20 (40 ml) and
CH2C12 (40 ml). The organic layer was separated and washed with NaHCO3(,at) (75 ml) and
NaCl(sat) (25 ml). The organic extract was then dried (Na2SO 4), filtered, and concentrated.
The 4'-(hydroxyethoxymethylether)-4,5',8-trimethylpsoralen (3) was purified by column
chromatography on 15 g silica gel eluting with CH2C12/MeOH (96:4). to produce an off
white solid (0.31 mg, 1.1 mmol, 90 % yield) (TLC rf 0.68 CH2C12: MeOH 90:10) H
NMR (CDC13): 7.58 (1H, s, H5), 6.22, (1H, s, H3), 4.68 (2H, s, OCH 2Ar), 3.6-3.8 (4H,
m, ethylene), 2.55 (3H, s, CH3), 2.48 (3H, s, CH3), 2.47 (3H, s, CH3).
4
'-[(Methyloxyethoxy)-0-[(2-cyanoethoxy)-N,N-diisopropylamino]-phosphoramidite]-
4,5' ,8-trimethylpsoralen (4)
(2-Cyanoethyl) N,N-diisopropylphosphoramidite (0.31 mg, 1.31 mmol) was added to 4'-
(hydroxyethoxymethyl ether)-4,5' ,8-trimethylpsoralen (3) (0.31 mg, 1.19 mmol) dissolved
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in THF (5 ml) and triethylamine (100 1I). After 30 min at room temperature, the reaction
was diluted with water (20 ml) and CH2Cl2 (20 ml). The organic solution was separated and
washed with NaHCO 3(sat) (15 ml) and NaCl(sa) (15 ml). The organic extract was dried with
Na2SO4, filtered, and concentrated. The 4'-[(methyloxytheoxyl)-O-[(2-cyanoethoxy)-N,N-
diisopropylamino]-phosphoramidite]-4,5', 8-trimethylpsoralen (4) was purified by column
chromatography on 15 g silica gel eluting with CH2C12/MeOH (96:4). Although the isolated
material contained some impurities, this material was used without further purification for
solid phase DNA synthesis.
5 '-Trimethylpsoralen-methyloxyethoxy-CAGGTTGGTGTGGTTGGG (5)
The oligodeoxynucleotide sequence 5'-CAG GTT GGT GTG GTT GGG-3' (10 /zmol) was
synthesized on an Applied Biosystems DNA synthesizer using phosphoramidite chemistry.
The psoralen phosphoramidite (4) was applied manually via two disposable 1 ml syringes to
the resin-bound oligonucleotide. One syringe contained the phosphoramidite (4) (20 mg)
dissolved in CH 3CN (100 /zl) while the other contained ABI tetrazole/CH3CN solution (100
/Al). The syringes were attached to the ends of the oligonucleotide column and then passed
repeatedly over the resin for 5 min. The column was placed back on the DNA synthesizer
and subjected to washing and oxidation steps only. To cleave the oligonucleotide from the
resin, NH4OH(con) (3 x 5 ml) was passed through the oligonucleotide column. The
ammonium solution containing the oligonucleotide was collected and heated overnight at 60
'C. The deprotected oligonucleotide was purified by gel electrophoresis (Z. Chen, personal
communication).
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4'-((1,5-Pentanedithiol)methylether)-4,5 ',8-trimethylpsoralen (6)
4'-Bromomethyl-trimethylpsoralen (2) was suspended in 1,5 pentanedithiol (3 ml) and heated
(100 C). After heating for 1.5 hr, the reaction was cooled and diluted with CH 2CL2 (50
ml). The organic solution was washed with H20 (10 ml) and NaCl(,a) (10 ml). The organic
solution was dried with Na2SO 4, filtered, and concentrated. The crude 4'-((1,5-
pentanedithiol)methylether)-4,5',8-trimethylpsoralen (6) was purified by column
chromatography on 15 g silica gel eluting with CH2Cl2/MeOH (96:4) an off white solid. H
NMR (CDCl 3): 7.52 (1H, s, H5), 6.13, (1H, s, H3), 3.72 (2H, s, H4'), 2.45 (3H, s,
CH3), 2.42 (3H, s, CH 3), 2.40 (3H, s, CH 3), 2.42 (2H, s, SCH2), 1.6-1.4 (8H, m, CH2's).
C20H2403S2 376.51 (calculated) GC-MS 376 [M + found], 241 [M-HS(CH 2)sSCH2]+.
5-Mercuri-2'-deoxycytidine carbonate (7)
5-Mercuri-2'-deoxycytidine carbonate (7) was prepared by Z. Chen. The mercurated
nucleoside was obtained by incubating 5-mercuri-2'-deoxycytidine 5'-triphosphate
carbonate, tris-triethylammonium salt with calf intestine phosphatase.
5-[4'-((1,5-Pentanedithiol)methylether)-4,5 ',8-trimethylpsoralen] mercuri-2'-
deoxycytidine carbonate (8)
4'-((1,5-Pentanedithiol)methylether)-4,5',8-trimethylpsoralen (6) dissolved in CH3CN (100
,ul) was mixed with 5-mercuri-2'-deoxycytidine carbonate (7) dissolved in H20 (100 /l).
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The reaction was monitored by reversed phase-HPLC on a C,8 column using gradient I.
The collected eluent for peaks 7 and 8 tested positive for mercury by atomic absorption.
4'-[[(Methylamino)ethyl]methylamino]methyl-4,5 ',8-trimethylpsoralen (9)
4'-Bromomethyl trimethylpsoralen (2) (0.32 mg) was suspended in N,N'-
dimethylethylenediamine and heated (100 C). After heating for 90 min, the reaction was
cooled and diluted with CH2C12 (50 ml). The organic solution was washed with H20 (10
ml) and NaCl(sat) (10 ml). The organic solution was dried with Na2SO4, filtered, and
concentrated. The 4'-[[(methylamino)ethyl]methylamino]methyl-4,5',8-trimethylpsoralen (9)
was purified by column chromatography on 15 g silica gel eluting with CH2Cl2/MeOH
(96:4) to yield an off white solid (yield not determined). (TLC rf 0.12 CH2C12: MeOH
95:5) 'H NMR (CDC13): 7.63 (1H, s, H5), 6.23, (1H, s, H3), 4.06 (2H, s, NCH2Ar), 2.8-
2.5 (4H, dt, NCH2CH2), 2.45 (3H, s, CH3), 2.42 (3H, s, CH3), 2.40 (3H, s, CH3), 2.35
(3H, s, NCH3), 2.23 (3H, s, NCH3). C19H2403N2 328 (calculated) GC-MS 328 [M+], 241
[M-CH3N(CH2)2NCH] +.
4'-[[[(Methylamino)ethyl]methylamino]methyl]-4,5 ',8-trimethylpsoralen succinate (10)
Succinic anhydride (20 mg, 0.20 mmol, 200 M%) and DMAP (4 mg, 0.03 mmol, 30 M%)
was added to 4'-[[(methylamino)ethyl]methyl]trimethylpsoralen (9) (0.034 g 0.103 mmol)
dissolved in pyridine (0.5 ml). After 4 hr at room temperature, the reaction was
concentrated to dryness. The 4'-[[[(methylamino)ethyl] methylamino]methyl]-4,5',8-
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trimethylpsoralen succinate (10) was purified by column chromatography on 15 g silica gel
eluting with an increasing gradient of methanol starting with CH 2Cl 2/MeOH (85:15) to yield
an off white solid (yield not determined). (TLC rf 0.34 CH 2C12: MeOH 80:20) H NMR
(CDC13)(NCH 3 rotamers): 7.85 (1H, s, H5), 6.18 (1H, s, H3), 4.06 (2H, s, H4'), 3.70
(2H, d, succinate CH2), 3.45, 3.18, 2.98, 2.83 (NCH3 rotamers), 2.51 (3H, s, CH3), 2.50
(3H, s, CH 3), 2.49 (3H, s, CH 3), 2.45 (2H, d, succinate CH2).
4,4'-Dimethoxytritylcysteamine (11)
Cysteamine (0.200 g, 2.59 mmol) and 4,4'-dimethoxytritylchloride (1.02g, 3.02 mmol, 116
M%) were dissolved in pyridine (10 ml). After 6 hr at room temperature, additional 4,4'-
dimethoxytritylchloride (0.50 g, 58 M%) was added. After stirring overnight, the reaction
was concentrated to dryness. The residue was redissolved in CH2C12 (50ml) and washed
with H20 (50 ml), NaHCO 3 (sat) (15 ml), and NaCl(sat)(15 ml). The organic solution was dried
(Na2SO4), filtered and concentrated. The 4,4'-dimethoxytritylcysteamine (11) was purified
by column chromatography on 45 g silica gel eluting with CH2C12/MeOH (92:8) to yield an
off white solid (0.70 g, 1.90 mmol, 74 % yield). (TLC rf 0.64 CH2C12: MeOH 90:10) 'H
NMR (CDC13): 7.2-7.4 (m, DMT), 6.75 (d, DMT), 3.72 (6H, s, DMT-OCH 3), 3.4 (2H, s,
NH), 2.56 (2H, t, CH2), 2.32 (2H, t, CH2).
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4'-[[[(Methylamino)ethyl]methylamino]methyl]-4,5 ',8-trimethylpsoralen 4,4'-
dimethoxytritylcysteaminyl succinate ester (12)
4,4'-Dimethoxytritylcysteamine (11) (90 mg, 0.24 mmol, 200 M%) and DIC (40 ,, 0.26
mmol, 250 M%) was added to 4'-[[(methylamino)ethyl]methyl]-4,5 ',8-trimethylpsoralen
succinate (10) (0.103 mmol) dissolved in pyridine (4 ml). After 5 hr at room temperature,
additional 4,4'-dimethoxytritylcysteamine (11) (40 mg, 100 M%) and DIC (40 1l) were
added. After stirring overnight, the reaction was concentrated to dryness. The residue was
redissolved in CH2C12 (50 ml) and washed with H2 0 (15 ml), NaHCO3(st)(15 ml), and
NaCl(sat) (15 ml). The organic solution was dried with Na2SO4, filtered, and concentrated.
The 4'-[[[(methylamino)ethyl]methylamino]methyl]-4,5 ',8-trimethylpsoralen 4,4'-
dimethoxytritylcysteaminyl succinate ester (12) was purified by column chromatography on
20 g silica gel eluting with CH 2C12/MeOH (92:8) to yield an off white solid (50 mg, 0.064
mmol, 62% yield). (TLC rf 0.64 CH2C12: MeOH 90:10) 11H NMR (CDCl3)(two rotamers):
7.85 (1H, s, H5), 7.2-7.4 (m, DMT), 6.75 (d, DMT), 6.18 (1H, s, H3), 4.06 (2H, s, H4'),
3.72 (s, 6H, DMT-OCH3), 3.70 (2H, d, succinate CH2), 3.45, 3.18, 2.98, 2.83 (NCH3
rotamers), 2.56 (t, 2H, CH2), 2.51 (3H, s, CH3), 2.50 (3H, s, CH3), 2.49 (3H, s, CH3),
2.45 (2H, d, succinate CH2), 2.32 (t, 2H, CH 2).
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4'-[[[(Methylamino)ethyl]methylamino]methyl]-4,5 ',8-trimethylpsoralen cysteaminyl
succinate ester (13)
Trichloroacetic acid/CH 2C12 (200 l) (Applied Biosystems Oligonucleotide Reagent) was
added to 4'-[[(methylamino)ethyl]methyl]-4,5',8-trimethylpsoralen 4,4'-dimethoxytrityl
cysteaminyl succinate ester (12) (14 mg) dissolved in CH2C12 (5 ml). Almost immediately,
the reaction turned orange. After 30 min at room temperature, the organic solution was
diluted with CH 2C12 (10 ml) and washed with H20 (15ml), NaHCO 3 (,at) (15ml), and NaCl(sat)
(15ml). The organic solution was dried with Na2SO 4, filtered, and concentrated. The 4'-
[[[(methylamino)ethyl]methylamino]methyl]-4,5',8-trimethylpsoralen cysteaminyl succinate
ester (13) was purified by column chromatography on 20 g silica gel eluting with
CH2Cl2/MeOH (92:8) to yield an off white solid (yield not determined). 'H NMR
(CDCl3)(two rotatmers): 7.85 (1H, s, H5), 6.18 (1H, s, H3), 4.06 (2H, s, H4'), 3.70 (2H,
d, succinate CH2), 3.45, 3.18, 2.98, 2.83 (NCH3 rotamers), 2.56 (2H, t, CH2), 2.51 (3H,
s, CH 3), 2.50 (3H, s, CH3), 2.49 (3H, s, CH3), 2.45 (2H, d, succinate CH2), 2.32 (2H, t,
CH2).
N-(4'-[[[(Methylamino)ethyl]methylamino]methyl]-4,5 ' ,8-trimethylpsoralen)
succinimidyl 3-(2-pyridyldithio)propionate (14)
4'-[[(Methylamino)ethyl]methyl]trimethylpsoralen (9) (0.043 g 0.131 mmol) and N-
succinimidyl 3-(2-pyridyldithio)propionate (48 mg, 0.154 mmol, 120 M%) were dissolved in
pyridine (2 ml). After 4 hr at room temperature, the reaction mixture was concentrated to
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dryness. The N-(4'-[[[(methylamino)ethyl]methylamino]methyl]-4,5 ' ,8-trimethylpsoralen)
succinimidyl 3-(2-pyridyldithio)propionate (14) was purified by column chromatography on
10 g silica gel eluting with CH 2Cl2/MeOH (96:4). (0.046 g, 0.91 mmol, 70 % yield) (TLC
rf 0.55 CH2C12 : MeOH 90:10) 'H NMR (CDC13): 8.40 (1H, d, pyr), 7.58 (2H, d, pyr),
7.51 (1H, s, H5), 7.05 (1H, m, pyr), 6.58 (1H, m, pyr), 6.17 (1H, s, H3), 3.5.4 (2H, t),
2.97 (2H, t), 2.86 & 2.81 (3H, s, NCH3), 2.52 (3H, s, CH3), 2.45 (3H, s, CH3), 2.42 (3H,
s, CH 3), 2.25 & 2.21 (3H, s, NCH3), 1.50 (4H, m, CH 2.s), 1.20 (2H, m, CH 2-s). 13C
NMR (CDC13): 170.42, 161.40, 159.99, 154.50, 153.24, 149.49, 148.96, 136.93, 125.62,
120.61, 119.66, 115.84, 112.58, 112.53, 111.80, 108.81, 54.44, 42.32, 42.22, 35.61,
33.71, 32.81, 19.29, 12.28, 8.40
N-(4'-[[[(methylamino)ethyl]methylamino]methyl]-4,5 ',8-trimethylpsoralen) succinimidyl
6-[3-(2-pyridyldithio) propionamido] hexanoate ester (16)
4'-[[(Methylamino)ethyl]methyl]trimethylpsoralen (9) (0.021 g 0.064 mmol) and N-
succinimidyl 6-[3-(2-pyridyldithio) propionamido] hexanoate (30 mg, 0.071 mmol, 110 M%)
were dissolved in 2 ml pyridine. After 9 hr at room temperature, additional N-succinimidyl
6-[3-(2-pyridyldithio) propionamido] hexanoate (20 mg, 0.47 mmol, 74 M%) was added.
After 11 hr, the reaction was concentrated to dryness. The N-(4'-
[[[(methylamino)ethyl]methylamino] methyl]-4,5' ,8-trimethylpsoralen) succinimidyl 6-[3-(2-
pyridyldithio) propionamido] hexanoate ester (16) was purified by column chromatography
on 10 g silica gel eluting with CH2Cl2/MeOH (96:4). (TLC rf 0.55 CH2Cl2: MeOH 90:10)
'H NMR (CDC13): 8.37 (1H, d, pyr), 7.58 (2H, d, pyr), 7.52 (1H, s, H5), 7.05 (1H, m,
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pyr), 6.58 (1H, m, pyr), 6.17 (1H, s, H3), 3.6-3.4 (3H, m), 3.20 (2H, t), 3.00 (2H, t),
2.85 & 2.80 (3H, s, N-methyl amide), 2.49 (3H, s, CH3), 2.44 (3H, s, CH3), 2.40 (3H, s,
CH3), 2.25 & 2.21 (3H, s, N-methyl amide), 1.50 (4H, m, CH2-s), 1.20 (2H, m, CH2-s).
'
3C NMR (CDC13): 172.37, 170.45, 161.43, 159.47, 154.42, 153.31, 149.33, 148.90,
136.92, 125.38, 120.79, 119.96, 115.75, 112.52, 112.53, 111.89, 108.78, 55.35, 54.49,
52.48, 52.43, 51.82, 51.75, 48.16, 45.76, 45.66, 42.50, 39.23, 39.03, 35.76, 34.82,
33.87, 33.17, 33.09, 32.50, 29.22, 26.60, 24.56, 24.18, 19.49, 12.46, 8.60
4'-((1,5-Pentanediol)methylether)-4,5 ',8-trimethylpsoralen (18)
4'-Bromomethyl-4,5',8-trimethylpsoralen (2) (0.21 g) was suspended in 1,5 pentanediol
(6.00 ml) and heated (100 °C). After 2 hr, the reaction was allowed to cool to room
temperature and diluted with H20 (40 ml) and CH2C12 (40 ml). The organic solution was
collected and washed with NaHCO3(sa) (75 ml) and NaCl(sat) (40 ml). The organic extract
was dried with Na2SO4, filtered, and concentrated. The 4'-((1,5-pentanediol)methyl ether)-
4,5',8-trimethylpsoralen (18) was purified on 15 g silica gel eluting with CH2C12/MeOH
(96:4). 'H NMR (CDC13): 7.58 (1H, s, H5), 6.22, (1H, s, H3), 3.62 (2H, t, OCH2), 3.47
(2H, t, OCH2), 2.55 (3H, s, CH3), 2.48 (3H, s, CH3), 2.47 (3H, s, CH3), 1.6-1.4 (6H, m,
3 x CH2). C20H240 5 344.39 (calculated) GC-MS 344 (M+ found)
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(d)-Biotin (4'-(1,5-pentanediol)methylether-4,5',8-trimethylpsoralen) ester (19)
4'-((1,5-Pentanedithiol)methyl ether)-4,5',8-trimethylpsoralen (18) (21 mg, 0.061 mmol)
and biotin 4-nitrophenyl ester (0.048 g, 0.128 mmol, 210 M%) were dissolved in 0.5 ml
DMF and heated (80 C). After 30 min, DMAP (50 mg, 0.40 mmol) was added. After
stirring overnight with heat, the reaction mixture was diluted with CH2C12(50 ml) and
washed with H20 (15 ml), NaHCO 3(sat)(15 ml), and NaCl(sat) (15 ml). The organic solution
was dried with Na2SO4, filtered, and concentrated. Purification was done by reversed phase
HPLC on C18 column using Gradient II. 'H NMR (CDC13): 7.55 (1H, s, H5), 6.20 (1H, s,
H3), 5.26 (1H, br, NH), 4.95 (1H, br, NH), 4.57 (2H, s, H4'), 4.45 (1H, m, bio), 4.26
(1H, m, bio), 3.99 (2H, t, OCH2), 3.45 (2H, t, OCH2), 3.10 (1H, m, bio), 2.87 (1H, dd,
bio), 2.70 (1H, d, bio), 2.52 (3H, s, CH3), 2.46 (3H, s, CH3), 2.45 (3H, s, CH3), 2.24
(2H, t, a carbonyl), 1.61 (m, CH2), 1.40 (m, CH2), 0.80 (m, CH2). 13C NMR (CDCl 3):
173.53, 161.52, 160.51, 154.72, 153.30, 130.51, 125.17, 116.16, 112.12, 111.64, 109.14,
96.14, 69.83, 64.27, 63.12, 61.89, 60.08, 55.25, 40.52, 33.81, 29.69, 29.37, 28.46,
28.30, 28.23, 24.75, 22.80, 19.34, 12.33, 8.50.
(d)-Biotin (4'-[[[(methylamino)ethyl]methylamino]methyl]-4,5 ',8-trimethylpsoralen)
ester (20)
4'-(N,N'-Dimethylethylene diaminomethyl)-4,5' ,8-trimethylpsoralen (9) (0.144 g), biotin 4-
nitrophenyl ester (0.047 g) and DMAP (0.028 g, 0.22 mmol) were dissolved in 2 ml DMF.
After 3 hr at room temperature, DIC (200 l) and biotin (145 mg) were added. After
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stirring overnight, the reaction was diluted with CH2Cl2 (50 ml) and washed with H 20 (15
ml), NaHCO3 (,at)(15 ml), and NaCl(sat) (15 ml). The organic solution was dried with Na 2SO4,
filtered, and concentrated. Purification was by reversed phase HPLC on C,8 column using
Gradient II. H NMR (CDC13): appears two be two rotamers, 7.75 & 7.71 (1H, s, H5),
6.27 & 6.26 (1H, s, H3), 4.86 (2H, s, H4'), 4.46 (1H, m, bio), 4.20 (1H, m, bio), 3.65 &
3.62 (2H, s), 3.48 (2H, m), 3.34 & 3.30 (2H, s), 2.9 (2H, m), 3.10 (1H, m, bio), 2.70
(1H, m), 2.54 (3H, s, CH3), 2.51 (3H, s, CH3), 2.46 (3H, s, CH3), 2.35 & 2.34 (3H, s,
CH3), 2.20 & 2.06 (2H, t, ao carbonyl), 1.80-1.20 (m, CH2). 13C NMR (CDCl 3): 173.53,
161.52 , 160. 51 , 154. 72, 153.30, 130.51, 125.17, 116.16, 112.82, 112.12, 111.64,
109.15, 96.14, 69.83, 64.27, 63.12, 61.89, 60.78, 55.25, 40.52, 33.81, 29.69, 29.37,
28.46, 28.30, 28.23, 24.75, 22.80, 19.34 (CH3), 12.33 (CH3), 8.50 (CH 3). C 29H3805N4S
554.68 (calculated), FAB found 555 [MH]+
tert-Butylcarbonate-glycine-glycyl 4'-[[[(methylamino)ethyl] methylamino]methyl]-
4,5',8-trimethylpsoralen) ester (21)
4'-(N,N'-Dimethylethylene diaminomethyl)-4,5 ' ,8-trimethylpsoralen (9) (0.117 g, 0.357
mmol), BOC-gly-gly (0.143 g, 0.616 mmol, 170 M%) and DIC (100 /1, 0.643 mmol, 180
M%) were dissolved in pyridine (2 ml). After 5 hr at room temperature, the reaction was
concentrated to dryness. The residue was diluted with CH2C12 (20 ml) and washed with
NaHCO 3 (sat) (10 ml) and NaCl(at) (10 ml). The tert-butyl carbonate-glycine-glycyl 4'-
[[[(methylamino)ethyl] methylamino]methyl]-4,5',8-trimethylpsoralen) ester (21) was
purified by column chromatography on 10 g of silica gel eluting with CH 2Cl2/MeOH (92:8)
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yielding an off white solid (0.145 g, 0.276 mmol, 77% yield) (TLC rf 0.30 CH 2C12 : MeOH
90: 10) 'H NMR (CDC13): appears as two rotamers 7.6 (1H, br, NH), 7.5 (1H, s, H5),
7.0 (1H, br, NH), 6.2 (1H, s, H3), 5.25 (2H, s, H4'), 4.05 & 3.9 (1H, d), 3.8 (2H, t), 3.6
(m), 3.30 (2H, t), 2.82 (two singlets, NCH3), 2.60 (m, CH 2.s), 2.54 (3H, s, CH 3), 2.51
(3H, s, CH 3), 2.46 (3H, s, CH3), 2.25 (two singlets, NCH3), 1.4 (9H, s, BOC).
Glycine-glycyl 4'-[[[(methylamino)ethyl]methylamino]methyl]-4,5',8-trimethylpsoralen)
ester (22)
BOC-gly-gly-dialkylamine psoralen (21) (65 mg, 0.119 mmol) was dissolved in CH2Cl2 (2
ml) and treated with TFA (100 1d). Within 15 min at room temperature, the reaction was
concentrated to dryness. Aqueous workup was not done because this compound was soluble
in water. The glycine-glycyl 4'-[[[(methylamino)ethyl] methylamino]methyl] -4,5',8-
trimethylpsoralen) ester (22) was purified by column chromatography on 10 g silica gel
eluting with CH2C12/MeOH (84:16) containing trace triethylamine. (50 mg, 0. 12 mmol,
100% yield) (TLC rf 0.08 CH2Cl2/MeOH 80 : 20) The glycine-glycyl 4'-
[[[(methylamino)ethyl] methylamino]methyl] -4,5',8-trimethylpsoralen) ester (22) was
additionally purified by reversed phase C,8 HPLC using Gradient III. H NMR (CDC13):
appears as two rotamers 7.6 (1H, br, NH), 7.5 (1H, s, H5), 7.0 (1H, br, NH), 6.2 (1H, s,
H3), 5.25 (2H, s, H4'), 4.05 & 3.9 (1H, d), 3.8 (2H, t), 3.6 (m), 3.30 (2H, t), 2.82 (two
singlets, NCH3), 2.60 (m, CH2-s), 2.54 (3H, s, CH3), 2.51 (3H, s, CH3), 2.46 (3H, s,
CH3), 2.25 (two singlets, NCH3).
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17-Hemisuccinate estradiol N-hydroxysuccinimide ester (23)
N-Hydroxysuccinimide (25 mg, 0.22 mmol, 150 M%) and DIC (30 l, 0.29 mmol, 210
M%) were added to 17-hemisuccinate estradiol (53 mg, 0.142 mmol) suspended in CH2C12
(lml). After 2 hr at room temperature, the reaction was diluted with CH2CI2 (10 ml) and
washed with NaHCO3(sat) (10 ml) and NaCl(sat) (10 ml). 17-Hemisuccinate estradiol N-
hydroxy succinimide ester (23) was purified by column chromatography on 10 g silica gel
eluting with CH2Cl 2/MeOH (98:2) to produce an off white solid (0.054 g) 'H NMR
(CDCl3): 7.20 (1H, d, H5), 6.82 (1H, dd, H6), 6.77 (1H, d, H2), 2.87 (2H, dd), 2.5-1.8
(7H, m), 1.7-1.45 (6H, m), 0.89 (3H, s, CH3).
17-Hemisuccinate estradiol-glycine-glycyl 4'-[[[(methylamino)ethyl]
methylamino]methyl]-4,5',8-trimethylpsoralen) ester (24)
Gly-gly-dialkylamine (22) and NHS-succinate-estradiol (23) were allowed to react at room
temperature for 3 hr in CH2C12. No aqueous workup was done. The crude 17-
hemisuccinate estradiol-glycine-glycyl 4'-[[[(methylamino)ethyl] methylamino]methyl]-
4,5',8-trimethylpsoralen) ester (24) was purified by column chromatography on 10 g silica
gel eluting with CH 2C12/MeOH (84:16) containing trace Et 3N. (TLC rf 0.43 CH2Cl2/MeOH
80:20) C45Hs60 9N4 796 (calculated) FAB found [MH] + =797.
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17oa-1,3,5[10]-Estratriene-3/3-[benzylether]-17j/-diol (26)
Estrone (25) (1.07 g, 3.96 mmol) was dissolved in THF (10 ml) and treated with benzyl
bromide (1 ml, 8.41 mmol, 210 M%). After 2 hr, K2CO3 (0.229 g) and additional benzyl
bromide (1 ml, 210 M%) were added. After 12 hr at room temperature, sodium hydride
(0.30 g, 1.25 mmol) was added and the reaction stirred for 30 min. The reaction was
concentrated and the residue was resuspended in CH2C12 (20 ml) and quenched slowly with
H20 (20 ml). The organic solution was washed with NaHCO3(sat) (20 ml) and NaCl(sat) (20
ml), dried with Na2SO4, filtered, and concentrated. 17c-1 ,3,5[10]-Estratriene-3/j-[benzyl
ether]-173-diol (26) was purified by column chromatography on 25 g silica gel eluting with
CH2Cl2 to produce an off white solid (1.15 g, 3.19 mmol, 81% yield + 0.34 g mixed
fractions) (TLC rf 0.54 CH2Cl2: MeOH 98:2 ) H NMR (CDCl 3): 7.43-7.30 (5H, m, Bn),
7.18 (1H, d, H5), 6.76 (1H, dd, H6), 6.72 (1H, d, H2), 5.20 (2H, s, CH2Ar ), 2.86 (2H,
m), 2.6-1.9 (m, CH2.s), 1.6-1.3 (m, CH 2.s), 0.889 (3H, s, CH3)
17a-[3 '-Butynyl-1l'-ol]-1,3,5[10]-estratriene-30-[benzyl ether]-17,-diol (27)
Potassium() (0.33 g, 8.46 mmol) was added in small portions to chilled (-78 C) solution of
NH3() (15 ml) in a 3 neck 100 ml flask with chilled cold finger. Almost immediately the
solution turned black/blue. After the addition of 3-butyn-l-ol (0.70 ml , 0.926 mmol), the
cold bath was removed. Upon warming, the solution turns clear. After 15 min, pyridine
(10 ml) and the 17ac-1,3,5[10]-estratriene-3fl-[benzyl ether]-1703-diol (26) (0.76 g, 2.1
mmol) were added. After 2 hr, the reaction was concentrated. The residue was redissolved
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in CH 2Cl2 (20ml) and quenched slowly with H20 (20ml). The organic solution was washed
with NaHCO3(sat) (20ml) and NaCl(sat) (20ml), dried with Na2SO4, filtered, and concentrated
(1.22 g). 17oa-[3 '-Butynyl-1'-ol]- 1,3,5[10]-estratriene-3f -[benzyl ether]-17fl-diol (27) was
purified by column chromatography on 25 g silica gel eluting with CH2C12. (0.17 g, 0.39
mmol, 20 % yield + 0.22 g mixed fractions) (TLC rf 0.08 CH2C12 : MeOH 98:2 ) H NMR
(CDC13): 7.46-7.28 (5H, m, Bn), 7.16 (1H, d, H5), 6.72 (1H, dd, H6), 6.66 (1H, d, H2),
5.31 (2H, s, CH2Ar ), 3.64 (2H, t, CH 2OH), 2.86 (2H, m), 2.43 (2H, t, H3'), 2.4-2.2 (m,
CH2-s), 2.0-1.5 (m, CH2.s), 1.5-1.2 (m, CH2.s), 0.81 (3H, s, CH3). 13C NMR (CDC13):
156.01 (C1), 137.47 (C3), 136.73 (Bn), 132.54 (C4), 127.91 (Bn), 127.26 (Bn), 126.91
(Bn), 125.78 (C5), 114.25 (C2), 111.77 (C6), 84.62, 82.00, 78.98, 69.60, 60.37, 49.00,
48.72, 48.43, 48.29, 48.15, 47.86, 47.58, 47.30, 46.68, 43.28, 39.14, 38.31, 32.52,
29.42, 26.91, 26.11, 22.46, 22.36, 12.29.
17a-1,3,5[10]-Estratriene-3,B-[methoxymethyl ether]-17,-diol (28)
Chloromethylmethyl ether (2.00 ml 26.33 mmol, 140 M%) and sodium hydride (0.77 g, 32
mmol, 170 M%) were added to estrone (25) (5.03 g, 18.60 mmol) suspended in THF (85
ml). After 30 min at room temperature, additional sodium hydride (0.45 g, 18.75 mmol,
100 M%) was added. After 1 1/2 hr, the reaction was diluted with ethylacetate (100 ml)
and washed with NaHCO 3 (sat) (100 ml) and NaCl(at) (100 ml). The organic solution was dried
with Na2SO 4, filtered, and concentrated. 17oa-1,3,5[10]-Estratriene-3I3-[methoxymethyl
ether]-173-diol (28) was purified by column chromatography on 100 g silica gel eluting with
CH2C12/MeOH (98:2) to yield an off white solid (4.90 g, 15.8 mmol , 85% yield). (TLC rf
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0.48 CH2Cl2 : MeOH 98:2 ) H NMR (CDCl3): 7.20 (1H, d, H5), 6.82 (1H, dd, H6), 6.77
(1H, d, H2), 5.13 (2H, s, OCH2O), 3.46 (3H, s, OCH3), 2.87 (2H, dd, CH2), 2.5-1.8 (7H,
m, CH2), 1.7-1.45 (6H, m, CH2), 0.89 (3H, s, CH3). 13C NMR (CDC13): 155.11 (C1),
137.76 (C3), 133.21 (C4), 126.29 (C5), 116.17 (C2), 113.79 (C6), 94.35, 55.84, 55.78,
50.31, 47.92, 43.94, 38.19, 35.79, 31.48, 29.53, 26.43, 25.80, 21.51, 13.77.
5-Hexyn-l-t-butyldimethylsilyol (29)
t-Butyldimethylsilyl chloride (3.18 g, 21.2 mmol, 210 M%) and sodium hydride (0.74 g,
30.88 mmol) were added to 5-hexyn-l-ol (1.02 g, 10.19 mmol) dissolved in THF (10 ml).
The reaction was quenched after 20 min with water (20 ml) and diluted with ethylacetate (50
ml). The organic solution was collected and washed with NaCl(sat) (25 ml), dried with
Na2SO4, filtered, and concentrated. 5-hexyn-1-t-butyldimethylsilyol (29) was purified by
column chromatography on 25 g silica gel eluting with CH2C12 yielding a oil (1.78 g, 8.39
mmol, 82% yield). (TLC rf 0.60 4% ethylacetate/ hexane) H NMR (CDC13): 3.61 (2H, t, 2
x H1), 2.19 (2H,dt, 2 x H4), 1.92 (1H,t,H6), 1.7-1.5 (4H, m, 4 x CH2), 0.87 (9H, s,
tBuSi), 0.028 (6H, s, MeSi). 13C NMR (CDC13): 84.52 (C5), 68.23 (C6), 62.58 (C1),
31.81, 25.96 (SitBu), 25.69, 24.97, 18.33, 18.22, 12.52, -5.32 (SiMe).
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17-[5 '-Hexynyl-1'-t-butyldimethylsilylol]-1,3,5[10]-estratriene-3/ -[methoxymethyl
ether]-17,-diol (30)
5-Hexyn-1-t-butyldimethylsilyol (29) (0.66 g, 3.11 mmol, 210 M%) was dissolved in THF
(10 ml) and hexamethylphosphoramide (0.54 ml 0.56 g, 3.10 mmol, 210 M%). The
solution was chilled with a dry ice/ isopropanol bath before adding 2M BuLi (in Et2O) (1.5
ml, 3.0 mmol, 205 M%). After 10 min at -78 C, MOM-estrone (28) (0.46 g, 1.46 mmol)
was added and the cold bath removed. After 6 hr at room temperature, the reaction was
diluted with ethylacetate (25 ml) and H20 (25 ml). The organic solution was collected and
washed with NaHCO3 (sat (25 ml) and NaCl(sat) (25 ml), dried with Na2SO 4, filtered, and
concentrated. 17oa-[5 '-Hexynyl-1 '-t-butyldimethylsilylol]-1,3,5[10]-estratriene-3 -
[methoxymethyl ether]-17,-diol (30) was purified by column chromatography on 35 g silica
gel eluting with CH2C12 increasing to CH2Cl2/MeOH (98:2). (0.40 g 0.76 mmol 52 % yield
plus 0.32 g mixed fractions containing mom-estrone) (TLC rf 0.42 CH2C12: MeOH 98:2 )
1H NMR (CDC13): 7.12 (1H, d, H5), 7.73 (1H, dd, H6), 6.62 (1H, d, H2), 5.07 (2H, s,
OCH2O), 3.56 (2H, t, OCH2), 3.40 (3H, s, OCH3), 2.74 (2H, br, CH2), 2.26 (2H, t, 2 x
H4'), 2.4-1.2 (17H, m, CH2), 0.87 (9H, s, tBuSi), 0.81 (3H, s, CH3), 0.03 (6H, s,
MeSi). 13C NMR (CDC13): 154.77 (C1), 137.82 (C3), 133.72 (C4), 126.18 (C5), 116.04
(C2), 113.56 (C6), 94.30, 85.88, 83.88, 79.78, 62.57, 55.78, 49.44, 47.12, 43.71, 39.37,
39.13, 32.90, 32.01, 29.81, 27.29, 26.44, 25.96 (SitBu), 25.38, 22.82, 18.65, 18.32,
12.87, -5.20 (SiMe)
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17a-[5 '-Hexynyl-l'-ol]-1,3,5[10]-estratriene-3/-[methoxymethyl ether]-17/3-diol (31)
In a plastic vial, 17a-[5'-hexynyl-1 '-t-butyldimethylsilylol]- 1,3,5[10]-estratriene-313-
[methoxymethyl ether]-173-diol (30) (0.40 g, 0.76 mmol) dissolved in pyridine (5 ml) was
treated with 60-70% HF/pyridine (1.0 ml). After 15 min at room temperature, additional
HF/pyridine (1.0 ml) was added. After 30 min, the reaction was concentrated. The residue
was redissolved in CH2C12 (25 ml) and washed withH 20 (10 ml) and NaCl(,t) (10 ml). The
organic solution was dried with Na2SO4, filtered, and concentrated. 17a-[5'-hexynyl-1'-ol]-
1,3,5[10]-estratriene-3/ -[methoxymethyl ether]-17/-diol (31) was purified by column
chromatography on 25 g silica gel eluting with CH2C12/MeOH (95:5) with increasing to
CH2Cl2/MeOH (90:10). (0.31 g, 0.75 mmol, 99% yield) (TLC rf 0.40 CH 2C12 : MeOH
95:5) H NMR (CDC13): 7.12 (1H, d, 115), 6.73 (1H, dd, H6), 6.62 (1H, d, H2), 5.07
(2H, s, OCH20), 3.56 (2H, t, OCH2), 3.40 (3H, s, OCH 3), 2.74 (211, br, CH 2), 2.26 (2H,
t, H4'), 2.4-1.2 (17H, m, CH2) 0.81 (3H, s, CH3).13C NMR (CD 3OD): 156.17(C1), 138.68
(C3), 134.71 (C4), 127.60 (C5), 117.10 (C2), 114.63 (C6), 95.37 (MOM), 86.13, 85.26,
80.36, 62.35, 56.06, 50.70, 45.07, 40.85, 40.00, 34.14, 32.76, 30.72, 28.53, 27.64,
26.44, 23.74, 19.32, 13.59.
17a-[5 '-Hexynyl-1'-ol]-1,3,5[10]-estratriene-3/,17j3-diol (32)
17a-[5 '-Hexynyl-1'-ol]-1,3,5[10]-estratriene-3f-[methoxymethyl ether]-17f-diol (31) (61
mg) was dissolved in MeOH (2ml) and treated with HC1 (,o) (20 l ) at room temperature.
Additional HCl (con)(20 ,l and 40 1L, respectively) was added after 15 min and after 1 hr.
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After 3 hr, the reaction mixture was concentrated. The residue was redissolved in CH2C12
(25 ml) and washed with H20 (10 ml) and NaCl(sat) (10 ml). The organic solution was dried
with Na2SO4, filtered, and concentrated. 17oa-[5'-Hexynyl-l'-ol]-1,3,5[10]-estratriene-
3,, 173-diol (32) was purified by column chromatography on 20 g silica gel eluting with
CH 2C12/MeOH (90:10). (TLC rf 0.30 CH 2C12: MeOH 95:5) (50 mg) H NMR (CDCl3):
7.08 (1H, d, H5), 6.61 (1H, dd, H6), 6.55 (1H, d, H2), 3.64 (2H, t, CH2O), 2.73 (2H,
br), 2.24 (2H, t, H4'), 2.3 -1.2 (m, CH 2 s), 0.810 (3H, s, CH3). ' 3C NMR (CDC13):
153.50 (Cl), 138.02 (C3), 132.19 (C4), 126.35 (C5), 115.23 (C2), 112.70 (C6), 85.94,
84.09, 80.00, 62.33, 53.44, 49.51, 47.20, 43.71, 39.50, 39.18, 32.97, 31.90, 29.72,
27.33, 26.54, 25.18, 22.88, 18.69, 12.94
4-[p-(Bis[2-Chloroethyl]amino)-phenyl]pentyl amine (33)
Ethylchloroformate (1.00 ml, 7.19 mmol, 110 M%) dissolved in 5 ml acetone was added to
a cold solution (0 C) of chlorambucil (2.00 g, 6.57 mmol) dissolved in acetone (5 ml) and
trietheylamine (1 ml). Upon addition of the ethylchloroformate solution, a solid precipitated
from solution. After 10 min, sodium azide (0.754g, 6.95 mmol, 1.06 mmol) dissolved in 5
ml water was added whereby the white suspension disappeared. After 20 min, the reaction
was diluted with benzene (50 ml) and washed with ice water (100 ml) and NaCl(sa) (100 ml).
The benzene solution was then dried with Na2SO4, filtered, and then heated (65 'C). After
1 hr, the reaction was concentrated and the residue treated with HClCon) (25 ml). After 10
min, the reaction was concentrated to dryness. The 4-[p-(bis[2-Chloroethyl]amino)-
phenyl]pentyl amine (33), hydrochloride salt was collected by suspending the material in
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CH 2C12 and filtering the off white solid. 'H NMR (D 20): 7.40 (2H, d, Ar), 7.32 (2H, d,
Ar), 3.90 (4H, t, NCH2), 3.39 (4H, t, 2 x CH2Cl), 2.85 (2H, t, NCH2), 2.60 (2H, t,
CH2Ar), 1.82 (2H, m, CH 2). 13C NMR (D20): 146.34, 135,08, 133.09, 124.56, 61.27
(CH2Cl), 41.33 (H 2NCH2), 39.71 (CH 2NAr), 33.75 (CH2), 30.44 (CH2Ar),
17a-[5'-Hexynyl-l'-carbamoyl-[4-[p(bis[2-Chloroethyl]amino)-phenyl]pentyl amine]]-
1,3,5[10]-estratriene-33-[methoxymethyl ether]-17j-diol (34)
p-Nitrophenyl chloroformate (0.137 g, 0.68 mmol, 190 M%) was added to MOM-estrone
(31) (0.15 g, 0.36 mmol) dissolved in THF (3.5 ml) and pyridine (0.5 ml). After 30 min,
additional p-nitrophenyl chloroformate (0.084 g) was added. After 1.5 hr, the reaction
mixture was diluted with CH 2Cl2 (25 ml) and washed with H20 (10 ml) and NaCl(mt) (10
ml). The organic solution was dried with Na2SO4 , filtered, and concentrated. The crude
activated carbamoyl ester was used without purification in the next step. (TLC rf 0.82
CH2C12: MeOH 95:5)
4-[p-(bis[2-Chloroethyl]amino)-phenyl]pentyl amine (33) (0.101 g) was added to the crude
activated carbamoyl ester dissolved in (1:1) pyridine: THF (8 ml) and the mixture was then
heated (Tb= 60 C). Additional amine (33) was added after 1 1/2h (0.069 g) and after 4
1/2 hr (0.102 g). After 12 hr, the reaction was diluted with ethylacetate (40 ml) and
washed with NaHCO3 (sat) (25 ml) and NaCl(sat) (25 ml). The organic solution was dried with
Na 2SO 4, filtered, and concentrated. 17a-[5 '-Hexynyl-1 '-carbamoyl-[4-[p-(bis[2-
Chloroethyl]amino)-phenyl]pentyl amine]]- 1,3,5[10]-estratriene-33 -[methoxymethyl ether]-
173-diol (34) was purified by column chromatography on 25 g silica gel eluting with
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hexane/ethylacetate (2:1). (170 mg, 67% yield for two steps) (TLC rf 0.90 CH2CI2/MeOH
95:5). 11H NMR (CDCl3): 7.20 (1H, d, H5), 7.04 (2H, d, H2"), 6.80 (1H, dd, H6), 6.75
(1H, d, H2), 6.63 (2H, d, H113"), 5.12 (2H, s, OCH2O), 4.56 ,4.07 (2H, t, OCH2), 3.60
(8H, dd, NCH 2CH 2Cl), 3.45 (3H, s, OCH3), 3.13 (2H, q, NCH2), 2.83 (2H, m, CH 2), 2.52
(2H, t, Ar CH2), 2.30 (2H, t, 115'), 2.4-2.1 (m, CH 2-s), 2.1-1.2 (18H, m, CH2), 0.84 (3H,
s, CH3). '3C NMR (CDC13): 156.62 (C4"), 154.98 (C1), 144.22 (Cl"), 138.02 (C3),
133.86 (C4), 129.49 (C2"), 126.31 (C5), 116.22 (C2), 113.72 (C6), 112.32 (C3"), 94.45
(MOM), 85.51, 84.38, 79.86, 64.22, 55.83, 53.60 (CH2Cl), 49.48, 47.12, 43.68, 40.42
(Ar NCH2), 39.32, 39.07, 32.89, 31.74, 29.74, 28.25, 27.22, 26.37, 24.97, 22.76, 18.45,
12.77.
17a-[5 '-Hexynyl-1'-carbamoyl-[4-[p-(bis[2-Chloroethyl]amino)-phenyl]pentylamine]]-
1,3,5[10]-estratriene-31,17/3-diol (35)
Hydrochloric acid(Con) (100 l ) was added to 17a-[5 '-hexynyl-l'-carbamoyl-[4-[p-(bis[2-
chloroethyl]amino)-phenyl]pentyl amine]]-1,3,5[10]-estratriene-3/ -[methoxymethyl ether]-
17f-diol (34) (40 mg) dissolved in MeOH (2 ml). After 1 hr at room temperature, the
reaction mixture was concentrated. The residue was diluted with CH2C12 (15 ml) and
washed with H20 (10 ml) and NaCl(sat) (10 ml). The organic solution was dried with
Na2SO 4, filtered, and concentrated. 17c-[5'-Hexynyl-l'-carbamoyl-[4-[p-(bis[2-
Chloroethyl]amino)-phenyl]pentylamine]]-1,3,5[10]-estratriene-3,, 17B-diol (35) was purified
by column chromatography on 25 g silica gel eluting with CH 2C12/MeOH (96:4). The
purity was determined by reversed-phase HPLC on a C,18 column using gradient IV. (TLC
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rf 0.29 CH 2C12 /MeOH 95:5 or TLC rf 0.70 ethylacetate/hexane 2: 1 ) H NMR (CDC13):
7.15 (1H, d, H5), 7.06 (2H, d, H2"), 6.71 (2H, dd, H3"), 6.59 (1H, dd, H6), 6.53 (1H, d,
H2), 5.28 (1H, br, OH), 4.59 (1H, br, OH), 4.07 (2H, t, OCH2), 3.60 (8H, dq,
NCH 2CH 2C1), 3.1.3 (2H, q, NCH2), 2.79 (2H, m), 2.51 (2H, t, Ar CH2), 2.27 (2H, t,
H5'), 2.4-1.2 (H, m, CH 2.s), 0.85 (3H, s, CH3). 13C NMR (CDC13): 156.74 (C4"), 153.48
(C1), 144.17 (Cl"), 138.21 (C3), 132.48 (C4), 129.56 (C2"), 126.47 (C5), 115.27 (C2),
112.72 (C6), 112.46 (C3"), 85.61, 84.38, 79.98, 64.35, 53.69 (CH2Cl), 49.51, 47.18,
43.67, 40.51, 40.42 (ArNCH2), 39.42, 39.08, 39.00, 32.92, 31.79, 31.72, 29.64, 28.28,
27.25, 26.46, 25.01, 22.78, 18.50, 12.81, 12.50. Xmax = 258 (e = 1.6 x 104), Xax = 254 (e
= 1.6 x 104), Xmax = 280 ( =3.5 x 103). EIMS expected exact molecular weight
668.31477, high resolution result for m/z=668 (668.3154).
7-Octyn-1-t-butyldiphenylsilyol (36)
t-Butyldiphenylsilylchloride (22 ml, 84.60 mmol, 155 M% ) and sodium hydride (1.86 g,
77.5 mmol, 140 M%) were added to 6-bromo-l-hexanol (9.89 g, 54.40 mmol) dissolved in
THF (100 ml). After 1 hr at room temperature, additional sodium hydride (0.99 g, 41.25
mmol, 75 M%) and t-butyldiphenylsilylchloride (11 ml, 42.30 mmol, 78 M%) were added.
After 4 1/2 hr, the reaction was concentrated. The residue was redissolved in CH2Cl2 (100
ml) and quenched slowly with H20 (50 ml). The organic solution was washed with
NaHCO 3 (sat) (50 ml) and NaCl(sat) (50 ml), dried with Na2SO4, filtered, and concentrated. 7-
Octyn-l-t-butyldiphenylsilyol (36) was purified by column chromatography on 300 g silica
gel eluting with CH2Cl2 . (Note: this solvent is too fast and does not allow separation of the
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compound from tBDPSiOH. Use hexane systems as done for the 8-bromo-1-t-
butyldiphenylsilyl octanol). The impure 6-bromo-1-t-butyldiphenylsilyl hexanol was used
without any further purification in the next step. (TLC rf 0.60 ethylacetate/hexane 4:96 - use
H2SO4 stain).
8-Bromo-1-t-butyldiphenyl silyl octanol (9.10 g, 21.69 mmol) was added to an ice bath-
cooled suspension of 90% LAEDA (3.25 g, 31.76 mmol 150 M%) dissolved in 50 ml
DMSO(aynhydrs). After 3 hr, the reaction was diluted with CH2C12 (100 ml) and washed with
H20 (50 ml), NaHCO3 (sat) (50 ml), and NaCl(sat) (50 ml). The organic solution was dried
with Na2SO4, filtered, and concentrated. 7-Octyn-l-t-butyldiphenylsilyol (36) was purified
by column chromatography on 100 g silica gel eluting with ethylacetate/hexane (4:96). (4.61
g, 12.68 mmol, 60 % yield). (TLC rf 0.60 ethylacetate/hexane 4:96) (sulfuric acid or
anisaldehyde stain). H NMR (CDC13): 7.66 (4H, m, Ar), 7.39 (6H, m, Ar), 3.65 (2H, t,
H1), 2.16 (2H, dt, H6), 1.93 (1H, t, H8), 1.60-1.50 (4H, m, CH 2), 1.40-1.35 ( 4H, m,
CH2), 1.04 (9H, s, tBu).'3C NMR (CDC13): 135.56 (Cl', ArSi) 134.14 (C2', ArSi), 129.49
(C4', Ar Si), 127.56 (C3', Ar Si), 84.63 (C7), 68.12 (C8), 63.83 (C1), 32.40, 28.44,
27.09, 26.87 (C(CH3 )3), 25.27,, 19.22, 18.35.
9-Decyn-l-t-butyldiphenylsilyol (37)
t-Butyldiphenylsilylchloride (18 ml, 69.22 mmol, 140 M%) and sodium hydride (1.73 g,
72.08 mmol, 150 M%) were added to 8-bromo-l-octanol (10.15 g ,48.53 mmol) dissolved
in THF (100 ml). After 3 hr at room temperature, additional t-Butyldiphenylsilylchloride
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(7.23 g, 26.39 mmol, 55 M%) and sodium hydride (1.7 g, 150 M%) were added. After
stirring overnight at room temperature, the reaction was concentrated to near dryness. The
residue was redissolved in CH2C12 (100 ml) and washed with H20 (100 ml), NaHCO3(s,)(100
ml), and NaCl(sat) (100 ml). The organic solution was dried with Na2SO4, filtered, and
concentrated. 9-Decyn-l-t-butyldiphenylsilyol (37) was purified by column chromatography
on 300 g silica gel eluting with hexane increasing to ethylacetate/hexane (5:95). (15.08 g,
33.70 mmol, 70% yield) (TLC rf 0.58, ethylacetate/hexane 5:95 - use H2SO4 stain). 1H
NMR (CDC13): 7.68 (4H, m, Ar), 7.40 (6H, m, Ar), 3.67 (2H, t, H1), 2.18 (2H, dt, H8),
1.94 (1H, t, H10O), 1.60-1.50 (4H, m, 2 x CH2), 1.10-1.28 (8H, m, 4 x CH2), 1.06 (9H,
s,tBu). 13C NMR (CDC13): 135.47 (C1', Ar ) 134.05 (C2', Ar ), 129.39 (C4', Ar ), 127.47
(C3', Ar ), 63.95 (C1), 34.11, 32.90, 32.58, 29.24, 28.81, 28.20, 26.98 (C(CH3)3),
25.76, 19.34
8-Bromo-l-t-butyldiphenyl silyl octanol (15 g, 37 mmol) was added to an ice bath cooled
suspension of 90% LAEDA (5.16 g, 50.48 mmol 150 M%) dissolved in DMSO(ahyd,s) (50
ml). After 3 hr at room temperature, the reaction was diluted with CH2C12 (300 ml) and
washed with H20 (300 ml). The organic solution was dried with Na2SO 4, filtered, and
concentrated. 9-Decyn-l-t-butyldiphenylsilyol (37) was purified by column chromatography
on 150 g silica gel eluting with CH2Cl2. (10.0 g 25.5 mmol, 68 % yield) (TLC rf 0.60
ethylacetate/hexane 4:96) 1H NMR (CDC13): 7.68 (4H, m, Ar), 7.40 (6H, m, Ar), 3.67
(2H, t, Hi), 2.18 (2H, dt, H8), 1.94 (1H, t, H10), 1.60-1.50 (4H, m, 2 x CH2), 1.40-1.28
( 8H, m, 4 x CH2), 1.06 (9H, s, tBu). 13C NMR (CDC13): 135.45 (Cl', ArSi) 134.06 (C2',
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ArSi), 129.37 (C4', ArSi), 127.46 (C3', ArSi), 84.73 (C9), 68.08 (C10), 63.99 (C1),
32.68, 29.30, 29.15, 28.78, 28.57, 26.98 (C(CH3)3), 25.81, 19.34, 18.51.
17cz-[7'-Hexynyl-l'-t-butyldiphenylsilyol]-1,3,5[10]-estratriene-3# -[methoxymethyl
ether]-17/3-diol (38)
n-Butyllithium (2M in Et2O) (4.0 ml, 8.0 mmol) was added to 7-octyn-l-t-
butyldiphenylsilyol (36) (2.70 g, 7.43 mmol, 187 M%), dissolved in THF (25 ml) and
hexamethylphosphoramide (2.86 g, 15.97 mmol), and chilled with a dry ice/ isopropanol
bath. After 5 min, 17ca-1,3,5[10]-estratriene-30 -[methoxymethyl ether]-17B-diol (28) (1.25
g, 3.97 mmol) was added and the cold bath removed. After 5 hr, the reaction was
concentrated to dryness. The residue was redissolved in CH2C12 (100 ml) and washed with
NaHCO3 (sat) (50 ml) and NaCl(sat) (50 ml). The organic solution was dried with Na2SO 4,
filtered, and concentrated. 17or-[7'-Hexynyl-1 '-t-butyldiphenylsilyol]-1,3,5[10]-estratriene-
3,B -[methoxymethyl ether]-173-diol (38) was purified by column chromatography on 50 g
silica gel eluting with CH2Cl2 increasing to CH2C12/MeOH (98:2). (1.61 g, 2.41 mmol, 61%
yield ) (TLC rf 0.68 CH2C12: MeOH 98:2). H NMR (CDC13): 7.66 (4H, m, Ar Si), 7.38
(6H, m, Ar Si), 7.20 (1H, d, H5), 6.80 (1H,dd, H6), 6.76 (1H, d, H2), 5.28 (2H, s,
OCH2O), 3.64 (2H, t, OCH2), 3.46 (3H11, s, OCH3), 2.85 (2H, m, CH2), 2.22 (2H, t, H7'),
2.4-1.3 (m, CH2.s), 1.03 (9H, s, tBu), 0.85 (3H, s, CH3). 13C NMR (CDC13): 154.87 (C1),
137.95 (C3), 135.43 (C1', ArSi), 133.99 (C2', ArSi), 133.83 (C4), 129.37 (C4', ArSi),
127.45 (C3', ArSi), 126.30 (C5), 116.14 (C2), 113.66 (C6), 94.44, 86.33 (C8, alkyne),
83.70 (C7, alkyne), 79.97, 63.89 (C1, alkyne), 55.92, 49.52, 47.22, 43.80, 39.45, 39.20,
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32.96, 32.57 (alkyne), 29.89, 28.84, 28.73 (alkyne), 27.35, 27.17 (alkyne), 26.95
(C(CH3)3), 26.52, 25.35 (alkyne), 22.89, 19.31 (alkyne), 18.81 (alkyne), 12.92.
17a-[9'-Decynyl-l'-t-butyldiphenylsilyol]-1,3,510]-estratriene-313 -[methoxymethyl
ether]-17/3-diol (39)
n-Butyllithium (2M in Et2O) (4.0 ml, 8.0 mmol) was added to 9-decyn-l-t-
butyldiphenylsilyol (37) (1.54g, 4.24 mmol, 125 M%), dissolved in THF (25 ml) and
hexamethylphosphoramide (1.51 g, 8.44 mmol), and chilled with a dry ice/ isopropanol
bath. After 5 min, 17a-1,3,5[10]-estratriene-31 -[methoxymethyl ether]-173-diol (28) (1.25
g, 3.97 mmol) was added and the cold bath removed. After 6 hr, the reaction was
concentrated to dryness. The residue was redissolved in CH2C12 (50 ml) and washed with
NaHCO3 (sa) (25 ml) and NaCl(sat) (25 ml). The organic solution was dried with Na2SO4,
filtered, and concentrated (6.44 g crude). 17a-[9'-Decynyl-l'-t-butyldiphenylsilyol]-
1,3,5[10]-estratriene-33 -[methoxymethyl ether]-17j-diol (39) was purified by column
chromatography on 50 g silica gel eluting with CH2C12 increasing to CH2C12/MeOH (98:2).
(TLC rf 0.66 CH2C12: MeOH 98:2). 1H NMR (CDC13): 7.65 (4H, d, ArSi), 7.37 (6H, m,
ArSi), 7.18 (1H, d, H5), 6.82 (1H, dd, H6), 6.75 (1H, d, H2), 5.12 (2H, s, OCH2O), 3.61
(2H, t, OCH2), 3.45 (3H, s, OCH3), 2.81 (2H, m, CH2), 2.21 (2H, t, C8'), 2.4-1.2 (m,
CH2), 1.02 (9H, s, tBu), 0.84 (3H, s, CH3). 13C NMR (CDC13): 155.08 (C1), 138.08
(C3), 135.57 (C1", Ar Si), 134.22 (C2", Ar Si) 133.99 (C4), 129.45 (C4", Ar Si), 127.56
(C3", Ar Si), 126.37 (C5), 116.28 (C2), 113.78 (C6), 94.53 (E), 86.43 (E), 83.76 (C9'),
267
77.99 (C10'), 63.98 (C1'), 55.87, 49.53, 47.20, 43.77, 39.42, 32.91, 32.57, 29.79, 29.30,
29.04, 28.84, 28.77, 27.27, 26.90, 26.44, 25.74, 22.81, 19.21, 18.77, 12.82
17a-[7'-Octynyl-1'-ol]-1,3,5 [10]-estratriene-33-[methoxymethyl ether]-17,l-diol (40)
In a plastic vial, 17ca-[7'-hexynyl-1 '-t-butyldiphenylsilyol]-1,3,5[10]-estratriene-3 -
[methoxymethyl ether]-173-diol (38) (1.61 g, 2.41 mmol) dissolved in pyridine (25 ml) was
treated with 60-70% HF / pyridine (2.00 ml). After 30 min at room temperature, additional
HF/pyridine (5.00 ml) was added. After 1 hr, the reaction was concentrated to dryness.
The residue was redissolved in CH2C12 (100 ml) and washed with NaHCO3(,t) (50 ml) and
NaCl(sat) (50 ml). The organic solution was dried with Na2SO4, filtered, and concentrated.
The 17cx-[7'-octynyl-1'-ol]-1,3,5[10]-estratriene-30 -[methoxymethyl ether]-17,B-diol (40)
was purified by column chromatography on 50 g silica gel eluting with CH 2Cl2/MeOH
(96:4) increasing to CH2Cl2/MeOH (90:10). (0.71 g, 1.51 mmol, 63 % yield). (TLC rf
0.18 CH 2Cl2: MeOH 98:2) 'H NMR (CDC13): 7.13 (1H, d, H5), 6.74 (1H, dd, H6), 6.68
(1H, d, H2), 5.06 (2H, s, OCH 2O), 3.49 (2H, t, OCH 2), 3.39 (3H, s, OCH3), 2.75 (2H, m,
CH2), 2.17 (211, t, H7'), 2.4-1.3 (m, CH2-s), 0.77 (3H, s, CH3). 13C NMR (CDC13):
154.42 (C1), 137.60 (C3), 133.59 (C4), 125.92 (C5), 115.80 (C2), 113.28 (C6), 94.03,
85.27 (C8, alkyne), 83.56 (C7, alkyne), 79.18, 61.80 (C1, alkyne), 55.47, 49.13, 46.86,
43.47, 39.13, 38.67, 32.59, 32.09 (alkyne), 29.51, 28.43, 28.33 (alkyne), 27.03, 27.03
(alkyne), 26.21, 24.97 (alkyne), 22.52, 18.41 (alkyne), 12.56.
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17a-[9'-Decynyl-1'-ol]-1,3,5[10]-estratriene-3B-[methoxymethyl ether]-17,-diol (41)
In a plastic vial, 17c-[9'-decynyl-1 '-t-butyldiphenylsilyol]-1,3,5[10]-estratriene-3 -
[methoxymethyl ether]-173-diol (39) (4.5 g, 2.41 mmol (slightly contaminated with MOM-
estrone) dissolved in pyridine (75 ml) was treated with 60-70% HF/pyridine (5.00 ml).
After 45 min at room temperature, an additional 5.00 ml HF was added. After 4 hr, the
reaction was concentrated to dryness. The residue redissolved in CH2C12 (100 ml) and
washed with NaHCO3 (sat) (50 ml) and NaCl(sa,,) (50 ml). The organic solution was dried with
Na2SO4, filtered, and concentrated. 17cu-[9'-Decynyl-l'-ol]-1,3,5[10]-estratriene-3/3-
[methoxymethyl ether]-173-diol (41) was purified by column chromatography on 40 g silica
gel eluting with CH2Cl2/MeOH (96:4) increasing to CH2Cl2/MeOH(90:10). (1.71 g, 3.46
mmol, 53 % yield). (TLC rf 0.21 CH2Cl2: MeOH 98:8). 'H NMR (CDC13): 7.20 (1H, d,
H5), 6.81 (1H, dd, H6), 6.75 (1H, d, H2), 5.28 (2H, s, OCH2O), 3.57 (2H, t, OCH2),
3.46 (3H, s, OCH3), 2.82 (2H, br, CH2), 2.20 (2H, t, C8'), 2.4-1.2 (m, CH2), 0.84 (3H, s,
CH 3). 13C NMR (CDC13): 154.84 (C1), 137.97 (C3), 133.81 (C4), 126.25 (C5), 116.17
(C2), 113.66 (C6), 94.42, 86.24 (C8, alkyne), 83.77 (C7, alkyne), 79.92, 62.93 (C1,
alkyne), 55.90, 49.52, 47.20, 43.82, 39.41, 39.16, 32.94, 32.76 (alkyne), 29.86, 29.05,
28.77 (alkyne), 27.34, 26.49 (alkyne), 25.72 (alkyne), 22.85, 18.80 (alkyne), 12.91.
269
17a-[7'-Octynyl-l'-carbamoyl-[4-[p-(bis[2-chloroethyl]amino)-phenyl]pentyl amine]]-
1,3,5[10]-estratriene-3,-[methoxymethyl ether]-170f-diol (42)
p-Nitrophenyl chloroformate (0.20 g, 0.97 mmol, 135 M%) was added to 17a-[7'-octynyl-
1 '-ol]-1,3,5[10]-estratriene-33 -[methoxymethyl ether]-17/3-diol (40) (0.35 g, 0.74 mmol)
dissolved in THF (2 ml) and pyridine (1 ml). After 1 1/2 hr the reaction was diluted with
CH 2C12 (75 ml) and washed with H20 (2 x 25 ml) and NaCl(sat) (2 x 25 ml). The organic
solution was dried with Na2SO4, filtered, and concentrated. The crude activated carbamoyl
ester was used without purification in the next step. (TLC rf 0.60 CH2C12 /MeOH 98:2)
To the crude activated carbamoyl ester (34 mg) dissolved in pyridine (8 ml) was added the
5-[4-[N,N-bis(2-chloroethyl)amino]phenoxy]pentylamine / HCL salt (33) (0.101 g) and the
mixture heated (60 C). Additional amine (33) was added after 1 1/2 hr (0.069 g) and after
4 1/2 hr (0.102 g). After 12 hr, the reaction was diluted with ethylacetate (40 ml) and
washed with NaHCO3(,at) (2 x 25 ml) and NaCl(sat) (25 ml). The organic solution was dried
with Na2SO 4, filtered, and concentrated. 17a-[7'-Octynyl-l'-carbamoyl-[4-[p-(bis[2-
chloroethyl]amino)-phenyl]pentyl amine]]-1,3,5[10]-estratriene-3,B -[methoxymethyl ether]-
17,-diol (42) was purified by column chromatography on 50 g silica gel eluting with
CH2C12. (0.248 g, 0.34 mmol, 46 % yield for two steps ) (TLC rf 0.58 CH2Cl 2: MeOH
98:2). 'H NMR (CDC13): 7.2.0 (1H, d, H5), 6.80 (1H, dd, H6), 6.76 (1H, d, H2), 5.13
(2H, s, OCH2O), 4.60 (1H, br, OH), 4.03 (2H, t, OCH2), 3.60 (8H, dd, NCH2CH2Cl),
3.46 (3H, s, OCH3), 3.15 (2H, q, NCH2), 2.82 (2H, m, CH2), 2.52 (2H, t, ArCH2), 2.21
(2H, t, H5'), 2.4-1.2 (m, CH2.s ), 0.85 (3H, s, CH3). 13C NMR (CDC13): 156.50 (C4"),
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154.71 (C1), 144.02 (Cl"), 137.84 (C3), 133.71 (C4), 129.30 (C2"), 126.16 (C5), 116.02
(C2), 113.52 (C6), 111.98 (C3"), 94.27 (MOM), 85.81, 83.89, 76.58, 64.54, 55.78, 53.46
(CH 2Cl), 49.39, 47.09, 43.66, 40.46 (NCH 2), 39.31, 39.07, 32.85, 31.75, 29.76, 28.88 ,
28.48, 28.30, 27.23, 26.41, 25.21, 22.78, 18.67, 12.84. EIMS C42H58N2OsC12 exact
molecular weight 740.37228, high resolution result for m/z=740 (740.3728).
17ot-[9'-Decynyl-1l'-carbamoyl-[4-[p-(bis[2-chloroethyl]anino)-phenyl]pentyl amine]]-
1,3,5[10]-estratriene-3/ -[methoxymethyl ether]-17/3-diol (43)
p-Nitrophenylchloroformate (0.697 g, 3.46 mmol, 200 M%) was added to 17c-[9'-decynyl-
l'-ol]-1,3,5[10]-estratriene-3, -[methoxymethyl ether]-17/3-diol (41) (0.80 g, 1.71 mmol)
dissolved in THF (4 ml) and pyridine (2 ml). After 1 1/2 hr, the reaction was concentrated
to dryness. The residue was redissolved with CH 2C12 (50 ml) and washed with H 20 (25 ml)
and NaCl(sat) (25 ml). The organic solution was dried with Na2SO4, filtered, and
concentrated. The crude activated carbamoyl ester was used without purification in the next
step. (TLC rf 0.70 CH2C 2 /MeOH 98:2)
To the crude activated carbamoyl ester dissolved in pyridine (10 ml) was added the 5-[4-
[N,N-bis(2-chloroethyl)amino]phenoxy]pentylamine / HCL salt (33) (0.80 g). After 3 hr at
75 C, the reaction was concentrated. The residue was redissolved with CH2C12 (50 ml) and
washed with H20 (25 ml) and NaCl(sat) (25 ml). The organic solution was dried with
Na2SO4, filtered, and concentrated. 17cz-[9'-Decynyl-l'-carbamoyl-[4-[p-(bis[2-
chloroethyl]amino)-phenyl]pentyl amine]]- 1,3,5[10]-estratriene-3/j -[methoxymethyl ether]-
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173-diol (43) was purified by column chromatography on 50 g silica gel eluting with
CH 2Cl2/MeOH (98:2). (0.95 g, 1.50 mmol, 87 % yield for 2 steps) ( TLC rf 0.42 CH2Cl2
: MeOH 98:2 or 0.35 ethylacetate/hexane 1:2) 1H NMR (CDC13): H NMR (CDC13): 7.20
(1H, d, H5), 7.04 (2H, d, H2"), 6.80 (1H, dd, H6), 6.75 (1H, d, H2), 6.63 (2H, d, H3"),
5.12 (2H, s, OCH 2O), 4.56 (1H, br, OH), 4.07 (2H, t, OCH2), 3.60 (8H, dd,
NCH2CH2C1), 3.45 (3H, s, OCH3), 3.13 (2H, q, NCH2), 2.83 (2H, m, CH2), 2.52 (2H, t,
Ar CH 2), 2.30 (2H, t, H5'), 2.4-1.2 (m, CH2 .s), 0.84 (3H, s, CH3). 13C NMR (CDC13):
162.58 (C4"), 154.89 (C1), 144.16 (Cl"), 137.90 (C3), 133.76 (C4), 129.99 (OCH 2O),
129.31 (C2"), 125.99 (C5), 115.55 (C2), 113.64 (C6), 112.05 (C3"), 94.36 (OCH3),
86,82, 83.29, 80.35, 65.41, 55.88, 53.49 (CH 2Cl), 49.38, 47.19, 43.69, 40.50 (ArNCH2),
39.02, 32.85, 31.75, 31.60, 29.76, 29.16, 28.92, 28.71, 28.66, 27.24, 26.40, 25.75,
22.79, 18.74, 12.92
17a-[7'-Octynyl-l'-carbamoyl-[4-[p-(bis[2-chloroethyl]amino)-phenyl]pentyl amine]]-
1,3,5[10]-estratriene-31, 173-diol (44)
Hydrochloric acid(cOn) (100 ,l ) was added to 17a-[7'-octynyl-l'-carbamoyl-[4-[p-(bis[2-
chloroethyl]amino)-phenyl]pentyl amine]]- 1,3,5[10]-estratriene-33-[methoxymethyl ether]-
17j3-diol (42) (0.136 g, 0.18 mmol) dissolved in MeOH (3 ml). After 1 hr at room
temperature, additional HCl(con) (100 ,l ) was added. After 4 hr, the reaction was
concentrated. The residue was redissolved in CH 2C12 (20 ml) and washed with NaHCO 3(,.)
(10 ml) and NaCl(sat) (10 ml). The organic solution was dried with Na2SO 4, filtered, and
concentrated. 17a-[7'-Octynyl- 1 '-carbamoyl-[4-[p-(bis[2-chloroethyl]amino)-phenyl]pentyl
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amine]]-1,3,5[10]-estratriene-3/,17/3-diol (44) was purified by column chromatography on
20 g silica gel eluting with CH2C12/MeOH (96:4) increasing to CH2Cl2/MeOH (90:10). The
purity was determined by reversed-phase HPLC on a C 8 column using gradient IV. (TLC
rf 0.51, CH2Cl2/MeOH 98:2) H NMR (CDC13): 7.03 (1H, d, H5), 7.06 (2H, d, Ar), 6.64-
6.55 (4H, m, Ar), 5.8 (1H, br, OH), 4.59 (1H, br, OH), 4.04 (2H, t, OCH2), 3.63 (8H,
dq, NCH2CH2C1), 3.16 (2H, q, NCH2), 2.79 (2H, m, CH2), 2.52 (2H, t, ArCH2), 2.23
(2H, t, H5'), 2.4-1.3 ( m, CH 2.s), 0.85 (3H, s, CH3). 13C NMR (CDC13): 156.88 (C4"),
153.64 (C1), 144.26 (Cl"), 138.14 (C3), 132.27 (C4), 129.52 (C2"), 126.42 (C5), 115.26
(C2), 112.70 (C6), 112.14 (C3"), 86.12, 83.85, 79.99, 64.76, 53.52 (CH 2Cl), 49.42,
47.15, 43.63, 40.47 (NCH 2), 39.41, 39.04, 32.83, 31.73, 29.65, 28.86, 28.47, 28.31,
27.21, 26.45, 25.19, 22.77, 18.65, 12.81, 12.44. ax = 258 ( = 1.8 x 104), Xmx = 254 (e
= 1.7 x 104), X,,a = 280 ( =3.6 x 103). EIMS C40H54N20 4C12 exact molecular weight
696.34607, high resolution result for m/z=696 (696.3455)
17a-[9'-Decynyl-1'-carbamoyl-[4-[p-(bis[2-chloroethyl]amino)-phenyl]pentyl amine]]-
1,3,5110]-estratriene-33,17/-diol (45)
Hydrochloric acid(c,,n) (0.50 ml) was added to 17a-[9'-decynyl-l'-carbamoyl-[4-[p-(bis[2-
chloroethyl]amino)-phenyl]pentyl amine]]-1,3,5[10]-estratriene-3fl -[methoxymethyl ether]-
17,-diol (43) dissolved in MeOH (10 ml). After 1.5 hr at room temperature, additional
HC1 (0.25 ml) was added. After 4 hr, the reaction was concentrated to dryness. The
residue redissolved in CH 2C12 (50 ml) and washed with NaHCO3 (sat) (2 x 25 ml) and NaCl(sat)
(2 x 25 ml). The organic solution was dried with Na2SO 4, filtered, and concentrated. 17ca-
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[9'-Decynyl-1'-carbamoyl-[4-[p-(bis[2-chloroethyl]amino)-phenyl]pentyl amine]]-1,3,5[10]-
estratriene-3,17(3-diol (45) was purified by column chromatography on 50 g silica gel
eluting with CH2C12/MeOH (96:4). The purity was determined by reversed-phase HPLC on
a C18 column using gradient IV. (TLC rf 0.64 CH 2Cl2 : MeOH 95:5) 'H NMR (CDC13):
'H NMR (CDC13): 7.13 (1H, d, Ar), 7.03 (2H, d, Ar), 6.70-6.50 (4H, m, Ar), 6.14 (1H,
br), 4.56 (1H, br, OH), 4.75 (1H, br), 4.00 (2H, t, OCH2), 3.60 (8H, dd, NCH 2CH2Cl),
3.15 (2H, q, NCH2), 2.78 (2H, m, CH2), 2.53 (2H, t, ArCH2), 2.22 (2H, t, H5'), 2.4-1.2
(m, CH2.s ), 0.86 (3H, s, CH3). 13C NMR (CDCl 3): 156.78 (C4"), 154.60 (C1), 144.11
(Cl"), 137.88 (C3), 131.95 (C4), 129.37 (C2"), 126.23 (C5), 115.20 (C2), 112.68 (C6),
112.07 (C3"), 86.25, 83.69, 80.35, 65.00, 60.46, 53.54 (CH2CI), 49.44, 47.18, 43.72,
40.50 (ONCH2), 39.46, 39.08, 32.89, 31.78, 29.76, 29.70, 29.27, 28.99, 28.73, 27.32,
26.52, 25.83, 22.82, 18.77, 12.92. Xmax = 258 ( = 2.2 x 104), Xmax = 254 (e = 2.0 x 104),
Xma = 280 ( =4.0 x 103). EIMS C42H 58N204C12 exact molecular weight 724.37737, high
resolution result for m/z = 724 (724.3771).
17a-[7'-Octynyl-l'-ol]-1,3,5[10]-estratriene-3/,17/-diol (46)
17c-[7'-octynyl-1 '-ol]-1 ,3,5[10]-estratriene-3f -[methoxymethyl ether]-17/5-diol (40) (91 mg)
was dissolved in MeOH (3 ml) and treated with HCI (con) (100 ,t). After 45 min, additional
HC1 (con) (100 l) was added. After 1 1/2 hr, the reaction was concentrated. The residue
was redissolved in CH2Cl2 (20 ml) and washed with NaHCO3 (sat) (15 ml) and NaCl(sat) (15
ml). The organic solution was dried with Na2SO4, filtered, and concentrated. 17ot-[7'-
Octynyl-1'-ol]-1,3,5[10]-estratriene-33,17/5-diol (46) was purified by column
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chromatography on 30 g silica gel eluting with CH2C12/MeOH (96:4) increasing to
CH2Cl2/MeOH (92:8). (17 mg pure, and 20 mg mixed fractions) (TLC rf 0.31 CH2C12:
MeOH 95:5) H NMR (CDC13 / CD3OD): 6.97 (1H, d, H5), 6.45 (1H, dd, H6), 6.38 (1H,
d, H2), 3.39 (2H, t, CH2O), 2.62 (2H, m, CH2), 2.07 (2H, t, H7'), 2.2-1.0 (m, CH2-s),
0.673 (3H, s, CH3). 13C NMR (CDC13 / CD3OD): 154.05 (C1), 137.72 (C3), 131.44 (C4),
126.05 (C5), 114.91 (C2), 112.40 (C6), 85.37 (C8, alkyne), 83.57 (C7, alkyne), 79.36,
61.86 (C1, alkyne), 46.93, 43.46, 39.30, 38.64, 32.61, 32.05 (alkyne), 29.40, 29.11,
28.43, 28.31 (alkyne), 27.09, 26.23 (alkyne), 24.93 (alkyne), 22.46, 18.35 (alkyne),
12.44.
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